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Cemented and Uncemented Hip Implants 
in Patients With Rheumatoid Arthritis
James P. Waddell, MD, FRCSC
Department o f Surgery, St. Michael’s Hospital, Toronto, Ont. Member, Editorial Board Canadian 
Journal of Surgery
I n this issue of the Journal (pages 229 to 232), Kirk and colleagues 
review their results of hip replace­
ment in patients with rheumatoid 
arthritis. Orthopedic surgeons have 
always recognized patients with 
rheumatoid arthritis as a group 
with unique problems related to 
poor tissue healing, osteopenia, in­
volvement of multiple joints and a 
propensity for prosthetic problems 
after joint replacement. It is signifi­
cant that Kirk and colleagues have 
attempted to define the perfor­
mance characteristics and contrain­
dications for both cemented and 
uncemented total hip arthroplasty 
in this unique patient group.
Forty-two hips were replaced; 17 
hips were cemented to the host 
bone, and 25 hip prostheses were 
dependent upon tissue ingrowth for 
fixation. The average follow-up for 
cemented hips was 5 years and for 
uncemented hips 3 years.
At follow-up, average Harris hip 
function scores in the two groups 
were comparable, with no signifi­
cant difference. Rates of loosening 
and component migration as judged 
radiologically were also essentially 
the same in the two groups.
There have been concerns from a 
number of orthopedic surgeons that 
tissue ingrowth prostheses in pa­
tients with rheumatoid arthritis 
would be unsuccessful when com­
pared with cemented prostheses. 
This is because of poor bone in­
growth in patients with rheumatoid 
arthritis and a greater propensity 
for migration due to underlying 
osteopenia and decreased bone met­
abolic activity caused by concomi­
tant anti-inflammatory medication. 
Careful evaluation by the authors of 
these two groups of patients sug­
gests that this concern is not valid 
and that solutions other than ce­
menting could be considered in se­
lecting the appropriate prosthesis 
for patients with rheumatoid arthri­
tis involving the hip.
Although a 5-year follow-up is 
short in terms of durability and 
longevity for hip replacement, the 
fact that both groups had similar 
functional results and radiographic 
appearance suggests that there will 
be no dramatic differences in the 
foreseeable future. The use of unce­
mented implants for total hip re­
placement remains controversial be­
cause of a number of factors related 
to implant geometry, surface tex­
ture and periprosthetic osteolysis, 
which may be related to excessive 
contact between the endosteal sur­
face and the metal alloy of the 
prosthesis. It would appear, based 
on this study, that the use of 
uncemented implants in rheumatoid 
arthritis poses no greater risk of 
complication than cemented im­
plants in a similar patient group.*
QUILL ON SCALPEL
Progress of Parathyroid Surgery in Canada
Nis Schmidt, MD, MSc, FRCSC
Clinical professor and director o f surgical education, Department o f  Surgery. University o f  
British Columbia, Vancouver, BC. Member. Editorial Board, Canadian Journal of Surgery
The first recorded successful pa­rathyroidectomy in Canada was 
for end-stage von Recklinghausen’s 
disease in a bedridden 17-year-old 
girl in Indian Head, Sask.1 The 
procedure was performed under 
local anesthesia by Dr. Gordon 
Fahrni on May 1, 1933. A large 
2.5-cm tumour was located deep to 
the left sternoclavicular joint and 
extracted through the neck inci­
sion. Dr. Fahrni, who celebrated his 
106th birthday on Apr. 13, 1993, 
recounted this story to me again 
during a recent visit to his home. 
There are two important points to 
remember, he cautioned: first, the 
parathyroid tumour may not be in a 
patient’s neck: and second, there is 
no reliable test to locate the tumour 
other than a confident diagnosis 
and a surgeon experienced in para­
thyroid exploration.
Sixty years after that first opera­
tion and in spite of sophisticated 
advances in chemistry, nucleotide 
science and imaging technology, all 
our best tests and efforts do not
exceed the 80th percentile of diag­
nostic confidence and accuracy in 
localizing preoperatively the posi­
tion of a parathyroid tumour in the 
neck.2
In 1929, Dr. Fahrni visited Felix 
Mandl in Salzburg, Austria. He was 
the person credited with under­
standing the relationship between 
von Recklinghausen’s disease and 
parathyroid disease.3 Since then, 
countless clinical studies have been 
reported, comparing the sensitivity 
and reliability of various imaging or 
localizing investigations of parathy­
roid tumours. Yet the most success­
ful localizing procedure still re­
mains a well-executed, methodical 
and usually successful parathyroid 
exploration.
In this issue (pages 241 to 244), 
Yao, Jamieson and Blend report a 
study comparing magnetic reso­
nance imaging with isotope scan­
ning and ultrasonography in preop­
erative localization of diseased para­
thyroid glands. They conclude that 
the low sensitivity and high cost of
these preoperative localization 
study techniques render them un­
necessary in the management of 
uncomplicated parathyroid disease. 
In my experience, I agree complete­
ly. Dr Fahrni agrees also. In compli­
cated and reoperative parathyroid 
surgery, these investigations, espe­
cially ultrasonography followed by 
venous sampling and arteriography, 
are the most helpful localization 
studies available, but in first-time 
parathyroid exploration, surgical 
experience is still the best diagnos­
tic tool available for localizing the 
parathyroid tumour.
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Interval Appendectomy
John K. MacFarlane, MD, FACS, FRCSC
Chairman, Department o f Surgery, St. Paul’s Hospital, Vancouver, BC. Member, Editorial 
Board, Canadian Journal of Surgery
I n this issue (pages 268 to 270), Marya and colleagues examine 
the tradition of “interval appendec­
tomy.” They are to be congratulat­
ed on their thoughtful approach to 
solving the surgical conundrum 
posed by patients who have acute 
appendicitis producing an appen­
diceal mass. The traditional man­
agement of such patients evolved in 
the era of J.B. Murphy, when effec­
tive antibiotic therapy and appropri­
ate and safe anesthesia were rare.
With the evolution of more ag­
gressive surgical approaches to the 
acute gallbladder, to perforated di­
verticulitis and indeed to most intra­
abdominal conditions, it is not sur­
prising that the concept of waiting 
for the devolution of an appendiceal 
mass before removing the appendix 
has been challenged.
The 56 patients seen by the au­
thors between 1989 and 1991 were 
managed either traditionally — by
conservative treatment followed by 
interval appendectomy in 6 to 10 
weeks — or by early appendectomy. 
Unfortunately, Marya and col­
leagues do not tell us how the 
choice was made, and this may 
introduce some bias to the conclu­
sions. However, they have produced 
a convincing study, suggesting that 
early surgery is as efficient as the 
traditional conservative approach.
In three additional patients treat­
ed nonoperatively there was no fol­
low-up, suggesting perhaps that 
their illness had resolved. Two 
other patients in the early operation 
group required surgical drainage of 
an appendiceal abscess, and appen­
dectomy had to be postponed. Both 
groups of patients received the 
same antibiotic regimen.
The authors point to a slightly 
shorter overall hospital stay, a com­
parable postoperative infection rate 
and an earlier return to work for
the early operation group as sup­
porting this approach. A recent re­
port from Nitecki and colleagues1 
lends further support to this con­
cept; they have pointed out the 
utility of modern imaging tech­
niques as further guides to therapy 
and have concluded that elective 
interval appendectomy should be a 
thing of the past.
Once more we see surgical 
dogma being challenged by 
thoughtful and aggressive sur­
geons. It is refreshing to know that 
safe, effective surgical alternatives 
exist for the expeditious manage­
ment of intra-abdominal inflamma­
tory processes such as appendicitis 
with production of a mass.
Reference
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‘ Incidence of major bleeding was not significant. Adapted from Levine
No reported increased bleeding when compared to placebo23
No drug related intraoperative bleeding1...
...because LOVENOX is administered post-operatively1
Dose adjustments usually not required1
□  Almost total bioavailability and linear pharmacokinetics, result in no dose 
adjustments, even in elderly or dialyzed patients.1
Convenient dosage -  prefilled syringe -  30 mg b.i.d. SC
Begin treatment within the first 24 hours following orthopedic surgery. Administer 
1 x  30 mg unit-dose prefilled syringe b.i.d. subcutaneous, in abdomen. Usual duration 
o f treatment is from 7 to 14 days.
□  More than 10 million patients treated worldwide8
’Following orthopedic surgery of the hip and knee.
'Clearly'
Effective
DVT
Prophylaxis*
IELOVENOX
E N O X A P A R I N
PrLOVENOX®
E N O X A P A R I N
THERAPEUTIC CLASSIFICATION
Antithrombotic Agent
ACTION
LOVENOX (enoxaparin) is a low molecular weight heparin fragment, which 
is obtained by controlled depolymerization of natural heparin from porcine 
intestinal mucosa. It possesses antithrombotic action. With an average 
molecular weight of 4,500 Daltons (versus 15,000 Daltons for heparin), the 
enoxaparin molecule is too small to bind simultaneously to thrombin and 
antithrombin III, the primary anticoagulant factor in blood.
The ratio of anti-Xa/anti-lla activity is greater than 4 with enoxaparin, (whereas 
this ratio is equal to 1 with heparin). This dissociation between anti-Xa and 
anti-lla activities has been shown in experimental models with an anti­
thrombotic activity comparable to that of heparin while the bleeding effect is 
reduced. In man, clinical trials have not shown a causal relationship between 
the ratio of anti-Xa/anti-lla activity and clinical/pharmacological effects.
Pharmacokinetics
The pharmacokinetics of enoxaparin have been studied on the basis of plasma 
levels of anti-Xa activity.
Following a single subcutaneous injection, enoxaparin is rapidly and almost 
completely absorbed, with peak plasma activity appearing after 3 hours. 
Maximum anti-Xa levels and AUCs are positively correlated to the dose levels: 
between the doses of 20 and 80 mg s.c., maximum anti-Xa levels range from 
1.58 (±0.35) to 7.44 (± 1.47) ng/mL and the AUCs range from 11.79 (±3.30) 
to 70.76 (±15.49) h.ug.mL-1.
The ti/2 of plasma anti-Xa activity is between 4.18 (±2.21) and 3.46 (±0.86) 
hours and the mean residence time (MRT) of anti-Xa activity is about 6 hours, 
independent of the dose (between 20 and 80 mg s.c.), although anti-Xa 
activity can still be measured after 12 hours.
Information from a clinical trial with a very small number of volunteers 
indicates that enoxaparin, as detected by anti-factor Xa activity, does not 
appear to cross the placental barrier, at least during the second trimester of 
pregnancy.
Following repeated subcutaneous doses of enoxaparin, the T ^  for anti-Xa 
activity remained at 3 hours and there was no evidence of accumulation or 
alterations in distribution and clearance.
Enoxaparin is weakly metabolized in the liver by desulfation and 
depolymerization. Small amounts of the drug are eliminated by the kidneys in 
the intact or slightly degraded form.
In the elderly, peak concentration (T nJ was delayed by approximately 1 hour 
and there was some lengthening of both the apparent half-life (t1/2) and the 
mean residence time (MRT). There were no significant changes in the 
pharmacokinetic profiles of enoxaparin in elderly patients or in hemodialyzed 
patients with renal failure when compared to those of healthy subjects.
The dose and frequency of dosing do not have to be modified in elderly 
patients or dialyzed patients with renal insufficiency.
In non-dialyzed patients with severe renal impairment (mean renal creatinine 
clearance: 11,4mL/min), total clearance of enoxaparin was 1.9 times slower 
and the apparent half-lives of absorption and elimination 1.7 times more 
prolonged than in healthy subjects. These effects suggest that dose modifi­
cations may have to be considered in patients with severe renal impairment 
who are not hemodialyzed, when repeated high doses are required.
INDICATIONS and CLINICAL USE
LOVENOX (enoxaparin) is indicated for the prophylaxis of thromboembolic 
disorders (deep vein thrombosis) following orthopedic surgery of the hip 
or knee.
CONTRAINDICATIONS
-LOVENOX (enoxaparin) must not be administered by the intramuscular 
route.
-Allergy to LOVENOX (enoxaparin).
-Acute or subacute bacterial endocarditis.
-Major blood clotting disorders.
-History of thrombocytopenia with LOVENOX or in patients in whom an in 
vitro platelet-aggregation test in the presence of enoxaparin is positive. 
-Active gastric or duodenal ulcer.
-Hemorrhagic cerebrovascular accident (except if there are systemic 
emboli)
-Severe untreated hypertension.
-Diabetic or hemorrhagic retinopathy.
-Other conditions or diseases involving an increased risk of hemorrhage. 
WARNINGS
LOVENOX (enoxaparin) SHOULD BE USED WITH CARE IN PATIENTS 
WITH HEPATIC INSUFFICIENCY OR A HISTORY OF GASTROINTESTINAL 
ULCERATION.
Use in Pregnancy and Lactation and for Children. The safety of 
LOVENOX in pregnant women and children has not been established, although 
it is known that the drug does not appear to cross the placental barrier at 
least during the second trimester and that it exhibited no embryotoxic or 
teratogenic effects in experimental animals. LOVENOX should not be used in 
pregnant women and children unless the therapeutic benefits to the patients 
outweigh the possible risks.
There has been no experience with LOVENOX during human lactation.
Mothers receiving LOVENOX should avoid breast-feeding.
PRECAUTIONS
LOVENOX therapy should be stopped when epidural anesthesia is considered. 
Patient Monitoring
Platelet counts should be determined prior to the start of treatment with 
LOVENOX and, subsequently, twice weekly for the duration of treatment.
LOVENOX represents an alternative to heparin therapy in patients who have 
developed thrombocytopenia with conventional heparin. Prior to instituting 
LOVENOX, an in vitro platelet aggregation test should be performed.
Although this test is considered to have limitations, it may still be used as a 
guide: with a negative result, treatment with LOVENOX may be instituted, 
but patients must be monitored with particular care, to include platelet counts 
at least once daily. A positive result contraindicates LOVENOX.
As with all anti-thrombotic agents, there is a risk of systemic bleeding with 
LOVENOX administration. Patients should therefore be carefully monitored 
for bleeding complications. This may be done by regular physical 
examination of the patients, close observation of the surgical drain and 
periodic measurements of hemoglobin. Bleeding complications may be 
considered major if hemoglobin is decreased by ^  2g/dL or if a transfusion of 
2 or more units has been required. With normal prophylactic doses, 
LOVENOX does not modify global clotting tests of activated partial 
thromboplastin time (APTT), prothrombin time (PT) and thrombin clotting 
time (TT). Therefore, treatment can not be monitored with these tests.
Interactions. There have been no pharmacologic/toxicologic studies into 
the possible interaction between LOVENOX and other drugs. Because of the 
possibility of an interaction with blood clotting mechanisms, caution should 
be exercised if LOVENOX is combined with any of the following drugs: 
oral anticoagulants, inhibitors of platelet aggregation, nonsteroidal anti­
inflammatory agents, preparations containing acetylsalicylic acid or dextran.
ADVERSE REACTIONS
As with any antithrombotic treatment, hemorrhagic manifestations can occur. 
The incidence of hemorrhagic complications during LOVENOX (enoxaparin) 
treatment has been low.
The following bleeding events have been reported during clinical trials with 
LOVENOX in patients undergoing orthopedic surgery. Numbers in brackets 
denote the total incidence (in numbers of patients) for a population of 
449 patients.
Coagulation System No. Patients (Incidence)
Adverse Effects “Major”* “Minor”
Surgical wound hematoma 6(1.3%) 2 (0.4%)
Surgical wound hemorrhage 1 (0.2%) 0
Bruising 2(0.4%) 2 (0.4%)
Hematoma 1 (0.2%) 2 (0.4%)
Hematemesis 1 (0.2%) 1 (0.2%)
Nosebleed 0 2(0.4% )
Melena 1 (0.2%) 0
Coffee ground emesis 1 (0.2%) 0
Hematuria 1 (0.2%) 1 (0.2%)
Hemoptysis 0 1 (0.2%)
Oozing from wound site 0 1 (0.2%)
Ecchymoses 0 1 (0.2%)
* “Bleeding complication considered major if hemoglobin decreased by 
> 2g/dL or if a transfusion of 2 or more units was required.”
During Canadian clinical trials with LOVENOX, thrombocytopenia was 
reported in rare instances (0.4% of treated patients); see PRECAUTIONS.
Other adverse effects which occurred during treatment with LOVENOX are 
tabulated below:
Body System/Adverse Effects No. Patients (Incidence)
Body as a Whole
Leg pain 1 (0.2%)
Pain in hip 2 (0.4%)
Fever 1 (0.2%)
Cardiovascular
Arrhythmia 1 (0.2%)
Tachycardia 1 (0.2%)
Postural dizziness 1 (0.2%)
Unstable angina 1 (0.2%)
Hypotension 1 (0.2%)
Syncope 1 (0.2%)
Decreased arterial pressure 1 (0.2%)
Digestive
Vomiting 2 (0.4%)
CNS
Confusion 1 (0.2%)
Respiratory
Dyspnea 2 (0.4%)
Chest pain 3 (0.7%)
Hypoxia 1 (0.2%)
Metabolic and Nutritional
Leg edema 11 (2.4%)
Knee edema 2 (0.4%)
Foot edema 2 (0.4%)
Ankle edema 2 (0.4%)
Edema 1 (0.2%)
Leg swelling 1 (0.2%)
Pitting edema 1 (0.2%)
Skin/Appendages
Wound edema 4 (0.9%)
Discharge of surgical wound 4 (0.9%)
Injection site reaction 2 (0.4%)
Inflammation of incision 2 (0.4%)
Laboratory Tests: Values for hemoglobin, hematocrit, RBC and platelets 
generally decreased following surgery and during treatment with LOVENOX. 
These decreases generally parallelled those seen in placebo-treated patients 
and were considered the normal sequelae of major surgery; the observed 
mean values remained within clinically acceptable levels.
Increases in values for glucose and liver enzymes have also been reported 
during treatment with LOVENOX. While these responses may be related to 
the anesthetic and the various stresses related to major surgery, their relation 
to the drug cannot be excluded. The follow ing tabulation illustrates the 
incidence of such abnormalities:
No. Patients (Incidence)
2: 3 times a  6 times
Parameter normal maximum normal maximum
LDH 2 (0.4%)
SGOT 4 (0.9%)
SGPT 7 (1.6%) 3 (0.7%)
Alkaline Phosphatase 4 (0.9%) 1 (0.2%)
Glucose 1 (0.2%)
Total bilirubin 1 (0.2%)
Unspecified liver enzymes 10 (2.2%)
SYMPTOMS and TREATMENT OF OVERDOSAGE
Accidental overdosage of LOVENOX (enoxaparin) by subcutaneous 
administration may result in hemorrhagic complications. The anti-coagulant 
activity of the drug can be neutralized almost completely by administering a 
slow intravenous injection of protamine (either the sulfate or hydrochloride 
salt). The dose of protamine should be identical to the dose of enoxaparin 
injected, that is, 1 mg or 100 units of protamine to neutralize the anti-lla 
activity generated by 1 mg LOVENOX. The anti-Xa activity is never completely 
neutralized (maximum: about 60%). Particular care should be taken to avoid 
overdosage with protamine.
DOSAGE and ADMINISTRATION
Treatment with LOVENOX (enoxaparin) should begin within the first 24 hours 
following orthopedic surgery, as soon as primary hemostasis has been 
established. Administer the contents of one syringe every 12 hours, 
equivalent to 30mg enoxaparin b id . ,  by the subcutaneous route in the 
abdomen. The usual duration of treatment is from 7 to 14 days.
The subcutaneous injection of LOVENOX should be carried out with the 
patient in the decubitus position. Inject in the subcutaneous cellular tissue 
of the anterolateral and posterolateral abdominal girdle, alternatively on the 
left and right sides. With the thickness of skin held between the operator's 
thumb and finger, introduce the entire length of the needle vertically into 
the skin.
Important: The prefilled syringes are ready for use and no attempt should 
be made to expel air prior to giving the injection.
LOVENOX is not to be injected by any other route or added to intravenous 
solutions.
Under normal conditions of use, LOVENOX does not modify global clotting 
tests of activated partial thromboplastin time (APTT), prothrombin time (PT) 
and thrombin clotting time (TT). Therefore treatment cannot be monitored 
with these tests. The plasma levels of the drug can be verified by measuring 
anti-Xa and anti-lla activities.
AVAILABILITY OF DOSAGE FORMS
Prefilled syringes: 30 mg/0.3 mL in boxes of 10 syringes, each in an 
individual blister pack.
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Hematuria and Intravenous 
Pyelography in Children 
After Blunt Renal Trauma
To the editors. The article by Mid- 
dlebrook and Schillinger (Can J 
Surg 1993; 36: 59-62), in which 
they discuss hematuria and intrave­
nous pyelography in pediatric blunt 
renal trauma, requires comment.
In view of the small number of 
children studied, unfortunately 
without any statistical analysis, the 
conclusions are somewhat doubtful. 
It would have been interesting to 
know the total number of intrave­
nous pyelograms obtained for trau­
ma during the period under investi­
gation. The authors also refer to a 
greater propensity for children to 
have pedicle injuries but report no 
such injuries in their series.
Some statements require revi­
sion. For example, if the authors 
are managing children who are 2 
years of age, then a systolic blood 
pressure below 100 mm Hg may 
well be normal and not indicate 
hypotension. They mention that 
most of the injuries in the major 
group in their Table III were identi­
fied by intravenous pyelography. 
More information about the diagno­
sis of hepatic and splenic injuries, 
head injuries, thoracic injuries, and 
so on and their diagnosis by intra­
venous pyelography should have 
been given. Furthermore, in the 
discussion section the authors men­
tion that 73% of patients with trau­
matic hematuria have significant 
other abnormalities that were 
missed by intravenous pyelography. 
The minimal use of ultrasonogra­
phy, especially with Doppler, in this
study detracts from the value of the 
study, since ultrasonography at the 
Children’s Hospital of Eastern On­
tario is usually the first diagnostic 
test to be done in cases of abdomi­
nal trauma. A comparison between 
ultrasonography, intravenous pye­
lography and computed tomogra­
phy would have been more useful.
In the last part of their study, 
Middlebrook and Schillinger look at 
cost saving. For this reason, their 
choice of bed rest in hospital for the 
management of patients with nor­
mal findings on intravenous pyelog­
raphy and minimal hematuria needs 
to be questioned.
Steven Rubin, MD, FRCSC
Children's Hospital of Eastern Ontario 
Ottawa, ON 
K1H 8L1
The Case of Canadian 
General Surgeons
To the editors. In the April 1993 
issue of the Journal (pages 111 to 
113), Marvin Wexler, president of 
the Canadian Association of General 
Surgeons (CAGS), in responding to 
the article by Railton, Tholl and 
Sanmartin (pages 129 to 132), con­
tends that the Canadian Medical 
Association (CMA) “ . . . must make 
a commitment to general surgery to 
lobby politically and economically 
on behalf of that specialty and to 
forget the concept of a unified voice 
for all physicians.” In so doing, he 
further suggests that the CMA take 
the lead from the American Medical 
Association in going to bat for
Canadian general surgeons on com­
pensation issues. Clearly, there is a 
fundamental misunderstanding of 
the message being sent by Railton, 
Tholl and Sanmartin and of the role 
of the CMA.
There is no doubt that the CAGS 
has been playing an active role for a 
number of years in voicing and 
addressing the concerns of general 
surgeons on issues of national im­
portance. Indeed, that fact that 
Railton, Tholl and Sanmartin pub­
lished their work is evidence that 
this message getting through and 
that it is being factored into the 
development of CMA policies at a 
national level. To suggest that the 
CMA preferentially promote the 
cause of general surgeons in discus­
sions about Relative Value Guides is 
to dismiss the exclusive role of the 
CMA’s divisions on matters of fee 
relativities. Such matters are, con­
stitutionally, a provincial/territorial 
jurisdiction! The primary role of the 
CMA is, quite properly, to search 
for consensus across all its provin­
cial and territorial divisions and 
affiliates, including the national 
specialty societies; that is, to serve 
as an honest broker and a national 
voice of medicine.
On the national scene, it is vitally 
important that the medical profes­
sion speak with one voice if its 
message is to be heard by govern­
ments who are working increasingly 
in concert on issues such as physi­
cian resources. This is why the 
CMA engaged in an unprecedented 
process of consultations before pre­
paring its position on national phy­
sician resources planning to the 
Conference of Health Ministers on
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Jan. 27, 1992. The CAGS, as well 
as other national medical bodies, 
had an opportunity to be heard on 
this issue and will continue to be 
consulted on other matters of na­
tional importance.
In terms of the message to indi­
vidual general surgeons across the 
country that they need to “get 
involved,” there is little doubt that 
provincial governments are moving 
aggressively toward regionalized 
and decentralized management ap­
proaches to the health care system, 
including management of physician 
resources. General surgeons and 
other bodies of the medical profes­
sion must ensure that their legiti­
mate concerns and interests are 
represented at this level as well. 
The CMA cannot and should not be 
expected to intervene actively at the 
regional or provincial level. All it 
can do is help bodies within the 
medical profession to carry their 
message by providing the kind of
BOOK REVIEWS 
CRITIQUES DES LIVRES
The following books are also re­
viewed in this issue: Diagnosis of 
Colorectal and Ovarian Carcinoma. 
Application of Immunoscintigraph- 
ic Technology (Targeted Diagnosis 
and Therapy Series/6) (page 265); 
Surgery: Scientific Principles and 
Practice (page 270); Clinical Pedi­
atric Urology, 3rd edition (page 
280); Complications in Head and 
Neck Surgery (page 283); Atlas of 
Gynecologic Surgery (page 283); 
Tracheal Reconstruction in Infancy 
(page 284); Atlas of Laparoscopic 
Surgery (page 284).
OPERATIVE UROLOGY. Edited by 
Fray F. Marshall. 631 pp. Illust. W.B. 
Saunders Company/Harcourt Brace 
Jovanovich, Inc., Philadelphia. 1991. 
$162. ISBN 0-7216-6121-1
Textbooks on operative technique can 
be tedious, if not boring, so it was with 
some degree of trepidation that I set 
out to review this long text on operative 
urology, edited by Dr. Fray Marshall. 
However, after promising myself to 
keep an open mind and setting a course 
through the pages, I was pleasantly 
surprised.
This book covers the full range of 
current operative management of uro- 
logic problems. The text is divided into 
five sections with arguable indistinct 
areas of focus: adult surgery, outpatient 
surgery, pediatric surgery, surgery for 
trauma, and endoscopic surgery and 
extracorporeal shock wave lithotripsy. 
In 85 chapters, a total of 92 authors 
present their areas of expertise. As in 
any text by multiple authors, the quali­
ty of individual chapters varies. Atten­
tion is focused on preoperative evalua­
tion, surgical technique, postoperative 
management and complications.
In general the procedures are well 
illustrated by clear line drawings, al­
though there are scattered intraopera­
tive photographs and figures showing 
the radiologic findings. Each chapter 
gives the individual author’s preferred 
approach and is therefore a biased ac­
count rather than an all-inclusive trea­
tise on the topic presented. References 
supporting the text vary from none to 
many. Brief editorial comments are pro­
vided after most chapters, emphasizing 
critical points of technique and supple­
menting with clinical "pearls” of expe­
rience.
As I reviewed this book it became a 
friendly companion for reference, espe­
cially before infrequently performed sur­
information that Railton, Tholl and 
Sanmartin have captured in their 
article.
Hugh E. Scully, MD, FRCSC, FACS
Chairman
Council on Health Policy and Economics 
Canadian Medical Association 
Ottawa, Ont.
Richard H. Railton, MD, FRCSC
Past-president
Canadian Assocation of General Surgeons 
Past-honorary treasurer 
Canadian Medical Association 
Ottawa, Ont.
gical procedures. Unlike other text­
books of urologic surgery, this one is 
concise enough to allow reading be­
tween cases and sufficiently up to date 
to prevent embarrassment while at the 
mercy of a keen chief resident. Overall, 
this book is ideally suited for both 
practising urologists and urologists in 
training who are looking for a reliable 
reference to operative urology. I would 
not recommend it to the neophyte.
John Pike, MD, FRCSC
Assistant professor of surgery (urology) 
Memorial University of Newfoundland 
Janeway Child Health Centre 
St. John's, NF 
A1A 1R8
WYLIE’S ATLAS OF VASCULAR 
SURGERY: COMPLICATIONS RE­
QUIRING REOPERATION. Vol. 1. 
Ronald J. Stoney and David J. Effeney. 
208 pp. Illust. J.B. Lippincott Co., 
Philadelphia. 1991. $150 (US). ISBN 
0-397-50971-5
Based on the experience and expertise 
of two experienced vascular surgeons 
from the University of California at San
continued on page 265
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Your pulse quickens as you approach 
your Mercedes-Benz 500SL Roadster.
You’ve driven other sports cars 
before, but nothing has prepared you 
for the excitement you feel standing 
before your 500SL.
You walk around the car, marveling 
at the elegant lines that trace a perfect 
shape in gleaming steel.
The thought is exhilarating that 
a shape so satisfy ing should cloak 
performance so awesome.
You anticipate the power that will 
soon be under your control—the silken 
sm oo th n ess  of th e  315hp 5 - litre  
V-8 engine, pressing  you back into 
your seat as it propels you to 100 km /h 
in as little as 6.4 seconds.
In your m ind you see yourself 
breezing along some winding country 
road, the top down, the car gripping 
the road tightly, responding instantly 
to every command, as though it were 
a natural extension of your thoughts.
And you feel the security of know­
ing that here is an open-air car with 
the solidity and safety engineering of a 
Mercedes. A car that takes care of you 
in so many ways: by protecting you 
with energy-absorbing crumple zones 
front and rear; by helping to defend you 
and your passenger with air bags; and 
by arm ing you with a roll bar that 
deploys in about a 1/3 second if the sen­
sor detects that a rollover is imminent.
You open the door and settle into
the leather seat, feeling it grip you 
firmly. You press a button and the seat 
and rear view mirrors customize them­
selves to you, going through a series of 
adjustm ents that you have pre-set.
You fasten your seat belt and sit 
there  for a moment, ad m irin g  the 
perfection of everything around you, 
your senses flooded with expectation.
Then you turn  the key.
For additional information about 
the Mercedes-Benz 500SL, as well as 
the 3-litre 300SL and the V-12 600SL, 
call 1-800-387-4632.
Mercedes-Benz
© 1993 Mercedes-Benz Canada Inc., Toronto, Ont. Member of the Daimler-Benz Group.
HOW I DO IT
COMMENT JE M’Y PRENDS
Technique for Needle Localization Biopsy 
of the Breast
Paul H. Niloff, MD, FACS, FRCSC;* Steven G. Goff, MD, FACS;*
Donald Dewar, MD;t Donald Bane, MDt
W ith the increased use of mam­mography, needle localiza­
tion with excision of abnormal tis­
sue has become one of the most 
frequently performed procedures in 
breast surgery. One of the difficul­
ties often encountered has been 
satisfactory placement of the inci­
sion over the hook wire tip. Com­
pression techniques,1 sonography2 
and intraoperative fluoroscopy3 
have been advocated to achieve sat­
isfactory placement of the incision. 
If the localizer needle is left in situ 
until the patient is in the operating 
room, the needle tip may be palpat­
ed and an appropriate incision se­
lected to achieve the best cosmetic 
result. Both hook wire and methy­
lene blue have been used for the 
localization procedure, and each 
has its proponents.4-6 We use a 
combination of hook wire and dye, 
which allow the accurate removal of 
a minimum amount of tissue, con­
tributing to the cosmetic result.
Technique
All women are outpatients, and 
the procedure is done under local 
anesthesia with monitored anesthe­
sia care. After the radiologist has 
placed the localizer needle in its
final position, 0.2 to 0.3 mL of a 
mixture of 76% iodinated contrast 
and methylene blue in a 50:50 ratio 
in a tuberculin syringe is injected. A 
spring hook (Copan needle) is then 
placed through the localizer needle 
(Fig. 1). A post-insertion mammo­
gram is obtained to confirm the 
location of the radiopaque dye and 
the hook wire (Fig. 2). The localizer 
needle is then securely taped to the
FIG. 1. Needle localization of mammo- 
graphic abnormality.
breast with Steri-Strips (Fig. 3). 
Before transport to the operating 
room, the needle is covered with a 
plastic cup securely taped to the 
breast as an added precaution to 
prevent dislodgement (Fig. 4). The 
cup and Steri-Strips are removed in 
the operating room by the surgeon. 
The localizer needle tip is easily 
palpated, and the area is delineated 
with a marking pen, facilitating an
FIG. 2. Post-insertion mammogram.
From the *Department o f Surgery and f  Department o f  Radiology, Falm Beach Regional Hospital, Lake Worth, Fla., and Palms West Hospital. 
Loxahatchee. Fla.
Accepted for publication Nov. 2. 1992
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appropriate incision (Fig. 5). The 
localizer needle is then removed and 
the patient prepared for operation 
(Fig. 6).
Comment
We have used this technique for 
over 5 years with gratifying results. 
There have been proponents of both 
the hook wire and methylene blue 
techniques;1-2'4 in our experience, a 
combination of the two techniques 
with the addition of radiopaque dye 
has resulted in accurate removal of 
the mammographic lesions with a 
minimal amount of tissue. The pres­
ence of the dye is particularly bene­
ficial if the hook wire becomes 
dislodged as can sometimes happen
in soft, fatty breast tissue. With 
minimal delay in starting the proce­
dure after dye injection, unsatisfac­
tory results due to dye dispersion 
have not been a problem. If the 
localizer needle is left in place until 
the patient is in the operating room, 
a precise, cosmetically acceptable 
incision can be made without the 
need to follow the needle tract or 
dye tract from the point of skin 
insertion. We have not experienced 
any problems with needle dislodge- 
ment during transport.
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ASSOCIATION CANADIENNE DE CHIRURGIENS GENERAUX
Presidential Address, 1992. Life and Times 
of an Urban Surgeon, Circa 1990
Frank W. Turner, MB, ChB, MSc, FRCSC, FACS
After considering some of the successes and failures of the Canadian Association of 
General Surgeons as they relate to the nonacademic surgeon, the author describes 
in detail the practice of one nonacademic urban surgeon to provide a historical 
record and a guide to the educational needs of such surgeons. He compares academic 
and nonacademic surgical practice, emphasizing the perhaps unrecognized benefits 
of the latter. Future change in nonurban general surgical practice is postulated.
Apres avoir examine certains des echecs et des reussites de l’Association canadienne 
des chirurgiens generaux dans la mesure ou ils sont lies au chirurgien non 
enseignant, l’auteur decrit en detail la pratique d’un chirurgien non enseignant en 
milieu urbain pour constituer un historique et un guide des besoins en formation de 
tels chirurgiens. II compare 1’exercice de la chirurgie en milieu universitaire et 
ailleurs, en insistant sur les avantages peut-etre meconnus des autres secteurs de 
pratique. II fait etat des changements qui vont toucher l’exercice de la chirurgie 
generate en region rurale.
I t is an honour and a privilege to address you today.
Casting around for a topic on 
which to speak to you, my first 
thought was to debate the relevance 
of the Canadian Association of Gen­
eral Surgeons (CAGS) to the ''run- 
of-the-mill” practising general sur­
geon. I have been actively involved 
in the CAGS in one form or another 
since its inception in 1977. I have 
watched as it has striven to become 
the voice of general surgery in 
Canada, and there have been many 
successes, particularly in the field 
of education. Yet it remains a tru­
ism that about one-third of the 
general surgeons in this country 
see no need to belong to the CAGS 
and many of those who do belong 
wonder just what the Association 
does for them. This problem, I 
believe, is almost insurmountable in 
a country divided into provincial 
jurisdictions, because what is per­
ceived to be lacking is political 
clout, and that we do not have.
The day-to-day concerns of the 
working surgeon revolve around 
beds and operating time, which are 
strictly local matters, around in­
come, which is a provincial matter,
and around image and preservation 
of territory, which are matters for 
our Association. We have paid lip 
service to improving the image of 
the general surgeon but have in fact 
done little about it. Many of our 
members do not see it as a problem, 
and perhaps they are right. In view 
of the ongoing struggles with gov­
ernment that consume every physi­
cian’s thoughts these days, perhaps 
our image is unimportant. Yet in 
the past we have lost out at the 
bargaining table because we are 
perceived as doing routine, hum­
drum work and have received little
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or no recognition for the hours we 
keep or for the acuity of many of 
our patient’s illnesses. Our name is 
no help — how many of the public 
can distinguish between a general 
surgeon and a general practitioner, 
who frequently lists his or her skills 
as both physician and surgeon? 
How many of us have not been 
asked “Are you a specialist?” In 
future negotiations with govern­
ment it is going to be particularly 
important that we are recognized 
for what we are — highly trained 
surgical specialists. Of some note, 
Barer and Stoddart in their widely 
quoted report1 had trouble with 
this: they referred to the need for 
more “generalist specialists.” Per­
haps we need a new name, but I 
have yet to hear one that is both 
apt and brief.
The problem may solve itself as 
we become conscripts of the civil 
service. I believe pay scales are 
based on qualifications, years of 
training, special skills, and so on, as 
well as on hours worked. Perhaps 
our time is coming!
The need to defend our turf has 
been addressed by the Association, 
but I am disturbed by the prolifera­
tion of narrow subspecialties and 
the impact that this has outside the 
larger teaching hospitals. I recog­
nize the desire of people with simi­
lar interests to band together to 
promote knowledge in their field, 
but it is incumbent upon them to 
propagate such knowledge for the 
benefit of patients in nonacademic 
hospitals. It is absurd, for example, 
to expect that only a colorectal 
surgeon is fit to do proctologic 
surgery. Yet hospital credentialling 
committees and referring practition­
ers are prone to misunderstand 
such certification, seeing it more as 
a paper that excludes others rather 
than denoting its holder as having a 
special interest.
As an aside, I would point out 
one disadvantage of such superspe­
cialization, and again I will use the 
colorectal surgeon as an example. I 
refer to the advent of laparoscopic 
colonic resections, which are in­
creasingly being done by those who 
have honed their skills doing lapa­
roscopic cholecystectomy and ap­
pendectomy. Such skills are not 
easily acquired, and colorectal sur­
geons may find themselves trailing 
well behind in a field in which they 
are supposed to be leaders.
The Nonacademic Urban 
Surgeon
There is one thing that I have 
done which most of you have not, 
and that is to switch ships in mid­
stream, plunging from the stately 
barge of academia to the rocky raft 
of community surgery. Some of you 
will know that I practised for 14 
years on the staff of a university 
hospital and then, for a number of 
reasons that are not germane to 
this discussion, moved to a much 
smaller urban community. This, I 
believe, gives me a unique perspec­
tive, which I would like to share 
with you.
First, I have a word or two to 
offer on the widely used but rarely 
defined term “community sur­
geon.” Generally used to imply a 
nonacademic surgeon who works in 
a smaller urban or rural communi­
ty, such use of the term has led to 
much confusion and misunder­
standing, particularly in the debates 
that rage as to appropriate training. 
A community is, after all, defined as 
a social group of any size whose 
members reside in a specific locali­
ty, share government and have a 
common cultural and historical her­
itage. We are therefore all com­
munity surgeons and should aban­
don this term as a means of desig­
nating those who work in small 
nonurban communities.
Barer and Stoddart1 suggested
that “the culture of tertiary care 
centres re-enforces the view that 
practice in smaller communities im­
plies second class medicine.” Again, 
we are led to believe that there exist 
only two extremes — the tertiary 
care centre and the small communi­
ty. What is being ignored is the 
reality that most of us work in 
neither of these extremes but in the 
huge middle ground of the nonaca­
demic urban hospital.
On occasion since departing the 
world of academic surgery, I have 
been asked by residents just what it 
is like “out there.” They seem 
surprised when I say it really isn’t 
much different. I thought therefore 
that a look at just what 1 did, 
surgically speaking, might help to 
bring into focus what is expected of 
a nonacademic urban-based general 
surgeon. I also thought it might be 
interesting to document this as we 
come to the end of fee-for-service 
practice in Canada, for that is sure­
ly what is happening as govern­
ments seek to control medical costs.
Choices and Restrictions
Let me state right away that no 
practice is typical. We all have 
personal quirks that affect our 
choice of work. For example, I have 
declined to do vasectomies for no 
better reason than I can’t be both­
ered. Other choices are to some 
extent the result of circumstance; 
we have skilled orthopedic and plas­
tic surgeons available so why dilute 
the field of hand surgery even fur­
ther? Some of my colleagues work 
much harder than I from choice, so 
the numbers I present cannot be 
interpreted as a standard.
I live and work in a community of 
70 000 with a referral base of at 
least twice that number. The hospi­
tal has about 400 acute care beds, 
6 active operating rooms, 8 anes­
thetists and 27 surgeons of whom 5
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practise only general surgery. Two 
more do mostly vascular surgery 
but fill in with general surgery in 
times of famine. We have orthope­
dic surgeons, urologic surgeons, 
plastic surgeons, gynecologic sur­
geons and a neurosurgeon, so we 
almost never have to stray seriously 
outside our specialty. Apart from 
choice, my ability to work is limited 
by the availability of operating time; 
I have no designated beds, but with 
the increased usage of outpatient 
and short-stay facilities the limiting 
factor continues to be operating 
time. As I speak today I have about 
100 patients awaiting surgery. For 
example, patients scheduled for 
elective cholecystectomy currently 
wait up to 6 months for admission 
to the short-stay unit.
Surgical Workload, 1990
For this record, I reviewed the 
year 1990, the last year before the 
advent of laparoscopic surgery in 
our community. During that year I 
took 6 weeks off work for holidays 
and 2 weeks for maintaining compe­
tence. In addition, our hospital re­
sponds to budgetary shortfalls by 
closing operating rooms, and I 
would estimate a further 2 weeks 
were lost because of this restriction.
In 1990 I was referred a total of 
663 new patients, two-thirds of 
whom were seen in the office and 
one-third in the hospital. I carried 
out 461 major procedures in the 
operating room. In addition, I as­
sisted other surgeons on 58 occa­
sions. This can be a most instruc­
tive experience and one that is 
frequently lacking in the teaching 
hospital. The opportunity to work 
with surgeons trained in different 
schools doing things in ways you 
never would can be fascinating — 
especially when their patients seem 
to do just as well as your own 
despite the “errors” that were com­
mitted. This need for assistance also 
provides an opportunity to work 
outside the field of general surgery 
and, if nothing else, allows a 
glimpse of just how much of the 
operating-room budget is consumed 
by prosthetics and equipment in 
other specialties.
I will not detail all the procedures 
done — my aim is simply to indi­
cate the scope and balance of one 
surgeon’s practice. As you might
T a b le  1. S urg ica l P ro ce d u re s  P e r fo rm e d  
D u rin g  1 990
Procedure No.
H e rn io rrha p h y 1 1 5
C h o le c y s te c to m y 66
A p p e n d e c to m y
B reas t
B reas t b io p s y  (w ith  o r  w ith o u t
23
lo c a liza tio n ) 63
P artia l o r  to ta l m a s te c to m y 2 6
A x illa ry  d is se c tio n 24
G y n eco m a s tia  e x c is io n  
C o lo re c ta l
5
R ig h t h e m ic o le c to m y 12
L e ft h e m ic o le c to m y 4
A n te r io r re se c tio n 8
A b d o m in o p e rin e a l re s e c tio n  
P ro c to c o le c to m y  a n d /o r  to ta l
6
c o le c to m y 4
H a rtm a n n ’s p ro ce d u re  
M is ce lla n e o u s  re s e c tio n s  fo r
2
C ro h n ’s d isease 8
L a p a ro to m y  fo r  o b s tru c tio n  
P an c re a to b ilia ry
12
C h o le c y s to je ju n o s to m y 2
C h o le d o c h o je ju n o s to m y 4
P an c re a tic  re sec tion 2
P ancrea tic  d ra inage  
G a s tric
2
G a s tro je ju n o s to m y 4
G a s tric  re se c tio n 6
P y lo ro p la s ty 1
V a g o to m y 3
F u n d o p lic a tio n  
H ead and neck
3
T h y ro id e c to m y 16
P a ra th y ro id e c to m y 11
P a ro tid e c to m y 2
C o n ge n ita l ne ck  c y s ts  
P ha ryn goesophagea l
2
d iv e r t ic u le c to m y  
A n o re c ta l and pe rinea l
1
H e m o rrh o id e c to m y , f is s u re c to m y  
T ra n sa n a l e xc is io n  o f re c ta l
12
tu m o u rs 3
E xc is io n  o f p ilo n id a l s in u s  
M is ce lla n e o u s
5
A d re n a le c to m y  
S p le n e c to m y  (h e m a to lo g ic
2
d isease ) 2
In tu s s u s c e p tio n 2
expect, the bills were paid by 
“hernias and gallbladders” (Table 
I). Breast surgery is also a major 
component. Bowel surgery looms 
large in my recollection, but the 
figures don’t meet my expectations! 
Pancreatobiliary procedures were 
poorly represented in 1990. Gastric 
procedures as you might expect are 
now much less common. Head and 
neck procedures, in my opinion, 
remain in the realm of general sur­
gery. Anorectal and perineal disease 
were not major problems. Miscella­
neous but fun-to-do procedures in­
cluded adrenalectomy, splenectomy 
for hematologic disease and surgi­
cal reduction of intussusceptions.
Notable by its infrequency was 
venous surgery, our vascular sur­
geons having commandeered that 
field. Notably, I did not do any 
orthopedic, urologic or neurologic 
surgery. In the course of other 
procedures I did carry out three 
salpingo-oophorectomies and one 
hysterectomy.
Also notable by its absence was 
endoscopy. Although we occasion­
ally slip a gastroscope down in the 
operating room and do not regard 
this as requiring any skill not ordi­
narily available to a surgeon, I 
belong to the generation that mis­
takenly did not have time for endos­
copy and had left the work to 
others. The CAGS has, of course, 
taken a very active role in remedy­
ing this error.
Academic Versus Nonacademic 
Urban Hospitals
So wherein lie the differences 
between the work I do and that of 
surgeons in tertiary care centres? 
The most obvious difference is in 
balance, witness the number of her­
nia repairs. More importantly, in the 
nonacademic urban hospital we are 
not burdened with the mishaps of 
“elsewhere general” or with the
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general surgical emergencies devel­
oping in patients on specialized 
units such as cardiac and transplant 
units. Strangely, there is relatively 
little trauma. We do have motor 
vehicles, but most of the injuries in 
those who survive motor vehicle 
accidents seem to involve the head 
or limbs. Personal violence is not 
common in our community and 
what there is seems to be carried 
out with knives rather than guns.
Now to the pleasures of practis­
ing outside a teaching hospital. My 
colleague, Dr. Charles Lye, in his 
presidential address to the Canadian 
Society of Vascular Surgeons in 
1991, said “Community surgery is 
less hectic than academic surgery, if 
only because one’s agenda is more 
focused. Patient care is generally 
the only major concern’’ (personal 
communication, 1992). Deadlines 
for lectures, clinical presentations, 
publications, grant applications and 
so on do not interfere with the 
primary function of patient care.
The lack of students and house- 
staff also brings about a significant 
reduction in stress. In the teaching 
hospital setting, I came to know 
and respect a large number of fine 
young doctors, and I do not wish to 
demean them. Their company was 
stimulating and it was rewarding to 
help them attain their surgical 
skills. But, there is no doubt that it 
is more efficient and less stressful 
to work without them. Overall I 
think that patients are better served 
by the undivided care of their at­
tending surgeon. When problems 
occur, solutions are sought immedi­
ately from the surgeon in charge 
and do not have to work their way 
through several layers of house- 
staff. Surprisingly, there are few 
night calls — probably because of 
anticipation by the surgeon and 
increased self-reliance on the part of 
the nursing staff in the absence of 
housestaff.
In the operating room, assistance
is provided by another surgeon for 
the more difficult procedures. A 
second assistant is almost never 
required; a good mechanical retrac­
tor does all that a second assistant 
can do and never tires. Operating 
times are relatively short, which 1 
firmly believe is to the patient’s 
benefit. To document this, I looked 
at the skin-to-skin times of two 
representative procedures, in each 
instance taking the last 10 consecu­
tive cases, whether fat or thin pa­
tients, male or female (Table II).
Of incidental note, our x-ray 
technicians provide excellent sup­
port and are usually in the room 
exactly when needed.
Before I moved to Kelowna, 
Roger Cumming, with whom I was 
to share a practice, warned me that 
my patients would “do better in the 
smaller hospital,” and so it seems. 
Complications are rare enough to 
be a source of great consternation 
when they do occur. This apparent 
well-being is, of course, strictly sub­
jective, and it may be that similar 
patients now do just as well in 
teaching hospitals. We all use anti­
biotics more intelligently, provide 
better pain control and, at least in 
my own case, have learned how 
infrequently nasogastric tubes and 
drains are really needed. More and 
more surgery is done on an outpa­
tient basis, and even those patients 
who are admitted stay for a much 
shorter period which, despite the 
occasional family protest, seems to 
be to their benefit.
For those with a research bent, it 
is possible to carry out clinical trials 
in smaller hospitals, either by con­
tributing patients to large multicen­
T a b le  II. R e p re se n ta tive  O pera ting  T im e s
M ean  tim e
P rocedure (ran g e ), m in
Open c h o le c y s te c to m y  w ith  
ch o la n g io g ra p h y  
A n te r io r re s e c tio n  fo r
3 6  (29  -  50)
c a rc in o m a 79  (63  -  95 )
tre trials or by making up your 
own. There tends to be less paper 
to shuffle and fewer committees to 
convince. For example, I have long 
doubted the value of the ritualistic 
antiseptic skin preparation that is 
so universally a part of the operat­
ing-room routine. We have all ob­
served that clean lacerations in un­
prepared healthy skin rarely become 
infected. So Dr. Cumming and I 
simply arranged that on our pa­
tients who were to undergo clean 
elective surgery, an antiseptic skin 
preparation would or would not be 
used according to a random card 
selection determined by the circulat­
ing nurse. The results confirmed 
our expectation, and here I will 
indulge the president’s prerogative 
to bypass the Program Committee 
and show them to you.
Five hundred and ninety-three 
patients were randomly assigned 
into two groups. Group 1 received 
standard skin preparation in the 
operating room with chlorhexidine. 
In group 2 this preparation was 
omitted. Patients receiving prophy­
lactic or therapeutic antibiotics and 
those with disease predisposing to 
infections were excluded. Follow-up 
was complete. The principal opera­
tive procedures as you might expect 
were cholecystectomy (180 pa­
tients) and inguinal herniorrhaphy 
(184 patients). Overall infection 
rates were; 0.7% in group 1 (2 of 
295 patients) and 1.0% in group 2 
(3 of 298 patients). Both rates 
would normally be considered ac­
ceptable for clean, elective surgery, 
and the results suggest that omis­
sion of routine skin “degerming” 
does not predispose to infection. 
Obviously, the numbers are small, 
and a much bigger study would be 
needed to make them meaningful. I 
show them to you not for their 
scientific values so much as to 
illustrate how questions can be 
posed and answers sought outside 
the larger teaching hospital.
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When I made the transition from 
big city to little city, I thought, or 
perhaps hoped, that it would be 
necessary from time to time to refer 
the more difficult patients to the 
tertiary care centre. In reality, this 
happens very infrequently and then 
only for very specialized care; typi­
cal examples are major burns, pa­
tients in need of transplants, sick 
neonates and so on. With the odd 
exception, patients will do almost 
anything to avoid a move from their 
home community. 1 would like to 
quote one other example. I am 
constantly surprised how many 
women will choose to have a breast 
removed rather than face 4 weeks 
of radiotherapy in a city that is only 
a 4-hour drive away.
Before concluding this descrip­
tion of small-city hospital life, I 
would like to bring to your atten­
tion the very real value of having 
family practitioners in the hospital. 
Their knowledge of the patient’s 
home situation, previous illnesses, 
medications taken and work-related 
stresses can be of immense value in 
understanding the patient’s reaction 
to an illness. In addition, family 
practitioners virtually take over the 
care of the terminally ill and look 
after most of the communication 
with patients’ families.
Because I am not burdened with 
teaching and research commit­
ments, I have time to pursue activi­
ties outside medicine. My wife and I 
run a small business, which has the 
advantages of providing a common 
interest and, particularly for me, 
contact with healthy people who are 
not meeting me with fear in their 
hearts. This business will also, I
hope, provide the pension I do not 
otherwise have!
I have not dwelt upon the disad­
vantages of small city practice be­
cause they really are few. A more 
conscious effort is needed to stay 
up to date. In the teaching hospital, 
colleagues and housestaff constant­
ly report and analyse new ideas and 
techniques. In the nonacademic 
world, it is sometimes more difficult 
to maintain perspective, particularly 
when the information is provided by 
a commercial source. But by attend­
ing meetings such as this it is 
usually possible to obtain the unbi­
ased information we need both to 
stay competent and to avoid huge 
expenditures on equipment that 
may only represent a passing fad.
So that is what I do. Historians 
are always interested in exactly 
what people did as opposed to what 
they said they did. So they may be 
interested to know that for doing 
what I did, I earned a gross income 
of $209 000 which after overhead 
and taxes translated into $102 000 
take-home pay. I will not comment 
further on the remuneration except 
to say that I live well, and this 
income only looks paltry in light of 
the truly extraordinary incomes 
achieved by colleagues in other spe­
cialties.
Future Considerations
Obviously what I have described 
to you is not the life and times of a 
small-town/rural surgeon, but I be­
lieve it is more representative of the 
typical general surgeon of today 
and tomorrow. I do not believe the
isolated small-town surgeon can 
continue to exist. We are not train­
ing surgeons for that type of prac­
tice, nor do I believe the new gener­
ation of surgeons will seek that 
kind of life. I also do not believe 
that governments will fund the 
technology that will increasingly be 
needed; such expensive equipment 
will only be provided in regional 
centres where several surgeons in­
cluding those of other disciplines 
can put it to full use — in today’s 
terms, make it cost effective.
And let us make no mistake 
about the future. The field of lapa­
roscopic surgery is exploding, and 
those who do not take time to 
master its intricacies are doomed to 
see their practices wither away as 
the consumer demands referral to a 
surgeon skilled in its techniques.
This need for regionalization, I 
know, begs the question of who will 
look after the acutely ill or trauma­
tized patient when the roads are 
blocked by snow and planes can’t 
fly. I suspect this is a relatively rare 
occurrence, and those who choose 
to live in remote areas may have to 
consider such an event in making 
the decision, much as they might 
accept a possibly lower standard of 
education for their children.
In conclusion, may I thank you 
for the privilege of addressing you 
about the profile of an urban sur­
geon in the 1990s.
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Canadian Laparoscopic Surgery Survey
Marvin J. Wexler, MD, FACS, FRCSC; E. John Hinchey, MD, FACS, FRCSC; John Sampalis, PhD; 
Jeffrey Barkun, MD, FRCSC
Objective: To assess the status of laparoscopic general surgery in Canada and the 
training experience and educational needs of Canadian surgeons, particularly with 
laparoscopic cholecystectomy (LC).
Design: All of Canada’s practising general surgeons were surveyed by mail 
approximately 15 months after the general availability of laparoscopic video 
equipment. Questionnaires completed by 736 surgeons form the basis of the 
analysis.
Setting: The respondent profile produced a good sample distribution to assess 
differences related to age, experience, location and type of practice; 30% practised in 
communities of 50 000 or less; 38% in hospitals with 250 or fewer beds and 57% in 
community hospitals.
Results: Eighty-four percent had already learned LC, and 51% of them had 
performed more than 25 LCs. The number performed correlated directly with the 
number of cholecystectomies usually performed yearly before laparoscopy. Age and 
lack of relevance to practice were reasons for not learning. Ninety-one percent took 
formal training courses, usually university sponsored and in Canada. Complications 
were experienced by 44% of respondents. Bile leak (26%), hemorrhage (15%) and 
bile-duct injury (9%) were the most common and increased as the number of 
cholecystectomies usually performed prior to LC increased. Age, sex, type and 
location of hospital and size of city were not significant factors. The data show a 
consistent (p < 0.001) increase in the proportion of surgeons who encountered a 
complication as the number of LCs performed increased.
Conclusions: LC has been introduced in Canada in an unpredicted, rapid and 
seemingly orderly and responsible fashion in all areas, types and sizes of 
communities. It has been equally well applied by surgeons of all ages and size of 
practice whether practising in the smaller community or in the university centre. 
The dogma of complications releated to a “ learning curve”  is not supported by the 
author’s data, and experience with complications is not restricted to the occasional 
biliary surgeon. Continued vigilance is necessary.
Objectif: Evaluer la situation de la chirurgie generate par laparoscopie au Canada 
et l’experience de la formation et les besoins en education des chirurgiens 
canadiens, particulierement en ce qui concerne la cholecystectomie laparoscopique 
(CL).
Conception : Un sondage postal a ete mene aupres de tous les chirurgiens generaux 
qui pratiquent au Canada environ 15 mois apres que des appareils video de 
laparoscopie soient generalement devenus accessibles. L’analyse est fondee sur les 
questionnaires remplis par 736 chirurgiens.
Contexte : Le profil des repondants a produit une bonne distribution dans 
l’echantillon pour evaluer les differences liees a l’age, l’experience, le lieu et le type 
de pratique; 30 % des chirurgiens pratiquaient dans des collectivites de 50 000 
habitants ou moins; 38 % dans des hopitaux de 250 lits ou moins et 57 % dans des 
hopitaux communautaires.
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Resultats : Quatre-vingt-quatre pourcent des repondants avaient deja appris la CL, et 
51 % d’entre eux avaient effectue plus de 25 CL. Le nombre d’interventions 
pratiquees est en correlation directe avec le nombre annuel de cholecystectomies 
habituellement pratiquees avant l’accessibilite a la laparoscopie. L’age et le manque 
de pertinence a la pratique etaient les raisons pour ne pas apprendre cette 
technique. Quatre-vingt-onze pourcent des chirurgiens ont suivi des cours de 
formation officiels, habituellement parraines par des universites au Canada. 
Quarante-quatre pourcent des repondants avaient une experience de complications. 
Les fuites de bile (26 %), les hemorragies (15 %) et les lesions des canaux biliaires 
(9 %) etaient les complications les plus frequentes, et elles ont augmente a mesure 
que s ’accroissait le nombre de cholecystectomies normalement pratiquees avant 
l’accessibilite a la CL. L’age et le sexe du praticien, le type et la situation de l’hopital 
et l’importance de la ville n’etaient pas des facteurs significatifs. Les donnees 
temoignent d’une augmentation constante (p < 0,001) de la proportion des 
chirurgiens qui ont fait face a une complication a mesure que s ’accroissait le nombre 
de CL pratiquees.
Conclusions : La LC a ete adoptee au Canada d’une maniere soudaine, rapide et 
apparemment ordonnee et responsable quels que soient la region, le type et 
l’importance des collectivites. Sa mise en oeuvre par les chirurgiens a ete tout aussi 
appropriee quels que soient leur age et l’importance de leur clientele, dans de 
petites collectivites ou dans des centres universitaires. Le dogme selon lequel les 
complications sont liees a une «courbe d’apprentissage* n’est pas corrobore par les 
donnees de l’auteur, et l’experience des complications ne se limite pas a une 
occasionnelle chirurgie des canaux biliaires. Une vigilance soutenue est de mise.
I t is probable that no new proce­dure in surgery has been intro­
duced more rapidly or has captured 
the interest of the profession and 
patient population alike than lapa­
roscopic cholecystectomy. A recent 
study by the Institute for Scientific 
Information, in which a complex 
co-citation analysis method of the 
1991 scientific literature was used,1 
ranked laparoscopic cholecystecto­
my as the most active field in all of 
science for that year, outranking 
such areas as the effect of serotonin 
on blood vessels and the origin of 
human immunodeficiency virus iso­
lates!
General surgeons came under in­
tense pressure from the public to 
offer them this new technology. 
This vigorous consumer demand 
was exacerbated by the medical in­
dustry and fueled by expectations of 
minimal patient discomfort postop- 
eratively, shorter hospital stay and 
the patient’s almost immediate re­
turn to normal activity. There have 
been a number of reports of compli­
cations, particularly bile-duct inju­
ry, and resulting law suits, which
have led to criticism over the speed 
with which this laparoscopic tech­
nique was introduced.
There is considerable interest in 
how such a new, highly technical 
procedure can be learned and intro­
duced safely into surgical practice. 
The purpose of this survey is to 
assess the status of laparoscopic 
general surgery in Canada and the 
training experience and educational 
needs of Canadian surgeons, partic­
ularly with respect to laparoscopic 
cholecystectomy.
Material and Methods
In April and May 1992, approxi­
mately 15 months after video lapa­
roscopic equipment became general­
ly available in Canada, we mailed 
1400 questionnaires to all practis­
ing Canadian general surgeons, 
who were identified from the updat­
ed Southam database. The ques­
tionnaire was designed to obtain a 
description of the respondents’ pro­
files with respect to the following 
demographic data: location of prac­
tice and hospital affiliation; training 
with respect to laparoscopic chole­
cystectomy; and experience with 
this procedure, including complica­
tions.
Within 6 months of the original 
mailing, 736 completed question­
naires were returned. They form the 
basis of this initial analysis.
Descriptive statistics were used to 
describe the results of the survey. 
Proportions were calculated with 
the number of respondents as the 
denominator; when appropriate the 
denominator used was the number 
of respondents in specific catego­
ries. Differences with respect to the 
distributions of response choices 
between groups of respondents 
were calculated using the x2 statis­
tic. Differences were considered sta­
tistically significant at a probability 
of 0.05.
The unit of analysis in the report­
ed results was the respondent. 
Therefore, all results pertaining to 
the complications experienced are 
presented with the responding sur­
geon as the unit of analysis. In 
interpreting these data, the propor-
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tions reported should not be consid­
ered as rates of complications be­
cause this implies a proportion 
where the procedure or patient is 
the unit of analysis. The data ob­
tained in this survey do not provide 
us with the information required to 
compute these rates. Instead, the 
proportions reported represent the 
number of respondents that have 
experienced the specific complica­
tion in their practice at least once.
Results
Demographic Profile
Table I shows the demographic 
profile of the 736 respondents. 
There was an almost equal distribu­
tion among the three age groups 
with a smaller number (17%) of the 
respondents being over 60 years of 
age. Only 5% of the responding
surgeons were women. Three hun­
dred and fifteen (44%) were located 
in a city with a population over 
250 000; however, almost one-third 
(30%) were practising in communi­
ties with populations of 50 000 or 
less. Although 62% practised in a 
hospital with 251 beds or more, 
over one-third (38%) were in medi­
um or small hospitals with 250 
beds or fewer. The majority of the 
respondents (57%) were practising 
in a community hospital.
Forty-eight percent of the re­
spondents normally performed more 
than 50 cholecystectomies annual­
ly, using all approaches; only 19% 
routinely performed less than 26.
Table I also shows the profile of 
the respondents according to 
whether they had learned laparo­
scopic cholecystectomy (LC) at the 
time of the survey. A significantly 
(p < 0.0001) lower proportion of 
surgeons over the age of 60 years
(65%) had learned this procedure 
compared with the proportions of 
surgeons from the other age cate­
gories (90%). There were no sex 
differences. A significantly (p =  
0.01) lower proportion of surgeons 
practising in cities of over 250 000 
people reported learning LC (81%) 
compared with approximately 90% 
of surgeons who were practising in 
smaller communities. Similarly, 
general surgeons practising in large 
hospitals (more than 500 beds) had 
the lowest proportion learning LC 
followed by surgeons practising in 
very small hospitals (100 beds or 
fewer) (p < 0.0001). Surgeons in 
primary university hospitals showed 
the lowest percentage having 
learned LC (77%) compared with 
those practising in university- 
affiliated hospitals (87%) and those 
practising in community hospitals 
(89%) (p = 0.002).
There was a direct association
Tab le  1. Profile of Respondents and Distribution According to Whether They Learned Laparoscopic Cholecystectomy (LC) (N =  736)
D em ographic  features C ategory T o ta l*
N u m b e r  ( % )
L e a rn e d  LC
Y e s  No p v a l u e t
Age. yr 3 0 - 4 0 189 (26) 169 (90) 19 (10 ) <  0.0001
41 - 5 0 219(30) 201 (92) 18 (8)
51 - 6 0 193 (27) 169 (89) 21 (11)
> 60 121 (17) 75 (65) 40 (35)
Sex Male 666 (95) 569 (86) 89 (14) 0.77
Female 34 (5) 3 0 (8 8 ) 4 (1 2 )
City size (per thousand <  10 41 (6) 36 (88) 5 (1 2 ) 0.01
population) 1 1 - 3 0 99 (14 ) 88 (89) 11 (11)
31 -  50 72(10) 67 (93) 5 (7)
51 -  250 190 (26) 170 (90) 18 (10 )
> 250 315(44) 250 (81) 58 (19)
Hospital size (no. of <  100 79 (11) 6 3 (8 1 ) 15 (19 ) <  0.0001
beds) 101 -  250 194 (27) 179 (94) 12 (6)
251 -  500 251 (36) 2 1 8 (8 8 ) 31 (12)
> 500 184 (26) 143 (79) 38 (21)
Hospital type Primary university 128(18) 96 (77) 29 (23) 0.002
University affiliated 183 (25) 155 (87) 24 (13)
Community 407 (57) 361 (89) 4 4 (11 )
Cholecystectomy, no./yr <  15 63 (9) 22 (37) 37 (62) <  0.0001
prior to LC 1 6 - 2 5 73(10) 58 (81) 14 (19)
2 6 - 5 0 230 (33) 2 0 7 (9 0 ) 2 2 (10 )
> 50 333 (48) 322 (97) 9 (3)
'Colum ns do not equal row totals because some items were not answered by all respondents. 
tThe respondent groups fo r which p values were calculated are outlined in the text.
CJS, VOL. 36. NO. 3. JUNE 1993 219
LAPAROSCOPIC SURGERY SURVEY
between the number of cholecystec­
tomies usually performed annually 
before laparoscopy and the propor­
tion of respondents who reported 
having learned laparoscopic sur­
gery. Only 37% of surgeons who 
performed 15 or fewer cholecystec­
tomies per year learned the laparo­
scopic approach, and this propor­
tion increased to 97% as the num­
ber of cholecystectomies increased 
to over 50 per year (p < 0.0001).
Training Experience
Table II describes the laparoscop­
ic training experience of the 736 
respondents. At the time of survey, 
620 (84%) had already learned LC. 
Of these, 90% had already started 
performing the procedure in pa­
tients. The majority (61%) had 
begun with a more experienced sur­
geon; approximately half started 
with a partner of similar experience, 
whereas under 10% began alone. 
With respect to assistance during 
LC, another surgeon was present 
most frequently (69%), followed by 
a non-surgeon physician (39%) or a 
resident (35%). Nurses or physician- 
assistants were infrequently em­
ployed (in less than 12% of cases).
Lack of equipment was the most 
commonly quoted reason for having 
been trained but not starting lapa­
roscopic surgery among the 64 
(10%) respondents in that category.
Of the responding surgeons, 116 
(16%) had not taken formal laparo­
scopic training. Among these, two- 
thirds had no intention of learning, 
generally because the procedure 
was irrelevent to their practice 
(37%) or because of age and ap­
proaching retirement (33%).
Of the respondents who had 
learned laparoscopic surgery, 91% 
had taken a formal course (Table 
III). The majority (79%) had taken 
a university-sponsored course. In­
dustry or non-university-sponsored 
courses were taken by 15% and 4%
of respondents respectively. The 
majority (88%) had taken their 
course in Canada. Most were ex­
posed to didactic lectures, hands-on 
experience with animals and video­
tapes. Only 44% of trainees had 
direct hands-on experience in hu­
mans as part of their course. Al­
though 461 (74%) of the 620 re­
spondents who received formal 
training felt the course allowed 
them the expertise or confidence to 
commence laparoscopic surgery in 
humans, the majority sought addi­
tional "training” by visiting an ex­
perienced surgeon (clinical precep­
tor) (55%), observing videotapes
T a b le  II. T ra in in g  fo r  LC in R espond ing  
S u rge o n s  (N = 7 3 6 )
P ara m e te r No. (°/o)*
Learned  LC 6 2 0  (84)
Have s ta rte d
p e r fo rm in g  LC 5 5 6  (90)
A lone 52 (9)
S im ila r expe rienced
p a rtn e r 2 6 9 (4 8 )
M ore  e xpe rienced
p ro c to r 3 3 9  (61 )
A s s is ta n t in  LCs
A n o th e r su rgeon 3 8 2 (6 9 )
N o n -su rg e o n
p h ys ic ia n 2 1 8 (3 9 )
R e s ide n t 195  (35 )
P hys ic ia n  a ss is ta n t 5 5 (1 0 )
N urse 6 6 (1 2 )
N o t ye t s ta rte d  LC 6 4 (1 0 )
because  o f
La ck  o f e q u ip m e n t 28  (44 )
Lack o f p riv ile g e s 6 (9)
La ck  o f co n fid e n c e 2 (3)
La ck  o f p a tie n ts 3  (5 )
La ck  o f in te re s t 3 (5 )
No re leva n ce  to
p ra c tice 7 (1 1 )
T im e  co n s u m in g 2 (3 )
O the r 2 0 (3 1 )
H ave n o t lea rned  LC 1 1 6 (1 6 )
P lan to  learn  LC 4 0  (34)
D o n o t p lan  to  learn LC 7 6  (66)
because  o f
La ck  o f e q u ip m e n t 4  (5 )
Lack  o f p riv ile g e s 1 (1 )
Lack  o f co n fid e n c e 2 (3 )
Lack  o f p a tie n ts 3 (4 )
Lack  o f in te re s t 7 (9 )
No re leva n ce  to
p ra c tice 28 (37 )
T im e  c o n s u m in g 3 (4 )
O the r (age,
re tire m e n t, e tc ) 25  (3 3 )
(57%) and proctorship in their own 
hospital with a laparoscopic sur­
geon (48%). Additional courses, ex­
perience with animals, training 
boxes and sponsored symposia by 
major organizations were infre­
quent sources of additional training 
and were considered to be of least 
value. Similarly, reading the litera­
ture, although fequently performed, 
was thought to be of lesser value.
Laparoscopic Practice Profile
Of the 556 respondents who had 
started performing LC, 286 (51%) 
had already performed more than 
25 operations; 158 (28%) had per­
formed more than 50 operations 
(Table IV). Only 107 (19%) had 
performed 10 or fewer LCs. The 
number of procedures attempted is 
outlined according to the surgeon’s 
demographic profile. Surgeons in 
larger cities and larger hospitals
T a b le  III. M e th o d s  o f Lea rn ing  
L a p a ro s co p ic  S urge ry  in R esp o n d en ts  W ho  
R ece ived Form a l T ra in in g  (n = 6 2 0 )
P ara m e te r No. (% )
Had ta ke n  a cou rse 5 6 4  (91 )
T y p e  o f co u rse
U n iv e rs ity  spo n so re d 4 4 5  (79 )
In d u s try  spo n so re d 8 2 (1 5 )
N o n -u n iv e rs ity  ho sp ita l 22  (4)
L o ca tio n
Canada 4 9 6  (88 )
U n ited  S ta te s 61 (1 1 )
E urope 5 (1 )
C o m p o n e n ts
D id a c tic  lec tu res 5 4 5  (97 )
A n im a ls  (hands on) 542  (96 )
V id e o tap e s 5 1 4 (9 1 )
H u m a n s  (h ands on ) 2 4 8  (44 )
H um ans (o b se rva tio n
o n ly ) 196 (35 )
A d d it io n a l tra in in g
V id e o tap e s 3 2 3 (5 7 )
L ite ra tu re  rev iew 3 1 6 (5 6 )
V is ite d  experienced
su rg e o n 3 0 9 (5 5 )
P ro c to rs h ip  in ow n
h o sp ita l 2 6 8 (4 8 )
T ra in in g  bo x 1 1 3 (2 0 )
A d d it io n a l an im a l labs 9 0 (1 6 )
S econd  cou rse 7 9 (1 4 )
S ym p o s ia 7 7 (1 4 )
O the r 45  (8)
R es idency 17 (3)
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were more likely to have performed 
more than 50 LCs. Surgeons in 
primary university or university- 
affiliated hospitals were also more 
likely to have performed at least 50 
LCs. The number of LCs performed 
directly correlated with the number 
of cholecystectomies usually per­
formed every year before the intro­
duction of LC. All of these associa­
tions are statistically significant (p 
< 0.003).
Experience and Complications
The majority (71%) of surgeons 
used a closed (Veress) needle tech­
nique for pneumoperitoneal access. 
An open (Hasson) method was used 
by only 40%. The majority of sur­
geons selectively used intraopera­
tive cystic duct cholangiography 
during LC, 3% used it routinely and 
33% never used it (Table V).
A substantial number of surgeons 
had experienced complications. Of 
the 556 respondents who performed 
LC, 142 (26%) reported at least one 
bile leak and 84 (15%) reported 
hemorrhage as a major complica­
tion. Bile-duct injury was reported 
by 50 (9%) respondents, peritonitis 
by 20 (4%) and bowel injury by 21 
(4%), vascular injury by 10 (2%) and 
death related to LC by 3 (1%). No 
correlation was found between fail­
ure to perform operative cholangi­
ography and the development of 
biliary complications.
The possible association between 
respondent profile and the propor­
tion of respondents who said they 
experienced one of the seven com­
plications listed was examined. 
These data showed that the propor­
tion having a complication was not 
different when age, sex, size of 
practice and type of hospital or size
of city in which they practised were 
considered. Although there was a 
trend of respondents from larger 
cities having a higher proportion
T a b le  V . E xp e rie n c e  A m o n g  R e s p o n d e n ts
W h o  P e r fo rm e d  LC  (n = 5 5 6 )
P a ra m e te r N o . (% )
T e ch n iq u e  o f p n e u m o p e r ito n e a l
a cc e ss
C lo sed  (V e re s s  n e e d le ) 3 9 2  (7 1 )
O pen (H a ss o n  m e th o d ) 2 2 2  (4 0 )
D is p o s a b le  t ro c h a rs 1 0 5 (1 9 )
N o n d is p o s a b le  t ro c h a rs 1 2 9  (2 3 )
D is p o s a b le  and
n o n d is p o s a b le  t ro c h a rs 1 5 3  (2 8 )
C h o la n g io g ra p h y
N eve r 1 8 6  (3 3 )
S e le c tive 3 5 7  (64 )
A lw a y s 13 (2 )
C o m p lic a tio n s
B ile -d u c t leak 1 4 2  (26 )
H e m o rrh a g e 8 4 (1 5 )
B ile -d u c t in ju ry 5 0  (9 )
B ow e l in ju ry 21 (4 )
V a s c u la r in ju ry 10  (2 )
P e r ito n it is 2 0  (4 )
D eath 3 (1 )
T a b le  IV . P ro file  o f 5 5 6  R e sp o n d en ts  W h o  P e r fo rm e d  LC A c c o rd in g  to  th e  N u m b e r A tte m p te d
D em ographic  fea tu res Category <  10
LCs a tte m p ted , no. (% )  
11 -  2 5  2 6  -  50 >  5 0 p  v a lu e d
N o. o f re sp o n d e n ts 1 0 7 (1 9 ) 161 (2 9 ) 1 2 8  (2 3 ) 1 5 8  (2 8 )
Age, y r 3 0 - 4 0 2 7 (1 8 ) 39 (2 5 ) 3 7  (2 4 ) 51 (3 3 ) 0 .5 3
41 - 5 0 3 2 ( 1 8 ) 48 (2 7 ) 41 (2 3 ) 5 5 ( 3 1 )
51 - 6 0 31 (2 0 ) 4 7 ( 3 1 ) 3 5  (2 3 ) 3 8  (2 5 )
>  60 1 4 (2 0 ) 26  (3 8 ) 1 5 ( 2 2 ) 1 3 ( 1 9 )
Sex M a le 9 8 ( 1 9 ) 148 (2 9 ) 1 2 4  (2 4 ) 1 4 2  (2 8 ) 0 .2 4
Fem ale 6 ( 2 5 ) 1 0 (4 2 ) 2 (8 ) 6 ( 2 5 )
C ity  size (pe r th o usa n d <  10 8 ( 4 0 ) 6 ( 3 0 ) 3 ( 1 5 ) 3 ( 1 5 ) <  0 .0 0 0 1
po p u la tio n ) 1 1 - 3 0 1 9 (2 5 ) 32 (4 2 ) 1 4 ( 1 8 ) 1 1 ( 1 4 )
31 - 5 0 1 8 (3 0 ) 1 9 (3 2 ) 1 1 (1 8 ) 1 2 ( 2 0 )
51 -  250 2 9 (1 8 ) 4 9 ( 3 1 ) 3 8 ( 2 4 ) 4 4  (2 8 )
>  2 5 0 3 2  (14 ) 50 (2 2 ) 5 6  (2 5 ) 8 8  (3 9 )
H o sp ita l size (no . o f  beds) <  100 1 2 (2 4 ) 20 (4 0 ) 9 ( 1 8 ) 9 ( 1 8 ) 0 .0 0 0 1
101 - 2 5 0 4 0  (2 5 ) 54 (3 4 ) 3 5  (2 2 ) 2 9 ( 1 8 )
251 -  500 34  (1 7 ) 55 (2 7 ) 4 7  (2 3 ) 6 8  (3 3 )
>  5 0 0 1 7 (1 3 ) 29 (2 3 ) 31 (2 4 ) 5 0  (3 9 )
H osp ita l type P rim a ry  u n iv e rs ity 1 6 (2 0 ) 1 7 (2 1 ) 1 9 (2 3 ) 2 9  (3 6 ) 0 .0 0 3
U n iv e rs ity  a f f ilia te d 1 7 (1 2 ) 38 (2 6 ) 3 7  (2 5 ) 5 5  (3 7 )
C o m m u n ity 71 (2 2 ) 1 0 5 (3 3 ) 70  (2 2 ) 7 3  (2 3 )
C h o le cy s te c to m y , n o . /y r <  15 1 0 (7 7 ) 2 ( 1 5 ) 1 (8 ) 0  (0 ) <  0 .0 0 0 1
p rio r to  LC 1 6 - 2 5 2 7 ( 5 1 ) 2 3 ( 4 3 ) 3  (6 ) 0  (0 )
2 6 - 5 0 41 (2 3 ) 77 (4 4 ) 4 5  (2 5 ) 14  (8 )
>  50 2 8  (9 ) 57 (1 8 ) 7 8  (2 5 ) 1 4 4  (4 7 )
'N u m b e rs  do  n o t a lw a ys  to ta l c o r re c t ly  because s o m e  ite m s  w e re  n o t answ e red  b y  a ll re s p o n d e n ts . 
tT h e  re sp o n d e n t g ro u p s  fo r  w h ic h  th e  p va lu es  w e re  ca lcu la te d  are o u tlin e d  in th e  te x t.
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reporting a complication, the num­
bers were not statistically signifi­
cant.
The number of respondents re­
porting a bile-duct leak, bile-duct 
injury, vascular injury or hemor­
rhage during laparoscopic surgery 
increased as the number of chole­
cystectomies usually performed per 
year, prior to laparoscopy, increased 
(Table VI). With respect to bile-duct 
leak, 33% of the surgeons who 
performed more than 50 cholecys­
tectomies annually by all approach­
es reported experience of this com­
plication with the laparoscopic 
method compared with 20% to 23% 
for those who performed 16 to 50 
LCs annually and only 9% for those 
who performed 15 or fewer LCs 
annually (p = 0.018). Similarly, 
with bile-duct injuries, 15% of the 
respondents who usually performed 
more than 50 LCs a year had
experience with this complication 
laparoscopically compared with 2% 
to 4% for those performing between 
16 and 50 LCs annually (p = 
0.001). Only surgeons who per­
formed more than 50 cholecystecto­
mies a year had experience with 
vascular injury (10 surgeons [4%]) 
(p = 0.04).
Table VI also shows the propor­
tion of respondents who reported 
complications, according to the 
method of initiating LC, the type of 
assistant used and the number of 
LCs attempted. These data indicate 
that a relatively higher but not 
statistically significant proportion 
of surgeons who began LC alone or 
with a similarly experienced sur­
geon reported bile-duct leak or inju­
ry compared with those who began 
this procedure with a more experi­
enced proctor. The surgical experi­
ence of a first assistant did not help
to avoid complications. The data do 
show a consistent and statistically 
significant (p = 0.0001) increase in 
the proportion of respondents who 
encountered bile-duct leak, bile- 
duct injury, hemorrhage or perito­
nitis as the number of LCs per­
formed increased.
The proportion of respondents 
reporting laparoscopic complica­
tions was compared with the cha­
racteristics of the training course 
taken. No association was found 
between the proportion of surgeons 
indicating complications and the 
components of the laparoscopic 
course taken. This finding was simi­
lar whether the course was taken in 
the United States or Canada. A 
higher proportion of respondents 
who took a course at a non-univer­
sity hospital reported bile-duct 
leaks (45%) compared with a uni­
versity- or industry-sponsored
Table VI. Complications Reported Versus Method of Initiation, Assistant and Experience With LC and Cholecystectomy Prior to LC*
Complication, no. (%)
Parameter
Bile-duct
leak
Bile-duct
injury
Bowel
injury
Vascular
injury
Hemor­
rhage
Peri­
tonitis Death
Cholecystectomy, no./yr
prior to LC
< 15 1 (9) 0 (0) 1(8) 0(0) 2(17) 0 (0) 0(0)
1 6 - 2 5 10 (20) 2 (4) 0(0) 0(0) 2 (4) 0 (0) 0(0)
2 6 - 5 0 37 (23) 4 (2) 5(3) 0(0) 22(13) 4 (3) 1(1)
> 50 
p valuet
94 (33) 
(0.018)
43 (15) 
(<0.001)
15(5) 10(4)
(0.04)
58 (21) 
(0.015)
16 (6) 2(1)
Initiation
Alone 14(30) 8(17) 2(4) 2(4) 8(17) 2 (4) 0(0)
Similarly experienced
colleague 76 (31) 25 (11) 14(6) 5(2) 53 (22) 12 (5) 2(1)
More experienced
proctor 72 (24) 23 (8) 7 (2) 6(2) 42(14) 8 (3) 1 (0.3)
Assistant
Another surgeon 85 (25) 25 (7) 15(4) 6(2) 51 (15) 13 (4) 1 (0.3)
Non-surgeon physician 64 (32) 20(10) 9(5) 3(2) 39 (20) 5 (3) 0(0)
Resident 55 (32) 24 (14) 8(5) 5(3) 23(14) 11 (7) 3(1.8)
Nurse 18(29) 4 (6) 2(3) 1(2) 13(21) 1 (2) 0(0)
Physician assistant 14(32) 8(17) 1(2) 4(9) 14(30) 3 (7) 0(0)
LCs attempted, no.
<  10 9 (9) 0 (0) 2(2) 0(0) 6 (6) 0 (0) 0(0)
11 - 2 5 28(19) 5 (4) 4(3) 1(1) 15(10) 0 (0) 0(0)
2 6 - 5 0 35 (31) 16(14) 6(5) 5(5) 21 (18) 6 (6) 0(0)
> 50 70 (47) 29 (20) 9(6) 4(3) 42(10) 14(10) 3(2)
p valuet (0.0001) (0.0001) (0.06) (0.0001) (0.0001) (0.06)
'Numbers do not always total correctly because some items were not answered by all respondents. 
tThe respondent groups for which significant p values were obtained are indicated -  see text.
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course (27%). This was also true for 
peritonitis (16% versus 3% to 4%).
Of the 556 surgeons who had 
performed LC, 245 (44%) had expe­
rience with one or more of the 
complications (Table VII). Of these, 
176 (32%) had experience with only 
one type of complication, 46 (8%) 
had experience with two different 
complications and 19 (3%) had ex­
perience with three types of compli­
cation. There was no significant 
clustering of types of complications 
reported by individual surgeons. 
Experience with any one complica­
tion did not increase the likelihood 
of having experience with any other 
type of adverse event.
Discussion
Within 15 months of the ready 
availability of video laparoscopic 
equipment in Canada, 85% of gener­
al surgeons responding to our ques­
tionnaire had already learned and 
most were already performing LC. 
More than 50% of those performing 
the procedure had performed over 
25 procedures, most being assisted 
by another general surgeon. The 
majority of those who had not yet 
learned LC had no intention of 
doing so, usually for reasons of age 
or lack of relevance to their prac­
tice. The reasons for the significant­
ly smaller proportion of those in 
large cities or hospitals and univer­
sity-based surgeons having failed to 
learn the technique is probably re­
lated to the more specialized inter­
ests or practice of surgeons in this 
environment. This reasoning is sup­
ported by the significant correlation 
between having learned LC and the 
number of cholecystectomies usual­
ly performed each year prior to LC.
The entire community of Canadi­
an general surgeons in both urban 
and rural practice, like their Ameri­
can counterparts, were quick to see 
the potential of the new minimal 
access surgery and to acquire the 
skills necessary for its performance. 
Our respondent profile is skewed 
toward the younger surgeon but 
with a relatively good sample distri­
bution to assess differences possibly 
related to size of hospital, size of 
community and type of practice 
(whether academic or community 
oriented). Thirty percent of respon­
dents practised in smaller communi­
ties of 50 000 or less, 38% in 
hospitals with 250 or fewer beds 
and 57% in a community hospital 
without university affiliation. The 
data show that 91% of surgeons 
took a formal training course, usu­
ally university sponsored and in 
Canada. This often did not include 
hands-on human experience. De­
spite feeling confident to begin 
human or clinical application, most 
surgeons followed the training with 
additional operative experience with 
proctors in their own or other insti­
tutions.
The rate of the major complica­
tions associated with this procedure 
from the patient's standpoint is im­
possible to determine from this sur­
vey. However, complications have 
been experienced by a number of 
surgeons. Forty-four percent re­
ported one or more complications. 
Bile-duct leakage, hemorrhage and 
bile-duct injury were the most com­
mon. Surgeons who initially learned 
laparoscopic surgery with a more 
experienced proctor were less likely 
to report experience with complica­
tions later in their practice.
The data suggest that experience 
with complications is not restricted 
to the occasional biliary surgeon 
but rather the surgeon who tradi­
tionally performed the largest num­
ber of cholecystectomies per year. 
Moreover, the data do not support 
the concept that most complications 
occur during the supposed inexperi­
enced phase. Rather, there is a 
continuing relationship between the 
number of LCs attempted and the 
proportion of surgeons experienc­
ing a complication. None of the 107 
surgeons (19% of respondents) who 
had attempted 10 or fewer LCs 
reported experience with a bile-duct 
injury. Only 5 of the 161 surgeons 
who performed 11 to 25 LCs (2996 
of respondents) had experience with 
a duct injury whereas 16 of the 128 
surgeons (23% of respondents) who 
attempted 26 to 50 LCs and 29 of 
158 (28% of respondents) who did 
more than 50 LCs had experience 
of a duct injury. Our data do not 
allow us to know at what point in 
each surgeon’s experience the com­
plication occurred. Despite this,
T a b le  V I I .  Distribution of Complications Reported
C o m p lic a tio n s ,
no.
R e s p o n -  
d e n ts , no.
(%)
C o m p lic a tio n , n o .
D e a th
B ile -d u c t
le a k
B ile -d u c t
in ju ry
B o w e l
in ju ry
V a s c u la r
in ju ry
H e m o r ­
rh a g e
P e r i ­
to n it is
1 176 (32) 90 25 9 5 44 3 0
2 46 (8) 36 12 5 2 27 8 2
3 19 (3) 17 10 7 2 15 6 0
4 3 (0.5) 3 3 0 0 2 3 1
5 1 (0.2) 1 1 0 1 1 1 0
Total 245 (44) 147 51 21 10 89 21 3
'Percent of total no. of respondents who performed LC (556)
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given the equal distribution of LCs 
attempted across groups and the 
stable technology over the short 
survey period, we may assume that 
the correlation found indicates that 
the popular notion of bile-duct inju­
ry being due to a surgeon’s “learn­
ing curve” is incorrect. With more 
experience the surgeon may at­
tempt more difficult cases and be 
less disposed to convert to open 
surgery in the face of a technical 
challenge. Also, bile-duct injury is 
not a phenomenon of the surgeon 
practising in a smaller hospital or a 
community with a lesser or inade­
quate volume of cases. Indeed, 
whereas proportionately more LCs 
were done in larger cities, larger 
hospitals and university or universi­
ty-affiliated centres, the proportion 
of surgeons from these areas re­
porting complications was similar to 
the proportion from the smaller, 
peripheral or rural hospitals. The 
view that this high-technology sur­
gery practised in smaller communi­
ties results in a less successful
SESAP VII Question /  Question SESAP VII
Item 169
Which of the following statements about pseudomembranous colitis is TRUE?
(A) The carrier rate for Clostridium difficile is 30% in healthy adults
(B) The disease can be caused by C. difficile in patients without antibiotic exposure
(C) Stool cultures are the preferred method of establishing a diagnosis
(D) The disease commonly can be caused by organisms other than C. difficile
(E) The disease is best treated with intravenous antibiotics
For the five answers given above select the one that is best.
For the critique of Item 169 see page 250.
(Reproduced by permission from SESAP ’92-’93 Syllabus; Surgical Education and Self-Assessment Program 
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College 
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
outcome is not supported by our 
findings.
Conclusions
LC has been introduced into the 
repertoire of the Canadian general 
surgeon in an unprecedented, rapid, 
yet seemingly orderly and responsi­
ble manner in all areas, types and 
sizes of communities. Although the 
number of surgeons reporting a 
complication appears surprisingly 
large, the data are reported from 
the surgeon’s rather than the pa­
tient’s perspective. With the excep­
tion of bile-duct or vascular injury, 
most complications have proved to 
be of minor consequence to the 
patient. They are not the result of 
too rapid a transition from animal 
to human in an irresponsible man­
ner as suggested by some lay crit­
ics.
This technique has been equally 
well applied by the surgeon in the 
smaller community as it has in the
tertiary care centre. Although older 
surgeons and those with subspecial­
ty interests have been reluctant and 
to embrace this new technology, it 
is clear that LC has been undertak­
en by surgeons of all ages and 
levels of experience with equal suc­
cess. The oft-perpetuated dogma of 
complications being related to the 
“learning curve” is not supported 
by our data. It is anticipated that 
further improvements in visual 
technology and instrumentation will 
decrease the number of complica­
tions. However, national, education­
al and training guidelines are essen­
tial. Continued vigilance is neces­
sary as the indications and applica­
tions of this new approach are 
extended.
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►
l Intravenous Regional Anesthesia
► in the Treatment of Forearm and Wrist 
* Fractures and Dislocations in Children
I Wayne A. Colizza, MD, CM; Edward Said, MD, FRCSC
Objective: To evaluate the efficacy and safety of intravenous regional anesthesia in 
the treatment of unilateral closed fractures and dislocations of forearm or wrist in 
children.
Design: A prospective study over 6 years.
Setting: The study was undertaken in the well-equipped emergency department of a 
community general hospital for ambulatory patients.
Patients: One hundred and thirty-nine children between the ages of 4 and 18 years 
with unilateral closed fractures and dislocations of forearm or wrist.
Intervention: All children received premedication with a combination of meperidine 
and promethazine (0.5 m g/kg intramuscularly) and regional upper limb anesthesia 
with 0.5% lidocaine solution (3 m g/kg intravenously) after inflation of an arm 
tourniquet.
Main Outcome Measures: The relief of pain, allowing closed reduction with 
intravenous regional anesthesia, and the incidence of complications.
Results: All patients had complete relief of pain allowing successful closed reduction 
in 133 patients (96%); tourniquet pain occurred in 10 patients (7%). There were no 
symptoms of lidocaine toxicity. There were no neurovascular or compartment 
syndrome complications.
Conclusions: Intravenous regional anesthesia for the treatment of fractures and 
dislocations of forearm and wrist in children was found to be simple, safe and 
effective.
Objectif: Evaluer l’efficacite et Tinnocuite de l’anesthesie regionale par voie 
intraveineuse, dans le traitement des fractures unilaterales fermees et des luxations 
au niveau du coude ou du poignet, chez l’enfant.
Conception : Une etude prospective d’une duree de 6 ans.
Contexte : L’etude a ete menee dans un sevice d’urgence bien amenage d’un hopital 
general communautaire pour patient ambulatoire.
Patients : Cent trente-neuf enfants ages de 4 a 18 ans souffrant de fractures 
unilaterales fermees et de luxation du coude, de l’avant-bras et du poignet. 
Intervention : Tous les enfants ont re?u une premedication constitute d’une 
association de meperidine et de promethazine (0,5 m g/kg par voie intramusculaire) 
et une anesthesie regionale du membre superieur a l’aide d’une solution de lidocaine 
a 0,5 % (3 mg/kg par voie intraveineuse) apres gonflement d’un garrot autour du 
bras.
Mesure des principaux resultats : Le soulagement de la douleur permettant une
From the Division o f  Orthopedic Surgery, Department o f  Surgery, McGill University, Montreal, Que.
Accepted for publication Nov. 19, 1992
Reprint requests to: Dr. Edward Said, Associate professor o f surgery, McGill University, Shriners Hospital fo r Crippled Children, 1529 Cedar Ave., 
Montreal, QC H3G 1A6
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reduction fermee sous anesthesie regionale intraveineuse, et la frequence des 
complications.
Resultats : Tous les patients ont eu un soulagement complet de la douleur 
permettant de reussir une reduction fermee chez 133 patients (96 %); une douleur 
due au garrot est survenue chez 10 patients (7 %). Aucun signe de toxicite a la 
lidocaine n’a ete observe. 11 n'y a eu aucune complication neurovasculaire ou 
syndrome des loges.
Conclusions : L’anesthesie regionale intraveineuse pour le traitement des fractures 
et dislocations du coude, de l’avant-bras et du poignet chez l'enfant s’est averee 
simple, sure et efficace.
C urrently, general anesthesia and hematoma block are the most 
common means of achieving anes­
thesia in the treatment of childhood 
upper limb injuries. Hematoma 
block is painful, and often relief is 
incomplete. When general anesthe­
sia is chosen primarily or in cases of 
hematoma block failure, admission 
to hospital is necessary, substantial­
ly increasing the cost of care and 
risk to the patient. In addition, 
treatment is often delayed because 
of the relatively low operative prior­
ity of these injuries or because the 
child has recently been fed.
Intravenous regional anesthesia 
in children has yet to gain wide 
support despite reports, though few 
in number, demonstrating its safe 
and effective application.1' 5 Objec­
tions to the use of intravenous 
regional anesthesia in children stem 
from concerns about patient coop­
eration, toxicity of lidocaine and 
failure of equipment or technique.
A prospective study was under­
taken to evaluate the efficacy and 
safety of intravenous regional anes­
thesia in the treatment of childhood 
forearm and wrist injuries.
Patients and Methods
During the 6 years 1985 to 
1991, all children who presented 
with upper limb fractures and dislo­
cations at or distal to the elbow and 
were treated by the senior author 
only were included in the study. 
Children with bilateral or open inju­
ries were excluded. The study pro­
tocol was in accordance with ap­
proved institutional guidelines.
Technique
The children’s parents were en­
couraged to remain at the bedside 
to provide support and facilitate 
patient compliance. All children re­
ceived a combination of meperidine 
and promethazine, 0.5 m g/kg in­
tramuscularly, as premedication. A 
single sphygmomanometer cuff, 
with continuous pressure monitor­
ing, was applied to the upper arm 
and attached to a simple hand-held 
pump to lessen the risk of tourni­
quet failure during transport to and 
from the radiology department (Fig. 
1). A butterfly needle of appropriate 
size was inserted into a dorsal hand 
vein of the injured limb and the 
tourniquet inflated to 200 to 225 
mm Hg. A solution of 0.5% lido­
caine at a dose of 3 m g/kg was 
injected intravenously. Closed re­
duction was undertaken, a below- 
elbow cast applied and radiography 
performed. The tourniquet was de­
flated 30 minutes after the lidocaine 
injection, and the cast was complet­
ed to the above-elbow level if neces­
sary. Patients were discharged from 
the emergency department usually 
within 30 minutes after completion 
of the treatment. They were ob­
served for symptoms of acute lido­
caine toxicity: nausea, vomiting, 
tinnitus, blurred vision, twitching 
or convulsions. The hand was 
checked for acute swelling, return 
of finger motion and capillary circu­
lation before discharge. Parents
were given detailed written instruc­
tions and urged to bring the child 
back to the emergency department 
if excessive swelling developed.
Results
Over the study period 139 chil­
dren (94 boys, 45 girls) were treat­
ed. They ranged in age from 4 to 
18 years (mean 10.5 years) (Fig. 2).
The most common injuries (66% 
of all fractures and dislocations of 
the forearm and wrist) were com­
bined fractures of the radius and 
ulna at the level of either the distal 
diaphysis or metaphysis (Table I). A 
spectrum of injury severity from 
angulated to completely displaced 
fractures was encountered and 
treated successfully by this tech­
nique (Fig. 3).
There were no failures of anes­
thesia. All patients had complete 
relief of pain. One tourniquet failure 
occurred at 15 minutes of tourni­
quet application, but no deleterious
w
FIG. 1. Single-cuff sphygmomanome­
ter attached to simple hand-held pump 
served as tourniquet.
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anesthetic side effects were noted.
Of the 139 children, 133 (96%) 
underwent successful reduction of 
their injuries in the emergency de­
partment with this anesthetic tech­
nique. All patients were released 
from hospital after their treatment. 
No overnight hospitalizations were 
necessary.
Reduction failed in six patients, 
all with combined fractures of radi­
us and ulna, necessitating admis­
sion to hospital and general anes­
thesia. Closed reduction was suc­
cessful in one child, but the remain­
ing five required open reduction and 
internal fixation. Soft-tissue inter­
position was found in three of these 
five patients.
Three patients with distal diaphy­
seal fractures of both the radius and 
ulna were found to have loss of
reduction at 1 week follow-up. 
These fractures, once again, were 
successfully reduced under intrave­
nous regional anesthesia.
There were no significant compli­
cations. Ten children (7%) had se­
vere tourniquet pain necessitating 
release of the tourniquet after 25 
minutes. The tourniquet was re­
leased after 30 minutes in the re­
maining patients. There were no 
symptoms or signs of lidocaine tox-
T a b le  1. Types and Frequency of Injuries 
Treated
In ju ry  type No. of c a s es
Distal diaphyses of radius and 
ulna 60
Distal metaphyses of radius 
and ulna 32
Distal epiphyses of radius and 
ulna (Salter l / l l) 24
Mid-diaphyses o f radius and 
ulna 14
Anterior dislocation of radial 
head 3
Trans-scaphoid, perilunate 
fracture dislocation 3
Proximal phalanx of index 
finger 1
Voiar dislocation of distal 
radioulnar jo in t 1
Posterior dislocation of elbow 1
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Age, yr
FIG. 2. Age distribution of children treated.
FIG. 3. (Left) Prereduction radiographs of forearm fracture in 8-year old boy. Note complete displacement of fracture fragments. 
(Right) Same extremity after satisfactory reduction and casting under intravenous regional anesthesia.
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icity. Seven patients (5%) had exces­
sive swelling within the the first few 
days after treatment for which their 
casts were bivalved. There were no 
neurovascular or compartment syn­
drome complications.
Discussion
The results of this study demon­
strate that intravenous regional an­
esthesia is a safe, easily adminis­
tered, well tolerated and effective 
method for the treatment of wrist 
and forearm injuries in children. 
Patient cooperation is best obtained 
through reassurance and careful ex­
planation of the technique, sedative 
premedication and the presence of 
the parent throughout the treat­
ment.
A single-cuff tourniquet with 
continuous pressure monitoring, at­
tached to a simple, hand-held pump 
is simple to use and is well tolerat­
ed.1-2 Double-cuff systems do allow 
for greater patient comfort, particu­
larly during interventions longer 
than 45 minutes.3 Because of the 
30-minute tourniquet time in our 
study, a double cuff was not re­
quired.
Lidocaine, when injected into the 
limb venous system, rapidly enters 
and diffuses through the extracellu­
lar fluid and muscle mass.6 This 
occurs in spite of minimal blood 
flow within the limb. Such phar­
macokinetics likely explain the ab­
sence of symptoms in our patient in 
whom the tourniquet failed at 15
minutes and in other similar report­
ed cases.5-7
It has been suggested that lido­
caine at a dose of 3 m g/kg poses a 
risk of toxicity in the outpatient 
setting.8-9 Our study does not sup­
port this finding nor do other 
studies in which the dose of lido­
caine equalled or even exceeded 3 
m g/kg.1-5 When lidocaine is given 
at this dose, the peak plasma lido­
caine concentration is reached 5 
minutes after tourniquet release and 
averages 1.4 jug/mL, with a maxi­
mum 2.7 /ug/mL.10 Plasma lido­
caine levels must exceed 4.4 
Mg/mL for signs of toxicity to 
develop.10
A 0.5% lidocaine solution was 
used rather than a 1.0% solution11 
in the belief that the increased 
volume improves the anesthesia, 
particularly in the younger child 
who requires a smaller dose.
In this study, intravenous region­
al anesthesia with 0.5% lidocaine 
solution at a dose of 3 mg/kg was 
a safe, effective and well-tolerated 
method of anesthesia for the treat­
ment of forearm and wrist fractures 
and dislocations in children. The 
technique is simple and easily per­
formed in the emergency depart­
ment by the orthopedic surgeon. It 
reduces hospital costs by avoiding 
admission.
We recommend that intravenous 
regional anesthesia be the anesthet­
ic method of choice in the treat­
ment of forearm and wrist fractures 
and dislocations in children. This 
method is not recommended for
bilateral or open fractures or out­
side well-equipped emergency de­
partments.
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Total Hip Arthroplasty in Rheumatoid 
Arthritis: Comparison of Cemented 
and Uncemented Implants
Patrick G. Kirk, MD; Cecil H. Rorabeck, MD, FRCSC; Robert B. Bourne, MD. FRCSC;
Brian Burkart, MD, FRCSC
In a group of patients who underwent total hip arthroplasty because of rheumatoid 
arthritis, the outcome in 42 hips was assessed. There were 17 cemented and 25 
uncemented prostheses. The average follow-up was 5 years for cemented prostheses 
and 3 years for uncemented prostheses. The average Harris hip scores were similar 
in the two groups (84 and 86 respectively). Radiologically, the incidence of 
migration of femoral and acetabular components was similar in the two groups. 
Component migration was not affected by component fixation. Uncemented implants 
may have a role in hip arthroplasty in patients with rheumatoid arthritis.
Dans un groupe de patients qui avaient subi une arthroplastie complete de la hanche 
pour cause de polyarthrite rhumatoi'de, on a evalue les resulats obtenus sur 42 
hanches. On comptait 17 protheses cimentees et 25 protheses non cimentees. Le 
suivi moyen a ete de 5 ans pour les protheses cimentees et de 3 ans pour les 
protheses non cimentees. Les indices moyens a l’echelle de la hanche de Harris ont 
ete similaires pour les deux groupes, soit 84 et 86 respectivement. A la 
radiographie, la frequence des migrations des composantes femorales et 
acetabulaires a ete semblable dans les deux groupes. La migration des composantes 
n’a pas ete affectee par leur mode de fixation. Les protheses non cimentees peuvent 
avoir un role a jouer dans les arthroplasties de la hanche pour les patients souffrant 
de polyarthrite rhumatoi'de.
T otal hip arthroplasty is a suc­cessful procedure in patients 
with rheumatoid arthritis. Long­
term follow-up studies have shown 
good implant survival in patients 
with cemented implants.1-3 Unger 
and colleagues3 reported a success 
rate of 80% after 12 years. In the 
study of Poss and colleagues,1 96% 
of patients had relief of pain after 
operation.
Uncemented implants were intro­
duced in the hope that biologic 
fixation would provide optimal fixa­
tion and prevent failures associated 
with cemented implants, thus pro­
longing implant survival. The early 
reports of total hip arthroplasty in 
which uncemented devices were 
used included patients with rheuma­
toid arthritis but did not separate 
them from the other patients.4-5 The 
purpose of this review is to evaluate 
the role of uncemented hip implants
in patients with rheumatoid arthri­
tis and to compare the results ob­
tained in these patients with those 
in a group of patients with cement­
ed components.
Patients and Methods
Between 1981 and 1989, 48 pa­
tients with rheumatoid arthritis un­
derwent total hip arthroplasty. In
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total, 52 hips were implanted. 
Twenty-five hips had a cemented 
implant (group 1) and 27 had an 
uncemented implant (group 2); the 
choice of implant was not prospec­
tively randomized and was the pref­
erence of the surgeon.
The age of patients in group 1 
ranged from 33 to 77 years (aver­
age 60 years). The follow-up was 
adequate for 17 hips (8 left and 9 
right) in this group. Three patients 
had inadequate radiographs for 
complete review; however, they did 
have Harris hip scores beyond 2 
years postoperatively. Five patients 
had neither adequate radiographs 
nor clinical follow-up. The type and 
number of prostheses inserted were 
as follows: HD2, 14; Harris- 
Galante, 2; Mallory-Head, 1.
The age of patients in group 2 
ranged from 24 to 71 years (aver­
age 57 years). The follow-up was 
adequate for 25 hips (8 left and 17 
right) in this group. Two patients 
could not be located. The type and 
number of prostheses inserted were 
as follows: PCA, 19; Mallory-Head, 
5; CLS (Protek), 1.
Follow-up included clinical and 
radiologic review. Clinical review 
consisted of Harris hip scoring and 
pain and function subscoring. Radi­
ologic review involved evaluation of 
preoperative, 6-week postoperative 
and most recent radiographs. On 
the postoperative radiographs, ace­
tabular and femoral components 
were evaluated as follows: The tear­
drop was used as a fixed reference 
point on the pelvis to evaluate the 
acetabular component.6-8 The verti­
cal and horizontal positions of the 
cup were determined as previously 
described.8 The position of the cup 
on the most recent radiograph was 
compared with that on the 6-week 
radiograph. A change of more than 
2 mm was defined as migration. 
Acetabular abduction was mea­
sured, and the most recent film was 
compared with the 6-week film.
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Radiolucencies about the acetabular 
component were also measured. For 
the cemented components, radiolu­
cencies greater than 2 mm involv­
ing 50% to 99% of the implant were 
defined as possible loosening, and 
global radiolucencies greater than 2 
mm were defined as probable loos­
ening.910
Radiographic review of the femo­
ral component consisted of mea­
surement of vertical stem position 
from a fixed point on the femur on 
both the 6-week and final radio­
graphs. A change in vertical posi­
tion of 5 mm or more was defined 
as subsidence. Change in compo­
nent alignment (varus or valgus) 
was also recorded. In the cemented 
components, radiolucencies were 
measured, and in the uncemented 
implants sclerotic lines were mea­
sured. Radiolucencies greater than 
2 mm involving 50% to 99% of the 
zones defined by Gruen11 were con­
sidered possible loosening. Like­
wise, lucencies greater than 2 mm 
globally around the prosthesis were 
considered probable loosening, and 
a shift in the component was con­
sidered as definite loosening.10
For the uncemented implants, 
which were primarily of the PCA 
type, evaluation of prosthesis fit as 
described by Callaghan, Dysart and 
Savory4 was made. No analysis of 
metaphyseal filling could be made 
on the anteroposterior radiograph 
because of lack of endosteal defini­
tion. If on the anteroposterior ra­
diograph the stem came in contact 
with the endosteum and on the 
lateral radiograph two of the three 
points of contact were made by the 
stem with the endosteum, the fit 
was good; if there was no contact 
with the endosteum and no three- 
point contact on the lateral film, the 
fit was poor.
Correlation between the Harris 
pain score and radiologic findings 
for the acetabular and femoral com­
ponents was attempted.
Results
For group 1 implants, the aver­
age follow-up was 5 years (range 
from 2 to 8 years). For group 2 
implants, the average follow-up was 
3 years (range from 2 to 7 years).
In group 1 patients, the average 
Harris hip score was 84 (range from 
70 to 97). The average pain score 
was 43 with no patient having a 
score less than 40. The average 
function score was 33 (range from 
18 to 45). Eight hips were rated 
excellent (90 to 100); two hips were 
rated good (80 to 89); seven hips 
were rated fair (70 to 79). There 
were no poor results in this group. 
The three patients who did not have 
adequate radiographs but had clini­
cal scores with a follow-up longer 
than 2 years had Harris hip scores 
of 66, 83 and 100. In all of these 
hips, the pain score was 44.
In group 2 patients, the average 
Harris hip score was 86 (range from 
60 to 100). The average pain score 
was 42; two hips in one patient had 
scores of 30, and the remainder had 
scores of 40 or 44. The average 
function score was 36 (range from 
16 to 47). Fourteen hips were rated 
excellent (90 to 100); 3 hips were 
rated good (80 to 89); 4 hips were 
rated fair (70 to 79); and 4 hips 
were rated poor. There were no 
ratings less than 60.
There were no failures or revi­
sions in either group.
Evaluation of the acetabular com­
ponent in group 1 hips demonstrat­
ed that four hips had superior mi­
gration of the component greater 
than 2 mm. In no hips was there 
medial migration greater than 2 
mm. In two patients there were 
radiolucencies greater than 2 mm in 
two of three zones of DeLee and 
Charnley.9 One of these hips had 
superior migration of 8 mm. There 
was no pain in the four cemented 
hips with superior migration (pain 
scores of 44 for all). The overall
Harris scores were 71, 72, 87 and 
97.
In group 2 hips, three acetabular 
components had superior migration 
greater than 2 mm. Two of them 
were in one patient, and the pain 
score for both hips was 30; the pain 
score for the third hip was 44. One 
hip had medial migration greater 
than 2 mm, associated with a pain 
score of 40. No patient had a 
sclerotic line with a gap greater 
than 2 mm in any of the acetabular 
zones.
Two group 1 hips had subsidence 
of the femoral component greater 
than 5 mm. One hip had radiolucen- 
cies greater than 2 mm in four of 
the seven zones of Gruen. This 
patient had femoral subsidence of 8 
mm but no pain. The other patient 
with subsidence greater than 5 mm 
also had no pain. Thus, two hips 
had radiographic evidence of defi­
nite loosening but were pain free.
Three group 2 hips had subsi­
dence of the femoral component 
greater than 5 mm (pain scores 40, 
40 and 30). Two of these hips had a 
good fit based on anteroposterior 
and lateral radiographs. Overall 
only 7 hips had a good fit, and the 
remaining 18 had a poor fit on 
either anteroposterior or lateral ra­
diographs. No hip had a sclerotic 
line with a gap greater than 2 mm 
in over 50% of the femoral zones. 
One patient in this group had acute 
subsidence of the component (10 
mm) within the first 6 weeks.
Discussion
Previous reports of total hip ar­
throplasty in patients with rheuma­
toid arthritis have shown good re­
sults.312' 14 With a 12-year follow­
up, Unger and colleagues3 reported 
a 16.7% revision rate for infection 
and mechanical loosening. Of the 
hip implants that survived, results 
were satisfactory in 97%. Likewise,
HIP IMPLANTS IN RHEUMATOID ARTHRITIS
Poss and colleagues1 reported that 
96% of patients had satisfactory 
results after 7 years of follow-up. In 
our entire group of patients, 90% 
had satisfactory results based on 
Harris hip scores. Two of the four 
patients with a poor rating had no 
pain and had low overall scores due 
to decreased function. The other 
two poor scores were in one patient 
with moderate pain. This patient 
had bilateral uncemented implants. 
The range of overall Harris hip 
scores and the average scores of 84 
and 86 are lower than scores ob­
tained for osteoarthritis because of 
the decreased functional ability of 
patients with rheumatoid arthritis.
The radiographic results in our 
two groups were interesting. There 
were no revisions for loosening of 
the implants in either group. Subsi­
dence of the femoral component 
was defined as a change in the 
vertical placement of the stem 
greater than 5mm, as previously 
described by Callaghan and associ­
ates.6 Subsidence was seen in both 
groups. Two femoral components in 
the cemented hips had definite loos­
ening with migration of the stem 
greater than 5 mm but were asymp­
tomatic. Three of the stems in the 
uncemented hips had subsidence 
but without a sclerotic line, and 
thus may have been loose, but 
specific criteria for loosening of this 
type of implant have not been de­
fined.
Acetabular migration was seen in 
both groups. Two acetabular com­
ponents in the cemented group had 
radiographic lucencies in two of 
three zones and one of these had 
migrated. Thus, one of the cement­
ed acetabular components was defi­
nitely loose, and the other was 
defined as possibly loose. The two 
other cups that migrated had no 
radiolucencies greater than 2 mm. 
None of these four patients in 
group 1 had pain, and none of the 
four patients in group 2 whose
acetabular cups migrated had pain. 
Acetabular migration in total hip 
arthroplasty for rheumatoid arthri­
tis occurs more frequently when the 
centre of rotation of the hip is not 
restored.1213 We did not correlate 
the original position of the acetabu­
lum with those components that 
migrated.
Acetabular failure has been re­
ported to be higher than femoral 
component failure in patients suf­
fering from rheumatoid arthritis 
compared with patients suffering 
from osteoarthritis.1'2,13'15'16 Long­
term studies have reported a slight­
ly higher failure rate of the acetabu­
lar component in those with rheu­
matoid arthritis than in those with 
osteoarthritis. In patients with 
rheumatoid arthritis who underwent 
cemented hip arthroplasty, Unger 
and colleagues3 reported acetabular 
loosening in 16% of hips compared 
with femoral loosening in 2% of 
hips. In a 10-year follow-up of 
cemented hips 35% (6 of 17) of 
patients with rheumatoid arthritis 
had acetabular loosening, a rate 
that was higher than in patients 
with osteoarthritis.16 Poss and col­
leagues1 also postulated a higher 
rate of acetabular failure after 5 
years.
This review has demonstrated 
that the incidence of component 
migration was the same for cement­
ed and uncemented hips with re­
spect to both acetabular and femo­
ral components. One postulated 
theory for migration of implants is 
that the migration may be due to 
periarticular osteopenia in patients 
with rheumatoid arthritis. Bogoch 
and associates17 have described in­
creased osteogenesis in an animal 
model of inflammatory arthritis. 
They noted a marked increase in 
osteoclastic activity with more 
newly formed bone than in nonarth- 
ritic animals. This newly formed 
bone may not be able to withstand 
the loads around the joint, and
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certainly protrusio is a common 
condition in rheumatoid arthritis. 
The method of implant fixation may 
not have an impact on migration.
In reports of uncemented total 
hip replacement, small numbers of 
patients with rheumatoid arthritis 
have been included. Engh and Mas- 
sin5 included 46 patients with rheu­
matoid arthritis in their series of 
343 hips; 74% of these hips had 
radiographic evidence of bone in­
growth in contrast to 82% of hips 
in patients with osteoarthritis. Two 
preliminary studies of uncemented 
total hip arthroplasty in patients 
with rheumatoid arthritis with very 
short follow-up reported good re­
sults clinically and radiological-
ly.14.18
Although we recognize that our 
series was not randomized, some 
conclusions may be drawn. There 
was no difference in the clinical 
outcome between cemented and 
uncemented components. Compo­
nent migration occurred in both 
groups. Overall, good results were 
obtained with cemented and unce­
mented hips. With advances in the 
understanding of bone ingrowth im­
plants and the indications for unce­
mented devices postulated on femo­
ral morphology,19 the same criteria 
for an uncemented device should be 
applied to the patient with rheuma­
toid arthritis.
Surprisingly, in the group with 
uncemented implants, only seven 
had a good fit of the prosthesis.
The remaining 18 prostheses were 
undersized, and in this circum­
stance one would expect subsidence 
and later failure. However, our re­
sults with an average follow-up of 3 
years show this may not be the 
case. A cemented femoral stem is 
likely the best alternative for pa­
tients with rheumatoid arthritis 
when the femoral geometry will not 
accept an uncemented stem.
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A cute Mesenteroaxial Gastric Volvulus 
in an Infant: A Case Report
Wojciech Brzezinski, MD, FRCSC;* Mervin M. Laskin, MD, FACS, FRCSC;t Kan S. Wong, MDf
Only 52 cases of gastric volvulus have been reported in children and infants. The 
pathophysiology of the condition relates to an abnormal rotation of the stomach.
The authors report a case of an 11-month-old infant who presented with an 
8-hour history of retching and obtundation. Abdominal distension and left 
upper-quadrant tenderness were the predominant physical findings. A diagnosis of 
mesenteroaxial gastric volvulus with eventration of the left hemidiaphram was made 
by means of plain-films and an upper gastrointestinal series. The child underwent 
laparotomy and gastrostomy, made a smooth recovery and was well 36 months 
postoperatively.
Seulement 52 cas de volvulus de l’estomac ont ete signales chez des enfants ou des 
bebes. La physiopathologie de cette affection est reliee a une rotation anormale de 
l’estomac.
Les auteurs decrivent le cas d’un bambin de 11 mois qui a ete vu apres 8 heures 
d’efforts pour vomir et d’emoussement des sensations. Une distension abdominale et 
une sensibilite du quadrant superieure constituaient les signes cliniques 
predominants. Un diagnostic de volvulus mesentero-axial de l’estomac avec 
eventration de l’hemidiaphragme gauche fut pose sur la foi de radiographies simples 
de l’abdomen et d’une serie de cliches gastro-intestinaux superieurs. L’enfant subit 
une laparotomie et une gastrostomie, se retablit sans probleme et il etait toujours 
bien portant, 36 mois apres l’operation.
A cute gastric volvulus is an un­common surgical emergency. 
In young children radiographic ex­
amination is particularly important 
in making the diagnosis early, be­
cause the symptoms and signs in 
this age group are not as clear and 
reliable as in adults. We report the
case of an infant with this condition 
who was treated successfully.
Case Report
An 11-month-old infant present­
ed to the emergency department
with an 8-hour history of irritability 
followed by retching without vomit­
ing. He was afebrile and lethargic. 
The abdomen was distended and 
there was left upper-quadrant ten­
derness. Blood and biochemistry 
profiles were normal. An upright 
plain film of the abdomen showed a
From the *Department o f  Surgery, Fort McMurray Regional Hospital, Fort McMurray, Alta., and the fDepartment o f  Surgery, University o f  Alberta 
and the $Department o f  Pediatrics, University o f  Alberta, Edmonton, Alta.
*Staff Surgeon, Fort McMurray Regional Hospital
fProfessor, Department o f  Surgery, University o f  Alberta
fAssistant Clinical Professor, Department o f Pediatrics, University o f  Alberta
Accepted for publication Jan. 8, 1992
Reprint requests to: Dr. Wojciech Brzezinski, Department o f Surgery, Fort McMurray Regional Hospital, 7 Hospital St., Fort McMurray, AB  
T9H 1P2
CJS, VOL. 36, NO. 3, JUNE 1993 233
BRZEZINSKI, LASKIN, WONG
double hemidiaphram (Fig. 1). An 
attempt at stomach decompression 
with a nasogastric tube was unsuc­
cessful. After a brief period of con­
servative management with intrave­
nous fluids, an upper gastrointesti­
nal contrast study was done 
through the nasogastric tube. A 
high-grade gastric outlet obstruc­
tion secondary to a mesenteroaxial 
gastric volvulus (Fig. 2) was demon­
strated. At laparotomy, eventration 
of the left hemidiaphram and a 
mesenteroaxial volvulus of the 
stomach without evidence of gastric 
wall ischemia were found. A simple 
gastrostomy was performed. The 
patient’s postoperative course was 
unremarkable. The gastrostomy 
tube was removed 14 days after 
operation. The child was asymptom­
atic 3 years postoperatively.
Discussion
Gastric volvulus is an uncommon 
abnormality. It was first described
by Berti1 in 1866. Since then over 
300 cases have been reported. 
Gastric volvulus is most common in 
adults; however, 52 cases have been 
reported in infants and children.2 
The pathophysiology of gastric vol­
vulus is related to the associated 
congenital abnormalities: failure of 
fixation of the stomach due to 
poorly developed gastrocolic or gas- 
trosplenic ligaments and a dia­
phragmatic defect such as paneso- 
phageal hernia or eventration.3 
However, up to one-third of the 
patients have no coexisting anoma­
lies and represent so-called primary 
gastric volvulus.4
There are three types of gastric 
volvulus: mesenteroaxial — rota­
tion of the stomach along the axis 
connecting the centre of the lesser 
and greater curvatures (Fig. 3A); 
organoaxial — rotation of the 
stomach along the axis connecting 
the cardia with the pylorus (Fig. 
3B) and a combined type. The de­
gree of rotation can vary from 180° 
to 360°.
Acute gastric volvulus is a sur­
gical emergency. If the rotation is 
greater than 180° a complete ob­
struction with strangulation, wall 
ischemia, perforation and associated 
morbidity and mortality can result. 
The classic triad of symptoms, de­
scribed by Borchardt,5 in 1904, 
consists of retching and inability to 
vomit, severe epigastric pain and 
distension and failure to insert a 
nasogastric tube. In infants and 
young children radiographic exami­
nation is particularly important in 
making the diagnosis early, because 
the symptoms and signs in this age 
group are not as clear and reliable 
as they are in adults. The upright 
chest x-ray film usually shows a 
broad air-fluid level in the left upper 
quadrant. Contrast studies of the 
upper gastrointestinal tract reveal
FIG. 2. Gastrografin injected through 
nasogastric tube demonstrates high- 
grade gastric outlet obstruction and 
“upside down” stomach.
FIG. 3. Rotational axis in mesen­
teroaxial (A) and organoaxial (B) vol­
vulus.
FIG. 1. Upright film of abdomen shows double air-fluid level in left upper quadrant 
and elevation of left hemidiaphram.
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rotated or “upside down” stomach 
with varying degrees of inlet and 
outlet obstruction depending on the 
type and severity of the volvulus.
Chronic gastric volvulus is usual­
ly characterized by postprandial 
pain, bloating, vomiting and early 
satiety. There is often a history of 
chronic symptoms for months or 
years before presentation. A barium 
meal may reproduce the symptoms, 
and volvulus can be seen on fluo­
roscopy.6 Standard upper gastroin­
testinal contrast studies are also 
useful in establishing the diagnosis. 
Endoscopy and therapeutic derota­
tion of the gastric volvulus are also 
being used for diagnosis.3
Definitive treatment of this condi­
tion should be surgical. Operation 
consists of reduction of the volvu­
lus, evaluation of the viability of the 
gastric wall and possibly repair of 
the associated intra-abdominal ab­
normalities. Recurrence can be pre­
vented by simple gastrostomy, ante­
rior gastropexy (with or without 
colonic displacement) or partial gas­
trectomy. The long-term results of 
surgical treatment have been excel­
lent, and no recurrences have been 
reported.
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Diagnoses Made by Frozen-Section 
Examination of Surgical Specimens 
in a Small Canadian Hospital
Malcolm M.M. Hayes, MMedPath; Edward A. Jones, MD, FRCPC; Dong-Yue Zhang, MB*
Examination of frozen sections, which is frequently used to make diagnoses at the 
Plains Health Centre, Regina, is expensive in terms of manpower and resources of 
the pathology department and should be used judiciously. The authors analysed the 
pathology records from January to December 1990 and found that more than 10% of 
surgical specimens were submitted for frozen-section diagnosis. A correct diagnosis 
was made in 94.8% of cases, and in approximately 1% of cases the diagnosis was 
deferred until paraffin sections were examined. An incorrect diagnosis by 
frozen-section examination was made in 4.2% of cases. In 13.2% of cases, 
frozen-section examination was apparently performed for reasons that were not 
medically legitimate. In a further 14.9% of cases the value of frozen-section 
examination was questionable. Clinicians need to be educated about the correct role 
of frozen-section examination in patient management, especially in this era of 
restricted hospital budgets.
L’examen des coupes en congelation, un moyen diagnostique frequemment utilise au 
Plains Health Centre de Regina, est couteux en ce qui a trait aux ressources 
humaines et materielles du service de pathologie, et on devrait y avoir recours de 
fa?on judicieuse. Les auteurs ont analyse les dossiers de pathologie de janvier a 
decembre 1990. Ils ont observe que plus de 10 % des prelevements chirurgicaux 
furent soumis pour un diagnostic par coupe en congelation. Un diagnostic juste fut 
pose dans 94,8 % des cas et, dans environ 1 % des cas le diagnostic fut reporte a 
l’examen des coupes en bloc de paraffine. L’examen par coupe en congelation donna 
un diagnostic errone dans 4,2 % des cas. Dans 13,2 % des cas l’examen par coupe en 
congelation a ete effectue pour des raisons qui n’etaient pas valables sur le plan 
medical. De plus, dans 14,9 % des cas, la pertinence de cet examen pourrait etre 
remise en question. Les cliniciens auraient besoin d’etre formes sur le role des 
examens par coupes en congelation dans le traitement des malades, particulierement 
en cette epoque de restrictions budgetaires en milieu hospitalier.
T he use of frozen sections to render a rapid diagnosis in sur­
gical pathology has been practised 
in many laboratories for decades.1
The prime purpose of this tech­
nique is to provide the surgeon with 
the information required for imme­
diate management of the patient.2
This information usually includes 
the diagnosis of a benign versus a 
malignant lesion, the presence or 
absence of metastatic disease or the
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presence of a tumour at resection 
lines and confirmation of the pres­
ence of diseased tissue in the ex­
cised sample. Occasionally, the di­
agnosis rendered at the time of 
frozen section also determines the 
immediate further handling of tis­
sues in the laboratory. For example, 
a breast carcinoma will be submit­
ted frozen for hormone-receptor 
analysis, inflamed tissues may be 
subjected to special culturing, and 
lymphomas may be processed for 
cell-marker and cytogenetic studies.
Despite the many advantages of 
diagnosis by frozen section, the 
technique is less reliable than tradi­
tional histopathologic examination 
of processed, paraffin-embedded tis­
sues, because frozen tissues become 
distorted, sections obtained using 
the cryostat and staining of unproc­
essed tissues are often of poor 
quality, sampling of the surgical 
specimen is limited and the demand 
for a rapid diagnosis produces psy­
chologic pressure. Furthermore, the 
inability to apply special staining or 
immunohistochemical procedures 
may be disadvantageous. Thus, fro­
zen sections are only advisable in 
clinical situations when rapid diag­
nosis is essential for the immediate 
management of the patient or han­
dling of the specimen, and in which 
the disadvantages of the technique 
are outweighed by the advantages 
of immediate diagnosis. Use of the 
frozen-section technique to provide 
a rapid diagnosis for social reasons, 
to communicate the diagnosis rap­
idly to the patient’s relatives or to 
satisfy the curiosity of the surgeon 
should be discouraged because of
the potential for error, the high 
cost to the laboratory in terms 
of manpower and stress and the 
potential for hampering the ulti­
mate proper evaluation of the speci­
men.
It was noted that an unusually 
high proportion of surgical patholo­
gy specimens at the Plains Health 
Centre were being submitted for 
frozen-section examination. Accord­
ingly, a survey was conducted to 
investigate the reliability of the 
frozen-section technique at the hos­
pital, to assess the rate of frozen- 
section examinations and to attempt 
to assess the validity of the requests 
for frozen-section examination.
Materials and Methods
All frozen sections prepared in 
the pathology laboratory of the 
Plains Health Centre, Regina, in 
1990 were reviewed. Each specimen 
was examined grossly by a patholo­
gist, a sample was taken, and the 
sample was embedded in ornithine 
carbamyl transferase-compound 
frozen-section medium and frozen 
rapidly in the cryostat. Sections 
were then cut, stained with tolu- 
idine blue and hematoxylin and 
eosin and examined by the patholo­
gist. In some cases, especially for 
small biopsy samples of brain neo­
plasms, smears rather than tissue 
sections were prepared. The frozen- 
section diagnosis was communicat­
ed to the operating room through 
an intercom system. A report was 
compiled immediately, and the re­
port was compared with the final
histopathology report. A copy was 
retained with the pathology record. 
A decision was made as to whether 
the frozen-section diagnosis corre­
lated with the final histologic diag­
nosis from the paraffin sections. 
Any inconsistencies between the 
frozen-section diagnosis and the 
final histologic diagnosis were cate­
gorized according to the reasons for 
the discrepancy.
Specimens were grouped accord­
ing to anatomic sites, and the validi­
ty of the request for frozen-section 
diagnosis was assessed, retrospec­
tively, from information available to 
the pathologist. The information 
was based on factors such as the 
age of the patient, the nature of the 
disease, the type of surgical proce­
dure, the location of the operating 
room in which the surgical proce­
dure was conducted, the likelihood 
of a reliable diagnosis using frozen 
section of a small sample of the 
lesion in each case and the intent of 
the surgeon in changing the imme­
diate management of the patient, 
depending on the frozen-section re­
sult. Thus, requests for frozen-sec­
tion diagnosis were judged to be 
“ indicated” , “not indicated” or “of 
uncertain benefit.”
Results
There were 596 requests for froz­
en-section diagnosis out of a total 
of 5852 surgical specimens. Breast 
tissue was the biopsy material sub­
mitted most frequently for frozen- 
section diagnosis (159 cases, 27%). 
Excised skin lesions were also com­
monly submitted for frozen-section 
diagnosis and for assessment of 
resection margins. Other tissues for 
which biopsy specimens were com­
monly obtained included lung, 
lymph node and thyroid.
The frozen-section diagnosis cor­
related with the final histologic di­
agnosis in 565 cases (94.8%). In 25
Table I. Results of Frozen-Section Examination of Fresh Surgical Tissue
Pathologist
Total no. 
specimens
No.
correct
No.
incorrect
Diagnosis
deferred % error
A 87 81 4 2 4.6
B 265 253 10 2 3.8
C 239 226 11 2 4.6
Other 5 5 0 0 0
Total 596 565 25 6 4.2
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cases (4.2%) the frozen-section di­
agnosis differed from the final his­
tologic diagnosis, and in 6 cases 
(1%) the diagnosis was deferred 
because a definite decision could 
not be made at the time of frozen 
section (Table I). The overall error 
rate was approximately 4.2% and 
was similar for the three patholo­
gists who reported on most of the 
specimens. Reasons for the incor­
rect diagnosis are given in Table II. 
Errors resulted from misinterpreta­
tion of the frozen-section slide in 12 
cases (Table III). Errors also result­
ed from failure to sample the lesion 
correctly macroscopically (11 cases) 
or when the lesion was present in 
the blocks submitted for frozen 
section but was not included in the 
prepared slide and was revealed 
only on deeper cutting of the block 
(2 cases) (Table IV).
A breakdown of cases submitted 
for frozen-section diagnosis accord­
ing to anatomic site is shown in 
Table V, which also summarizes the 
validity of the request for each type 
of surgical specimen.
Retrospective assessment of the 
validity of the requests for frozen- 
section examination revealed that 
79 (13.2%) of the 596 cases were 
considered to have insufficient indi­
cation for frozen-section examina­
tion. Twenty-four (15%) of the 159 
breast lesions should not have been 
submitted for frozen-section exami­
nation. This conclusion was based 
on the fact that the breast lesions 
were thought to be benign clinically 
and had been excised in the out­
patient department with no plan to 
proceed with further surgery should
Table II. D isc re p a n c ie s  B etw een  
F rozen -S ection  D ia g n o s is  and F ina l 
H is to lo g ic  D iagnos is
No. of
Reason cases
In te rp re ta tio n  e rro r 12
M a c ro s c o p ic  sa m p lin g  e rro r 11
M ic ro s c o p ic  sa m p lin g  e rro r 2
the frozen section show a malignant 
lesion. Most of these specimens had 
been sent for a rapid diagnosis for 
social reasons (to allay the patient’s 
anxiety or to provide an immediate 
answer for the patient’s relatives). 
Similarly, the requests for frozen- 
section examination of parotid- 
gland neoplasms (13 cases) were 
usually for the purpose of obtaining 
a rapid diagnosis to satisfy the 
curiosity of the surgeon rather than 
for obtaining information that 
would modify the immediate surgi­
cal management of the patient.
In some cases, the validity of the 
request for frozen-section diagnosis 
based on the information available 
to the pathologist was uncertain. 
The indication for frozen sections in 
the diagnosis of thyroid nodules 
was difficult to assess in 37 of 47 
cases because of the limited success 
of the frozen-section technique in
distinguishing between benign and 
malignant follicular lesions of the 
thyroid from a single section ob­
tained from the periphery of the 
tumour. Similarly, frozen-section di­
agnosis of small or occult breast 
lesions detected by mammography 
(28 of the 159 cases) is usually 
inadvisable and is probably contra­
indicated in the majority of cases.
Discussion
The role of the frozen-section 
technique in providing immediate 
intraoperative diagnosis of disease 
processes has been established in 
most major hospitals for many 
years.3-4 The rapid diagnosis is often 
helpful in allowing the surgeon to 
proceed immediately with a more 
definitive surgical operation or may 
influence the surgeon to modify the
Table III. C ases in W h ich  an In te rp re ta tio n  E rro r O ccurred  a t th e  T im e  o f F ro z e n -S e c tio n  
E xa m in a tio n  (n=  12)
Frozen-section
Clinical lesion diagnosis Final diagnosis
B rain tu m o u r E p e n d ym o m a ? G liosa rcom a
P ro b a b le  g e rm in o m a P itu ita ry  adenom a
G lio s is A s tro c y lo m a  (g ra d e  1)
C erebella r tu m o u r A d e n o c a rc in o m a  (c ys tic ) N e u ro ep ith e lia l c y s t
Lung  tu m o u r S m a ll ce ll ca rc in o m a A typ ic a l ca rc in o id
In f la m m a to ry  p ro ce ss? B ro n c h io lo a lve o la r
ca rc in o m a
C a rc in o m a C arc ino id
T h yro id  tu m o u r F o llic u la r adenom a P ap illa ry  c a rc in o m a
Anal b iopsy C o n d y lo m a S qu a m o us ca rc in o m a
S k in  tu m o u r B asa l ce ll ca rc in o m a S qu a m o us ca rc in o m a
S k in  tu m o u r B asa l ce ll ca rc in o m a S qu a m o us c a rc in o m a
B reast tu m o u r In tra d u c ta l ca rc in o m a ? E p ith e lios is
Table IV. C ases in W h ich  S a m p lin g  W as th e  C ause fo r  In c o rre c t F ro zen -S e c tio n  D ia g n o s is
Clinical No. of Frozen-section
diagnosis cases diagnosis Final diagnosis
B reast m ass 3 In tra d u c ta l ca rc in o m a Invas ive  d u c t c a rc in o m a
F ib ro a d e n o s is Invas ive  c a rc in o m a
P e rid u c ta l f ib ro s is In tra d uc ta l ca rc in o m a
B reast les ion 2 F ib ro a d e n o s is  (2 ) L o b u la r c a rc in o m a  in s itu  (2 )
T h y ro id  m ass 4 M u lt in o d u la r  g o itre  (2 ) Focal p a p illa ry  c a rc in o m a  (2)
A ty p ic a l adenom a F o llic u la r c a rc in o m a
F o llic u la r  a d enom a F o llic u la r ca rc in o m a
S kin  les ion 2 N o tu m o u r  seen  (2 ) R esidua l basa l ce ll ca rc in o m a
Renal tu m o u r 1 H e m a n g io m a
(w
A de n o ca rc in o m a
C erebe lla r m ass 1 H e m o s id e rin , f ib r in H e m a n g io b la s to m a
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operation in preparation for further 
therapy at a later date. For exam­
ple, the diagnosis of a malignant 
neoplasm may result in the surgeon 
performing a more radical resection 
so as to avoid a further operation 
later; absence of tumour at resec­
tion lines may allow more conserva­
tive excision of a skin lesion; and, 
for operations at deep sites, frozen- 
section diagnosis of a malignant 
neoplasm may allow the surgeon to 
insert radiopaque markers at specif­
ic anatomic sites to facilitate the 
planning of subsequent radiothera­
py. However, the frozen-section 
technique often falls short of the 
paraffin-section technique in provid­
ing the ideal standard of pathologi­
cal diagnosis. The limitations of the 
technique are inherent in the limit­
ed sampling of the specimen, the 
relatively poor quality of sections
and staining compared with paraffin 
sections, and the psychologic stress 
induced when the pathologist is 
forced to make a rapid decision.
Errors are made with frozen-sec­
tion diagnoses in all laboratories 
and by all pathologists. The per­
centage error rate in the series of 
cases we studied is similar to that 
reported recently by Oneson, Minke 
and Silverberg5 but greater than 
that reported in several other large 
studies6-7 in which the error rate 
was less than 2%. However, even on 
examination in retrospect very few 
of the errors appear to have been 
avoidable. Although small, the error 
rate remains significant in all hospi­
tals and tends to vary with the site 
of the biopsy and the nature of the 
disease process.5-8SI In the diagnosis 
of neoplasms of the breast, which 
constitute the majority of frozen-
section samples at most hospitals, 
the technique is particularly relia­
ble.1011 Fortunately, despite the oc­
casional errors in diagnosis, there 
were no major negative implications 
for the patients in this study.
Although the frozen-section rate 
at the Plains Heath Centre appears 
to be high, the request for frozen- 
section examination was considered 
to be contraindicated in only 13.2% 
of cases and of uncertain indication 
in a further 14.9% of cases. By 
contrast, other workers have re­
ported that almost half the frozen- 
section examinations performed 
in some hospitals in the United 
States were not indicated.12 The
high rate of frozen-section examina­
tion at the Plains Health Centre 
may be explained in part by the 
case mix of surgical procedures 
performed at the hospital, which is 
a major referral centre for neuro­
surgery and thoracic surgery, in 
addition to the usual complement of 
general surgery and plastic surgery.
Use of frozen sections by the
plastic surgeons appears to vary
according to the preferred manner
of individual practice. Some prefer 
to excise skin tumours according to 
margins defined as free of tumour 
by frozen-section examination, 
whereas others prefer to excise tu­
mours according to clinical judge­
ment and perform further excision 
later if the margins are found to be 
involved at paraffin-section exami­
nation or when clinical recurrence 
occurs. Mohs’ technique is not used 
at the Plains Health Centre.
The value of frozen-section ex­
amination for diagnosis of nodules 
of the thyroid gland is also debat­
able. Only a small percentage of 
thyroid nodules are malignant, and 
many of those are misdiagnosed as 
benign lesions by frozen-section ex­
amination because of inadequate 
sampling of the capsular zone in 
follicular neoplasms. This problem 
occurred in four cases in the pres-
Table V. Analysis of Frozen Sections According to Specimen Type or Anatomical Site and 
Whether Frozen-Section Examination Was Indicated
Type of tissue 
examined
Frozen-section examination
No. Indicated Not indicated Uncertain
Skin 82 79 0 3
Breast 159 107 24 28
Brain 54 50 3 1
Lung ± hilar node 60 53 3 4
Thyroid 47 6 4 37
Lymph node 58 44 8 6
Prostate 18 18 0 0
Bladder 13 11 1 1
Mouth/tongue 10 9 1 0
Kidney 6 6 0 0
Pituitary 5 0 4 1
Parathyroid 5 5 0 0
Liver 5 2 2 1
Salivary gland 13 0 13 0
Adrenal 2 0 2 0
Thymus 4 3 1 0
Colon/ileum 14 8 4 2
Stomach 8 6 1 1
Nasopharynx 1 0 1 0
Testis/vas deferens 5 5 0 0
Gallbladder 3 3 0 0
Esophagus 3 3 0 0
Retroperitoneum 4 4 0 0
Pancreas 3 2 0 1
Ovary 3 1 2 0
Post mediastinum 2 1 0 1
Bone 4 1 2 1
Soft tissue 4 1 3 0
Spleen 1 0 1 0
Total 596 428 79 89
% 100 71.8 13.2 14.9
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ent series. Rosen, Rosenblatt and 
Saltzman13 recently reported a sen­
sitivity of only 53% for the diagno­
sis of malignancy on frozen-section 
examination of 504 specimens of 
thyroid nodules. In many centres, 
most small, well-differentiated intra- 
thyroidal carcinomas of both papil­
lary and follicular type are treated 
by lobectomy alone with long-term 
results not significantly worse than 
those in patients subjected to more 
radical surgery.14 If this surgical 
policy is followed, there is even less 
justification for a frozen-section di­
agnosis in most patients with thy­
roid nodules.
Recent developments in the sur­
gical management of small breast 
tumours, especially nonpalpable le­
sions detected by screening mam­
mography, are essentially conserva­
tive, and the operative procedure is 
rarely altered regardless of the diag­
nosis of the lesion as benign or 
malignant. The disadvantages of 
frozen-section examination in this 
situation are considerable, because 
accurate diagnosis of small breast 
carcinomas often requires sections 
of the highest quality. Tissue dis­
torted by freezing and cut before 
adequate fixation may be rendered 
unsuitable for accurate interpreta­
tion and for reliable assessment of 
resection margins. Furthermore, re­
cent studies on the use of frozen 
sections in the diagnosis of small 
invasive and in situ breast lesions 
have shown an increasing percent­
age of deferred diagnoses (up to 
20%) and false-negative diagnoses 
(up to 76%), which reflects the 
difficulty of interpretation.1516
Conclusions
We have shown that despite the 
high rate of frozen-section examina­
tions at the Plains Health Centre, 
only a small percentage of frozen- 
section examinations are judged to 
be contraindicated. Most of these 
were performed for psychosocial 
reasons and should be discouraged 
in the future. The percentage of 
unnecessary frozen sections would 
be greater if the cases of thyroid 
nodules were included in the con­
traindicated category. The frozen- 
section technique has proved to be 
relatively reliable and remains a 
useful tool in the diagnostic arma­
mentarium of the pathology labora­
tory.
We thank the administration of the 
Plains Health Centre for permission to 
publish this report.
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Magnetic Resonance Imaging 
in Preoperative Localization of Diseased 
Parathyroid Glands: A Comparison 
With Isotope Scanning and Ultrasonography
Mylene Yao; Christopher Jamieson, MB, BS, FRCSC, FACS: Ralph Blend, MB, BS, DMRD, FRCPC
The value of magnetic resonance imaging (MRI) in the preoperative localization of 
parathyroid glands was assessed through a comparison of the findings with those 
obtained by ultrasonography and isotope scanning.
The localization findings in 37 patients with primary hyperparathyroidism were 
compared with the operative findings. The sensitivities of the three modalities as 
defined by the ability to detect a parathyroid adenoma were 67% (isotope scanning),
44% (ultrasonography) and 36% (MRI). The differences were not significant. The 
sensitivities as defined by the ability to predict the correct side of the lesion were 
48% (isotope scanning) 33% (ultrasonography) and 36% (MRI).
No correlation was found between the sensitivity of a given localization test and 
factors such as the presence of thyroid abnormalities, size of the lesion, type of 
lesion and preoperative calcium and parathormone levels.
The low sensitivity and high cost of all three preoperative localization studies 
render them unnecessary in the management of uncomplicated parathyroid disease.
However, if preoperative imaging is necessary, ultrasonography and isotope 
scanning are recommended, since MRI was not found to be superior.
On a evalue l’importance de l’imagerie par resonnance magnetique (IRM) utilisee en 
preoperatoire pour localiser les parathyroi'des au moyen d’une comparaison des 
resutats obtenus par cette methode avec ceux de l’echographie et ceux de la 
scintigraphie.
Les resultats des examens de localisation de 37 patients souffrant 
d’hyperparathyroi'die ont ete compares aux observations operatoires. La sensibilite 
des trois methodes, telle que definie par leur capacite de deceler un adenome 
parathyroi'dien fut de 67 % (scintigraphie), 44 % (echographie) et 36 % (IRM). La 
sensibilite telle que definie par la capacite de predire le cote exact de la lesion fut de 
48 % (scintigraphie), 33 % (echographie) et 36 % (IRM).
Aucune correlation n’a pu etre etablie entre la sensibilite de l’un ou l’autre des 
tests de localisation et des facteurs tels que la presence d’anomalies thyroi'diennes, 
la taille de la lesion, le type de lesion et les taux preoperatoires de calcium et de 
parathormone.
La faible sensibilite et les couts eleves des trois modes d’examen de localisation 
les rendent inutiles pour le traitement des pathologies parathyroidiennes non 
compliquees. Toutefois, s’il s’avere necessaire d’obtenir une visualisation 
preoperatoire, l’echographie ou la scintigraphie devraient etre preferees a 1’IRM 
puisque cette derniere ne s’est pas montree superieure.
The definitive treatment for hy- glands. The surgical risks of such a operative hypoparathyroidism. Pre-perparathyroidism is surgical procedure include damage to the operative localization studies may
removal of the diseased parathyroid recurrent laryngeal nerves and post- minimize these surgical risks by
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Accepted for publication Feb. 16. 1993
Reprint requests to: Dr. Christopher Jamieson, Suite .322. E.K. Jones Building, 160 Wellesley St. E, Toronto. ON M4 Y 1J3
CJS, VOL. 36. NO. 3, JUNE 1993 241
YAO, JAMIESON, BLEND
directing the surgeon to the area of 
disease and limiting the extent of 
dissection; moreover, it is important 
to gain experience in preoperative 
localization so that abnormal glands 
can be localized in more difficult 
cases, such as in patients who re­
quire re-exploration.
Ultrasonography (US) and thal­
lium-technetium subtraction scinti­
graphy (TTSS) are widely used 
noninvasive techniques for localiz­
ing glands, but the value of mag­
netic resonance imaging (MRI) in 
this area has not been fully ad­
dressed. In this study, the value of 
MRI was assessed through a com­
parison with US and TTSS of sensi­
tivity at three levels: detection of 
the lesion, prediction of the correct 
side and localization to the specific 
quadrant. Factors such as the pres­
ence of thyroid abnormalities, lesion 
size, disease type and preoperative 
calcium and parathormone levels 
were also examined to determine 
their correlation, if any, with the 
sensitivity of a given test.
Patients and Methods
Thirty-seven patients (27 women, 
10 men) with primary hyperpara­
thyroidism confirmed by elevated 
calcium and parathormone levels 
underwent one or more localization 
tests between July 1987 and April 
1990. The patients ranged in age 
from 21 to 87 years. Seven were 
asymptomatic, 6 complained of gen­
eral fatigue or depression, 24 pre­
sented with urolithiasis or other 
renal complications and 9 presented 
with bone pain or decreased bone 
density.
All patients were operated on by 
the same surgeon, who knew the 
results of all localization studies 
before operation. None of the pa­
tients had undergone neck explora­
tion. All had surgically confirmed 
parathyroid lesions. All had normal
calcium levels postoperatively and 
were considered cured, with the 
exception of one patient who had 
persistent hypercalcemia after three 
and one-third glands were removed 
because of hyperplasia. One patient 
had a palpable mass in the neck on 
physical examination.
All MRI examinations were per­
formed in 1989 with the non- 
upgraded Signa 1.5 T by GE Medi­
cal Systems Canada (Mississauga, 
Ont.), in conjunction with a surface 
neck coil. Tr  and TVweighted im­
ages were obtained for both the 
transverse and coronal sections of 
the neck. Real-time ultrasonogra­
phy was done with the Diasonics 
DRF 400 device (Diasonics Canada 
Lte, Dollard Des Ormeaux, Que.) 
with a 7.5-mHz transducer. Neck 
images with TTSS were acquired 
after the injection of 1.5 mCi of 
technetium 99m and again after the 
injection of 2 mCi of thallium 201. 
Subtraction of the technetium from 
the thallium images by the comput­
er yields an image of hyperfunction­
al parathyroid glands.
Six patients had TTSS only, 7 
had US only, 12 had TTSS and US 
only, 2 had TTSS and MRI only, 1 
had MRI and US only and 9 had all 
three tests. All three tests were not 
performed on every patient because 
of logistical difficulties, not because 
of clinical considerations.
The result of each localization 
study was compared with the opera­
tive findings, which were the stan­
dard. A false-negative finding indi­
cated failure of the test in detecting 
the lesion whereas, a true-positive 
finding signified that the test suc­
ceeded in detecting the lesion. The 
sensitivity of each modality at the 
three levels of localization was 
analysed by Fisher’s exact test for 
any differences. The prediction of 
laterality was considered incorrect if 
the test failed to report the side on 
which a lesion was found or if it 
reported both sides when the lesion
was found on one side only. Simi­
larly, the quadrant was considered 
to be predicted correctly if the test 
reported all the diseased glands and 
none of the normal glands.
Results
All patients in this study had 
confirmed parathyroid disease; 
thus, there were no true-negative or 
false-positive results, which made it 
unnecessary to consider the speci­
ficity and the negative predictive 
value. The positive predictive value 
was 100% in all instances. Opera­
tive findings revealed solitary ade­
noma in 34 patients, multiple ade­
nomas in 1 patient and multiple 
hyperplasia in 2 patients. The two 
patients with hyperplasia were ex­
cluded from the calculations of sen­
sitivity.
The sensitivity values of TTSS, 
US and MRI at the three levels of 
localization are tabulated in Table I. 
The sensitivity of TTSS, US and 
MRI in detecting parathyroid adeno­
ma was 67%, 44% and 36% respec­
tively. These differences were not 
significant.
When a given test successfully 
detected the adenoma, the probabil­
ity of it predicting the correct later­
ality was 73%, 75%, and 100% for 
TTSS, US and MRI respectively 
(Table II). These values were not 
significantly different.
Similarly, when the test success­
fully predicted the correct side, the 
probability of it predicting the cor­
rect quadrant was 15%, 78%, and 
25% for TTSS, US and MRI respec­
tively (Table III). Only four of the 
TTSS reports specified the quadrant 
of the lesion whereas all the US and 
MRI reports attempted to localize 
the lesion to the specific quadrant.
In comparisons of combinations 
of any two tests, both must be true 
positive to constitute a true-positive 
result for that combination. The
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sensitivity for each combination in 
detecting a lesion was TTSS plus 
US 43%, TTSS plus MRI 18% and 
US plus MRI 10% (Table IV). These 
values were lower than those for 
the respective individual tests but 
were not significantly different 
among themselves.
In the 12 patients who had MRI, 
the sensitivity of each modality in 
detecting a lesion was TTSS 55%, 
US 40% and MRI 33% (Table V). 
The differences between these val­
ues were not significant.
Thyroid abnormalities were found 
in five patients; four of them had 
benign thyroid nodules and one had 
Hashimoto’s thyroiditis with hyper­
plasia and multiple foci of papillary 
carcinoma. TTSS was done in two 
of these patients and gave a true­
positive result in both cases; MRI 
was used in three patients and gave 
a true-positive result in each case. 
All five patients had US and two of 
these were true positive. From this
small sample, abnormality of the 
thyroid did not seem to have a 
negative effect on the sensitivity of 
any of the localization tests.
Among patients who had para­
thyroid adenoma, the preoperative 
ionized calcium levels, available in 
22 patients, ranged from 1.33 to 
2.94 mmol/L. Preoperative para­
thormone levels, available in 29 
patients, ranged from 6.4 to 69 
pmol/L. The adenoma size, avail­
able in 34 patients, ranged from 
0.004 to 11.5 cm3. The null hy­
potheses that adenoma size, preop­
erative parathormone and ionized 
calcium levels had no effects on the 
ability of each individual test to 
detect the lesion were not rejected, 
with a p value of < 0.01 by the 
Wilcoxon rank-sum test. Therefore, 
this study was unable to correlate 
adenoma size, parathormone or cal­
cium levels with the sensitivity of 
the localization tests.
In the two patients with parathy­
roid hyperplasia, TTSS and US gave 
a true-positive result, while MRI 
reported a false-negative result on 
the only case in which it was used.
Discussion
The sensitivities of the three mo­
dalities in detecting parathyroid dis­
ease were not significantly different. 
These sensitivities were lower than 
those reported by Erdman and asso­
ciates1 (US 77% and MRI 81%), but 
the sensitivity of TTSS (65%) was 
comparable to that of our review. 
The sensitivity of MRI in our study 
was also significantly lower than 
the range of 64% to 79% reported 
by Higgins and Auffermann2 in the 
review of several studies. The dis­
crepancy in the sensitivity of MRI 
between this study and previous 
studies could be attributed to the 
different quality of machines, be­
cause in this study first-generation 
MRI equipment was used.
Table I. Sensitivity of Thallium-Technetium Subtraction Scintigraphy (TTSS), Ultrasonography 
(US) and Magnetic Resonance Imaging (MRI) in Detecting a Parathyroid Adenoma and Correctly 
Predicting the Side and Quadrant
Modality
Patients,
no.
Detection of 
adenoma, %
Correct prediction of
Side, °/o Quadrant, %
TTSS 27 67 48 7
US 27 44 33 26
MRI 11 36 36 9
Table II. Probability That TTSS, US and MRI Will Predict Correct Side of Adenoma When the Test
Has Detected It
Patients with adenoma Correct prediction
Modality detected, no. of side, %
TTSS 18 73
US 12 75
MRI 4 100
Table III. Probability That TTSS, US and MRI Will Predict Correct Quadrant of Adenoma When the 
Test Has Correctly Predicted the Side
Patients with side Correct prediction
Modality predicted correctly, no. of quadrant, %
TTSS 13 15
US 9 78
MRI 4 25
Table IV. Sensitivity in Detecting an Adenoma of Different Combinations of Two Techniques 
Considered as a Single Test on the Same Patient
Combination of 
modalities Patients, no.
Sensitivity in 
detecting lesion, %
TTSS +  US 21 43
TTSS +  MRI 11 18
US +  MRI 10 10
Table V. Sensitivity of Each Modality for All Patients Who Had MRI
Modality Patients, no. Sensitivity, %
TTSS 11 55
US 10 40
MRI 12 33
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Congruent with the findings of 
Erdman and associates,1 compari­
son of the different combinations of 
tests showed no significant differ­
ence in sensitivity although the sen­
sitivity of a combination of two 
tests was definitely lower than that 
of the individual tests alone.
Rafto and Seften3 reported that 
all modalities were less sensitive in 
detecting multigland hyperplasia 
than in detecting adenomas. Stein 
and Wexler4 also found that US and 
TTSS were less sensitive with re­
spect to hyperplasia. In MRI 
studies, this difficulty could be attri­
buted to the similar intensity given 
by hyperplastic glands in 7> and 
^-weighted images relative to that 
of thyroid tissue.5 Although TTSS 
and US were able to detect hyper­
plastic glands in our study, the 
small number of cases made it im­
possible to draw conclusions re­
garding the type of disease and its 
effect in localization studies.
The presence of thyroid adenoma 
or cyst can complicate MRI inter­
pretation by giving a high-intensity 
signal on the 72-weighted image, 
thus giving a false-positive result.1-2 
Such an effect was not found in this 
study as there were no false-positive 
results. In the patient who had 
Hashimoto’s thyroiditis, MRI suc­
ceeded in detecting the parathyroid 
lesion, because this modality can 
differentiate diffuse from focal dis­
ease. For example, Hashimoto’s 
thyroiditis can be distinguished 
from toxic multinodular goitre on 
MRI.3
The results indicated that there 
was no correlation between sensitiv­
ity for a given test and adenoma 
size. Contrary to previous studies 
that reported difficulty in identify­
ing parathyroid glands less than 0.5 
cm in diameter with TTSS,6' 8 the 
smallest adenoma, with a maximum 
dimension 0.2 cm, was detected by 
both TTSS and US in this study. 
The hypothesis that higher levels of
calcium and parathormone may be 
indicative of more active and thus 
more easily detected parathyroid 
glands was disproved, because no 
correlation could be found between 
these two variables and the sensitiv­
ity of each modality. These findings 
were similar to those of Stein and 
Wexler,4 which also failed to corre­
late the weight of the adenomatous 
gland and the degree of physiologi­
cal hyperfunction with the sensitivi­
ty of US and TTSS.
Since imaging techniques are ob­
tained only after investigations have 
indicated surgical exploration of the 
parathyroid to be necessary, and 
since they have a sensitivity of 80% 
at best,9 it may be questioned 
whether imaging should be done at 
all. Localization studies may help 
the surgeon plan the strategy for an 
operation. Results in this study in­
dicated that if TTSS, US or MRI 
succeeded in detecting the lesion, 
the modality would also be likely to 
predict laterality correctly. There­
fore, unilateral neck exploration 
would be justified in cases of soli­
tary adenoma if surgical findings 
corresponded with reports from lo­
calization studies and if the other 
gland on the side of the lesion was 
normal. Surgical complications 
such as hypocalcemia, which may 
result from extensive dissection and 
biopsy of all four glands, are thus 
minimized without the risk of per­
sistent hypercalcemia being signifi­
cantly increased. This view was also 
supported by Stein and Wexler.4
The estimated costs per test of 
the three imaging techniques were: 
TTSS $285, US $75 and MRI 
$1400. If any of these imaging 
techniques were to be used, US 
would be the one of choice initially 
because of its relatively low cost 
and ability to localize the lesion to 
the specific quadrant. Although 
MRI is superior to the other two 
techniques when the neck anatomy 
is distorted by previous surgery, it
is not recommended if metallic sur­
gical clips have been used. Al­
though the new non-metallic surgi­
cal clips allow for safe use of MRI, 
they may create artifacts which, in 
such a small area as the neck, can 
render the scans useless.
The sensitivity of MRI in detect­
ing parathyroid adenomas was rela­
tively less than that of US or TTSS. 
Its use can only be justified when 
difficulty in identifying parathyroid 
disease is anticipated. Given their 
high cost and limited sensitivity, 
preoperative localization studies are 
unnecessary in the management of 
uncomplicated parathyroid disease.
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Piperacillin Versus Cefazolin Given 
Perioperatively to High-Risk Patients 
Who Undergo Open Cholecystectomy:
A Double-Blind, Randomized Trial
Sigmund Krajden, MD, FRCPC;* Mohammad Yaman, MD, FRCSC;t Milan Fuksa, DSc, SM, AAM;* 
Jacob C. Langer, MD, FRCSC;§ John Rowan, MD, FRCSC;t Claude J. Burul, MD, FRCSC;t 
Douglas L. Wooster, MD, FACS, FRCSC;t Mervyn Deitel, MD, FRCSC, FACS;t 
Zenon J. Borowy, MD, FRCSC;t Lloyd C. Smith, MD, FRCSC;t 
Michael Baida, MD, FACS, FRCSC;t Judy Chong, BScPharm$
Objective: To study the efficacy, microbiologic features and toxicity of prophylactic 
cefazolin versus prophylactic piperacillin in high-risk patients who undergo open 
cholecystectomy.
Design: Double-blind randomized trial with follow-up for 6 weeks postoperatively. 
Setting: An 850-bed community hospital, located in a major Canadian city. Patients 
admitted to hospital who satisfied published criteria for being at high-risk for 
infection after open cholecystectomy were entered into the protocol, and those who 
satisfied the criteria and provided consent were entered into the study. Eighty-one 
patients were randomly assigned by computer to receive either piperacillin or 
cefazolin as the prophylactic agent.
Interventions: Open cholecystectomy.
Main outcome: Provides detailed information on the organisms found in the biliary 
tree in patients with acute cholecystitis, assesses the in-vitro activity of cefazolin 
versus piperacillin against the isolated organisms, expecting that piperacillin would 
be much more active against isolated anaerobes and gram-negative bacteria.
Results: Bactobilia was documented in 42% of patients in the cefazolin group and 
29% of patients in the piperacillin group. Piperacillin was active in vitro against 
94% of all isolates versus 56% for cefazolin (p < 0.005, McNemar’s test). Adverse 
effects and toxicities in both the piperacillin and cefazolin group were low and were 
not serious.
Conclusions: Both piperacillin and cefazolin are safe and effective prophylactic 
antimicrobials for high-risk patients who undergo open cholecystectomy. However, 
piperacillin had a much wider spectrum of in-vitro activity against the isolated 
pathogens, especially Enterococcus sp., Enterobacter cloacae and the anaerobes.
Objectif: Etudier l’efficacite, le spectre antibacterien et l’innocuite d’un traitement 
prophylactique a la cefazoline contre ceux de la piperacilline prophylactique chez 
des patients a risque eleve qui subissent une cholecystectomie ouverte.
Conception : Un essai randomise a double insu, avec un suivi postoperatoire de 6 
semaines.
Contexte : Un hopital communautaire de 850 lits situe dans une grande ville
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canadienne. Les patients hospitalises qui rencontraient les criteres reconnus de 
risque eleve d’infection apres une cholecystectomie ouverte, qui satisfaisaient les 
criteres et qui etaient consentants furent inclus dans l’etude. Quatre-vingt-un 
patients furent assignes au hasard, par ordinateur, a recevoir soit de la piperacilline 
ou de la cefazoline, comme traitement preventif.
Intervention : Une cholecystectomie ouverte.
Principaux parametres : Obtenir une information detaillee sur les microorganismes 
(aerobies et anaerobies) retrouves dans les voies biliaires chez les patients souffrant 
de cholecystite aigue, comparer les activites in vitro de la cefazoline et de la 
piperacilline contre les bacteries isolees, en supposant que la piperacilline allait 
s ’averer beaucoup plus active contre les isolats anaerobies et les bacteries gram 
negatif.
Resultats : Une bactobilie fut constatee chez 42 % des patients du groupe cefazoline 
et 29 % des patients du groupe piperacilline. La piperacilline etait active in vitro 
contre 94% des isolats, par rapport a 56 % pour la cefazoline (p < 0,005, test de 
McNemar). Les effets secondaires ou toxiques des deux antibiotiques ont ete peu 
nombreux et peu graves.
Conclusions : La piperacilline aussi bien que la cefazoline sont des antibiotiques 
surs et efficaces comme traitement preventif chez les patients a risque eleve qui 
doivent subir une cholecystectomie ouverte. La piperacilline avait cependant un 
spectre d’action in vitro beaucoup plus vaste contre les bacteries isolees, surtout 
Enterococcus sp., Enterobacter cloacae et les isolats anaerobies.
Antimicrobial prophylaxis for bi­liary tract surgery in elective1'3 
and high-risk patients4 6 reduces 
wound sepsis and bacteremia. The 
antimicrobials recommended for 
such prophylaxis are first-genera­
tion cephalosporins, such as cefazo- 
lin, because of their in-vitro activity 
against organisms isolated from the 
infected biliary tree and their high 
level of biliary excretion.7' 9 Cefazo- 
lin is active against Escherichia coli, 
the commonest isolate in the biliary 
tree, but is generally inactive 
against enterococci, the second 
commonest isolate (13% to 16%),10 
12 and against anaerobes (Clostridi­
um perfringens, Peptostreptococcus 
sp. and Bacteroides sp.), which are 
occasionally isolated (in up to 20% 
of cases) from the biliary tree.811
Piperacillin is also active against 
many of the gram-negative aerobes 
isolated from the biliary tree, in­
cluding E. coli, Klebsiella sp., Pro­
teus sp., Enterobacter sp. and the 
gram-positive Enterococcus,13' 16 
Also, piperacillin is active against 
Pseudomonas sp., whereas cefazo- 
lin is not,13 and against anaerobes. 
Finally, piperacillin achieves high 
concentrations in the biliary tree
(bile-to-serum ratio greater than 
4:1) and is excreted by this 
route.1417
The efficacy, safety and relative 
lack of toxicity of piperacillin has 
been established in the treatment of 
serious infections as well as in the 
prophylaxis of surgical proce­
dures.1819
This study was undertaken to 
examine the bacteriologic features 
and in-vitro sensitivities of isolates 
from the gallbladder and to com­
pare the safety and efficacy of pi­
peracillin versus cefazolin in the 
prophylaxis of high-risk patients 
who undergo open cholecystecto­
my. In addition, the sensitivity to 
piperacillin and cefazolin of all bac­
teria isolated from nonbiliary sites 
of infection were examined.
Patients and Methods
The study was conducted in a 
prospective, randomized, double­
blind manner. There were 103 pa­
tients at high risk for postoperative 
infection after open cholecystecto­
my. Patients considered to be at 
high risk were those over 70 years
old and those who had acute chole­
cystitis, obstructive jaundice, com­
mon bile duct stones, previous bili­
ary surgery, chills and fever within 
1 week of admission, acute chole­
cystitis within 1 month of admis­
sion or decreased host defences due 
to diabetes, uremia or immunosup­
pressive drugs.
The 103 patients were randomly 
allocated by computer to receive 
piperacillin or cefazolin prophylax­
is. Statistical analyses included 
McNemar’s test for matched pairs.20
The criteria for inclusion were as 
follows:
•  Any patient, over the age of 
18 years, admitted to hospital for 
open cholecystectomy, who was at 
increased risk for infection.
•  The absence of infection out­
side the biliary tree according to the 
history and physical examination.
Criteria for exclusion were:
•  Antimicrobial therapy within 7 
days of entry into the study.
•  A history of hypersensitivity 
to penicillin or cephalosporins.
•  Pregnancy.
•  Organisms cultured from 
blood samples taken preoperatively.
Twenty-two patients were exclud-
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ed from the study because of a 
change of antimicrobials (4 pa­
tients) and lack of bile cultures (18 
patients). Therefore, the charts of 
81 patients who satisfied the cri­
teria were analysed.
Antimicrobial Use
Both antimicrobials were admin­
istered by intermittent intravenous 
infusion over 30 minutes; the first 
dose (piperacillin 2.0 g, cefazolin 
1.0 g) was given on call (less than 1 
hour) to the operating room and 
then every 6 hours postoperatively 
for 24 hours.
Conduct of the Study
A complete clinical evaluation 
form detailing the patient’s history, 
presenting complaints and physical 
findings was completed. The labora­
tory tests carried out preoperatively 
and postoperatively are detailed in 
Table I. All patients were apprised 
of the aims of the study and the 
possible risks and the benefits and 
signed a consent form approved by 
the Ethics Subcommittee of the
Table I. Investigations Carried Out 
Preoperatively and Postoperatively on 81 
High-Risk Patients Who Underwent Open 
Cholecystectomy
Preoperatively
Complete blood count and differential 
count
Serum alanine aminotransferase, serum 
aspartate aminotransferase and total 
bilirubin measurements 
Serum urea nitrogen, creatinine, electro­
lytes and fasting plasma glucose mea­
surements 
Blood culture 
Urinalysis
Abdominal ultrasonography 
Chest radiography 
Postoperatively
Complete blood count and differential 
count
Serum alanine aminotransferase, serum 
aspartate aminotransferase and total 
bilirubin measurements 
Serum urea nitrogen, creatinine, electro­
lytes and fasting plasma glucose mea­
surement 
Urinalysis
Research Committee of St. Joseph’s 
Health Centre.
Gallbladder bile specimens ob­
tained at operation from all patients 
were cultured aerobically and anae­
robically. Operative findings and 
exact surgical procedures were doc­
umented. Postoperatively, patients 
were evaluated for drug toxicity and 
evidence of infection, including 
wound sepsis. The follow-up was 
for 6 weeks.
All isolates were identified by 
standard criteria.13 Sensitivity pat­
terns of facultative bacteria were 
determined by the agar dilution 
method14 with the multiple inocula 
device on undivided plates,15 and by 
the Kurzynski method for anaerobic 
bacteria.16 The following quality- 
control organisms were tested daily 
throughout the study: E. coli ATCC 
25922, Pseudomonas aeruginosa 
ATCC 27853, Staphylococcus au­
reus ATCC 25923 and Streptococ­
cus faecalis ATCC 33186. Bacterial 
isolates, infections and any change 
in laboratory parameters were com­
pared for both groups.
Results
The distribution of the 81 pa­
tients in the study according to the 
inclusion criteria are summarized in 
Table II; 40 received cefazolin and 
41 received piperacillin. The pa­
tients ranged in age from 22 to 82
years (mean 55 years) in the cefazo­
lin group and from 23 to 86 years 
(mean 58 years) in the piperacillin 
group. The female-to-male ratio was 
3:1 in the cefazolin group and 3.6:1 
in the piperacillin group. The leuko­
cyte count was elevated preopera­
tively in 22 (55%) patients in the 
cefazolin group and 23 (56%) in the 
piperacillin group. There were no 
bacteremic episodes preoperatively 
in either group.
Acute cholecystitis at surgery 
was confirmed in 25 (62%) patients 
in the cefazolin group and 22 (54%) 
patients in the piperacillin group. 
Intraoperative cholangiography for 
possible common bile duct stones 
was done in 11 patients in the
cefazolin group and 9 patients in 
the piperacillin group.
Cultures of bile grew bacteria in
17 (42%) of 40 patients in the
cefazolin group and 12 (29%) of 41 
patients in the piperacillin group. In 
patients from the cefazolin group,
18 (95%) of 19 organisms were
sensitive to piperacillin, whereas 12 
(63%) of 19 isolates were sensitive 
to cefazolin. In the piperacillin
group, 14 (93%) of 15 isolates were 
sensitive to piperacillin, whereas 
only 7 (47%) of 15 were sensitive to 
cefazolin. A combination of all the 
isolates demonstrated that 32 (94%) 
of the 34 isolates were sensitive to 
piperacillin whereas only 19 (56%) 
were sensitive to cefazolin (McNe- 
mar’s test, p < 0.005) (Table III).
Table II. Distribution of the 81 Patients According to Inclusion Criteria
Patients, no.
Inclusion criterion Cefazolin group Piperacillin group
Age > 70 yr 4 3
Acute cholecystitis 25 22
Obstructive jaundice, common-bile-duct 
stones or both 5 5
Chills and fever within 1 wk 1 2
Acute cholecystitis within 1 mo 3 5
Decreased host defences 2* 4 t
Total 40 41
'Diabetes mellitus 
t1 uremia, 3 diabetes mellitus
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Clearly, piperacillin provides better 
coverage for gallbladder isolates 
than cefazolin.
During the 6-week follow-up 
there were no changes in the leuko­
cyte count, liver function test re­
sults or serum creatinine levels, and 
there were no adverse reactions 
attributable to the antimicrobials in 
either of the two groups.
Three patients in each group had 
postoperative infections. Two from 
the cefazolin group had a urinary
tract infection and one had a wound 
infection. Specimens from the 
wound infection grew Enterobacter 
cloacae that was resistant to cefazo­
lin. None of the isolates of the three 
infections correlated with those of 
the gallbladder bile specimens. One 
patient in the cefazolin group had 
common bile duct exploration for 
stones, and two patients had acute­
ly inflamed gallbladders. Two pa­
tients from the piperacillin group 
had wound infections due to Kleb­
siella pneumoniae and Bacillus pan- 
tothenticus respectively, and a third 
patient had postoperative pneumo­
nia, urinary tract infection and a 
right subhepatic collection of pus 
which grew Klebsiella pneumoniae, 
Klebsiella oxytoca, P. aeruginosa 
and Enterococcus sp.). All three 
patients with obstructive jaundice 
underwent exploration of the com­
mon bile duct. None of the isolates 
of the five infections correlated with 
the results of gallbladder cultures.
Table HI- Organisms Isolated From Gallbladder Specimens in the Two Groups and the Sensitivities of the Organisms to Cefazolin and Piperacillin
Cefazolin group Piperacillin group
No of ____ Sensilivity to___  Nq Sensitivity to
Organisms___  ___  isolates Cefazolin Piperacillin isolates Cefazolin Piperacillin
Escherichia coli 
Enterobacter cloacae 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Pseudomonas aeruginosa 
Pseudomonas acidovorans 
Enterococcus sp 
^hem olytic  Streptococcus 
Staphylococcus aureus 
Bacillus sp
Peptococcus anaerobius 
Clostridium perfringens
Totalt_________________________________ _______________________ _________ 12________ 18____________15§_______ 7________  14
"One of two Klebsiella pneumoniae isolates and one of three enterococcal isolates showed moderate sensitivity to piperacillin 
tMcNemar’s test, p <  0.005 
fFrom 17 patients 
§From 12 patients
4 4 4 2 2 2
3 0 3 3 0 3
2 2 2 2 2 V
0 0 0 2 1 2
0 0 0 1 0 1
1 0 1 0 0 0
3 0 2 * 2 0 2
3 3 3 1 1 1
1 1 1 0 0 0
0 0 0 2 1 2
1 1 1 0 0 0
1 1 1 0 0 0
Table IV. Sensitivity Patterns of Organisms Isolated From Different Sites of Infection in the Study Groups
Site of 
infection Group
No. of 
infections Organism
No. of 
isolates
Sensitivity to 
cefazolin/ 
piperacillin*
Subhepatic space Piperacillin 1 Klebsiella pneumoniae 1 S/S
Klebsiella oxytoca 1 s / s
Pseudomonas aeruginosa 1 R/S
Enterococcus sp 1 R/S
Sputum Piperacillin 1 Escherichia coli 1 S /S
Proteus mirabilis 1 S /S
Staphylococcus aureus 1 S/SUrine Cefazolin 2 Providencia rettgeri 1 R/S
Piperacillin 1 Escherichia coli 1 S/S
Staphylococcus epidermidis 3 S/SWound Cefazolin 1 Bacillus pantothenticus 1 R/S
Piperacillin 2 Enterobacter cloacae 1 R/S
Klebsiella pneumoniae 1 R/S
Totalt 8 * 15 S/S =  9
_____________________________________________________________ R/S =  6
*S =  susceptible, R =  resistant
tMcNemar’s test, p < 0.001
^Includes different sites of infection in one patient
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In addition, the third patient in the 
piperacillin group had uremia and 
was in the intensive care unit for 1 
month. The sensitivity patterns of 
the organisms that were isolated 
from different sites of infection in 
both groups are summarized in 
Table IV.
When all the isolates from the 
gallbladder and other sites of infec­
tion were combined, a total of 48 
microorganisms from 19 different 
species were identified. Only 29 
(60%) of the 48 organisms were 
sensitive to cefazolin, but all (100%) 
were sensitive to piperacillin (p < 
0.001, McNemar's test).
Discussion
The results of this randomized, 
prospective, double-blind trial of ce­
fazolin versus piperacillin revealed 
no differences in toxicity, adverse 
effects or infection rates, immedi­
ately postoperatively or during the 
6-week follow-up in either group of 
patients.
The average incidence of positive 
bile culture in both groups (42% in
the cefazolin group and 29% in the 
piperacillin group), is similar to that 
reported in the literature.2-8 The 
commonest organism in our study 
was E. coli, which is also reported 
as the commonest bile isolate in 
most series. The second commonest 
isolate found in most studies, as 
in this one, was Enterobacter sp. 
Piperacillin was 100% effective 
against Enterobacter sp., whereas 
cefazolin had no effect.
The incidence of wound infection 
was about 3% in our series, and 
there were no significant differences 
between the two groups. All wound 
isolates were sensitive to piperacil­
lin but not to cefazolin. There was 
no correlation between the organ­
isms grown from the infected 
wound and those grown from gall­
bladder cultures in any of our pa­
tients. Since most wound infections 
after biliary tract surgery are 
caused by organisms isolated from 
bile,2-811 we conclude that prophy­
laxis was effective in both groups. 
This study also presents data that 
clearly show the marked superior 
in-vitro efficacy of piperacillin over 
cefazolin in the treatment of high-
risk patients who undergo open 
cholecystectomy. All species isolat­
ed from both gallbladder specimens 
and postoperative sites of infection 
were sensitive to piperacillin. Ce­
fazolin was ineffective against En­
terococcus sp., E. cloacae, P. 
aeruginosa, Pseudomonas acidovo- 
rans, Providencia rettgeri or B. pan- 
tothenticus. Only 2 of 48 isolates 
showed moderate sensitivity to pi­
peracillin, 1 Enterococcus isolate (1 
of 6) and 1 Klebsiella pneumoniae 
isolate (1 of 5).
One paper studied the efficacy of 
piperacillin in elective biliary sur­
gery; the dosage was 2 g, intramus­
cularly, 2 hours preoperatively, fol­
lowed by 2 g, intravenously, at the 
beginning of the operation.21 Blood 
levels of piperacillin exceeded 
100 m g/L in all cases adhering to 
the dosage regimen, which was well 
above the minimal inhibitory con­
centration for most strains of E. 
coli, Proteus sp., Staphylococcocus 
albus, Pseudomonas sp., S. faecalis 
(enterococci) and nonhemolytic 
streptococci. Both gallbladder and 
common bile duct levels of pipera­
cillin exceeded 50 m g/L .21 Only 1 
of 50 patients had an infection 
postoperatively.
In our study, postoperative uri­
nary sepsis and pneumonia, al­
though more common in the pipera­
cillin group, could not be related to 
perioperative prophylaxis. Similarly, 
the organisms grown from the one 
subhepatic complication did not 
correlate with the gallbladder iso­
lates in that patient.
We conclude that both piperacil­
lin and cefazolin are safe and effec­
tive prophylactic antimicrobials for 
high-risk patients who undergo 
open cholecystectomy. In vitro, 
piperacillin has advantages over ce­
fazolin due to greater coverage 
against Enterococcus, anaerobes 
and E. cloacae. Piperacillin was 
shown to be as effective as cefazolin 
in our study.
T a b le  V . S e n s it iv ity  to  C e fazo lin  and P ip e ra c illin  o f  a ll Iso la te s
O rgan ism
No. of 
iso la tes
S ensitive  to*
C e fazo lin  P iperacillin
Escherichia coli 8 8 8
Enterobacter cloacae 6 0 6
Klebsiella pneumoniae 5 5 5
Klebsiella oxytoca 2 1 2
Pseudomonas aeruginosa 3 0 3
Pseudomonas acidovorans 1 0 1
Proteus mirabilis 1 1 1
Providencia rettgeri 1 0 1
Staphylococcus aureus 2 2 2
Staphylococcus epidermidis 5 5 5
Enterococcus sp 6 0 6
Streptococcus mitis 1 1 1
Streptococcus salivarius 1 1 1
Streptococcus intermedius 1 1 1
V ir id a n s  s tre p to c o c c i 1 1 1
Bacillus pantothenticus 1 0 1
Bacillus sp 1 1 1
Peptostreptococcus anaerobius 1 1 1
Clostridium perfringens 1 1 1
T o ta l 48 29 48
'In c lu d in g  m o d e ra te ly  se n s itiv e
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Item 169
Clostridium difficile is isolated in 2% to 3% of healthy adults, 10% to 15% of hospitalized patients without 
diarrhea, 5% to 15% of adults without diarrhea who have recently received antimicrobials, and 90% to 100% of 
patients with antibiotic-associated diarrhea or colitis with positive toxin assays. Toxin detection, the preferred 
diagnostic method for C. difficile-induced diarrhea, gives a better clinical correlation than stool cultures. Most 
cases of pseudomembranous colitis observed during the past four decades have been associated with 
antimicrobial usage, but the disease has occasionally been seen in patients after operation or those who have 
other acute or chronic illnesses, and even rarely in previously healthy persons with no recent antimicrobial 
exposure and no other identified risk factor. Although Staphylococcus aureus was once believed to be an 
etiologic agent, most cases are now caused by C. difficile. The treatment is oral antimicrobial agents, most 
commonly vancomycin or metronidazole.
B
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Subtotal Splenectomy and Portal Variceal 
Disconnection in the Treatment of Portal 
Hypertension
Andy Petroianu, MD
Bleeding gastroesophageal varices caused by portal hypertension can be treated 
successfully by subtotal splenectomy and central splenorenal shunting. However, in 
elderly patients and those at high risk of hepatic failure, congestive heart failure 
and encephalopathy or when splenorenal anastomosis is impossible, an alternative is 
subtotal splenectomy and portal variceal disconnection. The author reports on the 
first nine patients who underwent this procedure and describes the operative 
technique. Complications of the operation were minimal. One patient had 
thrombocytosis, but this was controlled clinically. No patient experienced 
encephalopathy during a follow-up ranging from 10 months to 8 years. No 
rebleeding was noted in seven of the patients, but two had a bleeding duodenal 
ulcer, which was treated successfully. Liver function was preserved in all patients.
These results have encouraged the author to continue investigation of subtotal 
splenectomy and portal variceal disconnection.
Les hemorragies de varices gastro-oesophagiennes causees par une hypertension 
porte peuvent etre traitees avec succes par splenectomie sous-totale et par 
derivation splenorenale centrale. Toutefois, chez les patients ages et chez ceux qui 
sont a risque eleve de souffrir d’insuffisance hepatique ou cardiaque, ou 
d’encephalopathie, ou quand il est impossible de realiser une anastomose 
splenorenale, l’alternative consiste a pratiquer une splenectomie sous-totale avec 
interruption de la circulation porte vers la varice. L’auteur decrit les neuf premiers 
cas qu’il a soumis a cette intervention, de meme que la technique operatoire. Les 
complications operatoires sont minimes. Un patient a souffert d’une thrombocytose 
qui fut maitrisee cliniquement. Aucun patient n’a souffert d’encephalopathie 
pendant la periode de suveillance qui va de 10 mois a 8 ans. Aucune nouvelle 
hemorragie n’est survenue chez sept patients; deux ont toutefois eu des 
hemorragies d’ulceres duodenaux, lesquelles furent traitees avec succes. La fonction 
hepatique a pu etre preservee dans tous les cas. Ces resutats ont stimule 1 auteur a 
poursuivre ses recherches sur les effets a long terme de la splenectomie sous-totale 
avec interruption de la ciculation porte vers la varice.
L ife-threatening hemorrhage due to gastroesophageal varices is 
an indication for operation in pa­
tients with portal hypertension.1' 6 
The standard treatments for this 
condition consist of portal-systemic
shunting, portal-variceal disconnec­
tion and endoscopic sclerotherapy 
of esophageal varices.1' 3-5' 10 
Shunting procedures seem to be 
the most effective treatment. How­
ever, these methods may result in
postoperative problems such as he­
patic failure, cardiopulmonary con­
gestive dysfunction and enceph­
alopathy ,4-5-7' 911 especially in pa­
tients older than 50 years.1-3-7-911 
Another surgical option for high-
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risk patients is total splenectomy 
and portal-variceal disconnection. 
This avoids hepatic, cardiopulmo­
nary and cranial complications but 
may be harmful to hematologic and 
immunologic systems due to remov­
al of the spleen.3-5-7-912
Since 1981, investigators at the 
Federal University of Minas Gerais, 
Belo Horizonte, Brazil, have stud­
ied, experimentally and clinically, 
the treatment of portal hyperten­
sion by subtotal splenectomy and 
central splenorenal shunting.4-13-18
The first 11 patients who under­
went this procedure for the man­
agement of variceal bleeding due to 
portal hypertension caused by 
schistosomiasis all had an uncom­
plicated postoperative course. Re­
bleeding, encephalopathy and he­
patic and cardiopulmonary failure 
were not reported during a 9-year 
follow-up. The size of the varices 
decreased, and the size and function 
of the splenic remnants were un­
changed.
Despite these good results, the 
use of this procedure in elderly 
patients, those with previous signs 
of encephalopathy and those with 
hepatic or cardiopulmonary dys­
function is still of concern. For 
such patients, the use of subtotal 
splenectomy and portal-variceal dis­
connection is proposed. The suc­
cessful treatment of nine patients 
(seven men, two women) by this 
method is described.
Patients and Methods
The patients, ranging in age from 
14 to 60 years (mean [±SD] 40.1 ± 
16.2 years), who had hematemesis 
and melena due to infection with 
Schistosoma mansoni were admit­
ted to the Division of Digestive 
Surgery at the Hospital of Clinics of 
the Federal University of Minas Ge­
rais. All patients were classified as 
having Child’s group A hepatopa-
thy. They had hepatosplenomegaly 
and bleeding from gastroesophageal 
varices. Two of the patients were 
scheduled to undergo subtotal sple­
nectomy and central splenorenal 
shunting,4-13 but the splenic vein 
could not be released from strong 
fibrotic adhesions to the pancreas. 
Six patients had severe pancyto­
penia. One patient had psychiatric 
problems. Two others had previous­
ly suffered from hepatitis, but the 
liver function test results were nor­
mal. Another patient had pulmo­
nary hypertension due to schistoso­
miasis. Four patients (42, 56, 57 
and 60 years old respectively) were 
considered to be at risk for sple­
norenal anastomosis because of 
their age. One of them had heart 
failure.
The Operation
In seven of the patients, the 
abdominal cavity was entered 
through a supraumbilical median 
incision. In the other two patients, 
who were to have splenorenal anas­
tomosis, the approach was by a 
diagonal left subcostal incision. The 
peritoneum was carefully opened to
avoid damage to the umbilical vein. 
The splenic artery was ligated in the 
retrogastric space after division of 
the greater omentum. The spleen 
was gently displaced upward and its 
ligaments were divided between lig­
atures or with electrocautery. The 
splenic hilum was dissected and 
ligated with 2-0 silk sutures. Care 
was taken to preserve the spleno- 
gastric vessels.
The subtotal splenectomy was 
performed at the level of the spared 
splenogastric vessels. Two wide 
flaps (anterior and posterior) of the 
splenic capsule were retained. The 
bleeding large vessels of parenchy­
ma were sutured with 3-0 chromic 
catgut. Minor bleeding was con­
trolled with a continuous tight su­
ture of the parenchyma with 0 
chromic catgut on a 5-cm needle. A 
second continuous suture of 0 
chromic catgut was used to close 
the two flaps of splenic capsule 
(Fig. 1). When hemostasis was com­
plete, the splenic stump was re­
placed in its normal position.
Portal-variceal disconnection was 
achieved by tying the left and right 
gastric veins and all posterior gast­
ric veins with 2-0 or 3-0 silk. The
FIG. 1. Upper pole remnant of spleen after subtotal resection shows continuous 
suture of parenchyma (arrowhead) and closure of capsule.
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veins of the gastric lesser curvature 
were carefully tied to avoid damage 
to the vagal branches or the gastric 
wall. All vessels surrounding the 
lower third of the esophagus and 
cardia were also tied. After careful 
revision, the abdomen was closed.
Results
The duration of operation ranged 
from 2.5 to 3 hours. Blood loss was 
minimal and no blood transfusion 
was necessary. Technetium-99m 
sulfur colloid scintigraphy on the 
day after the operation demonstrat­
ed the viability of the splenic rem­
nants in all patients (Fig. 2). The 
pancytopenia had resolved by the 
3rd postoperative day in all cases. 
Thrombocytosis (platelet count up 
to 2100 X 109/L) developed in one 
patient during the 1st month post- 
operatively, but resolved without 
further complications after careful 
clinical monitoring and administra­
tion of acetylsalicylic acid (2 g/d). 
The platelet count 5 months after 
operation was 310 X 109/L .
No signs of encephalopathy were 
noted during a follow-up that 
ranged from 10 months to 8 years. 
No variceal rebleeding was noted in 
seven patients, but the other two 
each had a duodenal ulcer, success-
FIG. 2. Image obtained from techne- 
tium-99m sulfur colloid scintigraphy 
on day after subtotal splenectomy and 
portal-variceal disconnection demon­
strates viability of liver and spleen 
(arrow).
fully treated with ranitidine. Liver 
function was preserved in all pa­
tients. Esophagogastroscopy done 
several months after operation re­
vealed a reduction in variceal size. 
No other major or minor complica­
tions were reported.
Comment
Segmental splenectomy has been 
reported since the last century, but 
it was only after the report of 
Campos Christo19 that this proce­
dure introduced into surgical prac­
tice.41319-20 Subtotal splenectomy 
has been carried out in cases of 
trauma and some hematologic ill­
nesses to preserve the immunologic 
function of the spleen.
The rationale for subtotal sple­
nectomy in portal hypertension is to 
retain the advantages of total sple­
nectomy without losing splenic 
function.4-5-7 91113 Our experimental 
and clinical studies demonstrated 
that it is unnecessary to preserve 
the splenic hilum to maintain the 
viability and function of the upper 
pole.4-13-10-18
The interruption of blood flow 
from the spleen directly to the por­
tal vein reduces the blood volume 
and pressure in the portal system. 
However, I believe that at least part 
of the splenic blood reaches the 
portal vein through the gastric 
veins. On the other hand, experi­
mental studies have described effec­
tive splenic function even when part 
of this organ is transplanted out of 
the portal circulation.21-22 Investiga­
tions at the Federal University of 
Minas Gerais showed that the rem­
nant upper pole and the spleno- 
gastric vessels do not interfere with 
portal hypertension or gastroeso­
phageal varices.4-13
The blood pressure of the upper 
pole of the spleen vascularized by 
the splenogastric vessels was re­
duced, and serious blood loss dur­
ing the subtotal splenectomy was 
thereby avoided. In my experience, 
continuous suture of splenic paren­
chyma has been sufficient to pro­
vide complete splenic hemostasis.
Follow-up scintigraphy and com­
puted tomography showed that 
splenic function was maintained and 
that the dimensions of the splenic 
remnants were unchanged during 
the years of follow-up. Hematologic 
studies confirmed the complete res­
olution of the pancytopenia in all 
cases. Liver function is rarely al­
tered by schistosomiasis, and none 
of our patients, including the two 
who had had hepatitis, presented 
such complications perioperatively.
Subtotal splenectomy and central 
splenorenal shunting continues to 
be performed successfully for portal 
hypertension. However, this proce­
dure is contraindicated for patients 
at high risk of hepatic failure or 
who have cardiopulmonary conges­
tive dysfunction or encephalopathy. 
Subtotal splenectomy and portal- 
variceal disconnection appears to be 
a satisfactory option in these cir­
cumstances and when splenorenal 
anastomosis is impossible.
The value of partial preservation 
of the spleen has been shown in the 
management of trauma and some 
hematologic conditions.19-23 The 
small number of patients and the 
follow-up of 9 years are not enough 
to confirm the advantages of this 
procedure on portal hypertension. 
However, the absence of infectious 
complications and the normal he­
matologic test results over the years 
indicate preservation of immunolog­
ic function by the remnant spleen. 
These findings together with the 
experimental and clinical studies 
demonstrating effective capture of 
foreign colloids by the macrophages 
of the remnant spleen414-17 support 
the efficacy of our surgical tech­
nique of subtotal splenectomy and 
portal-variceal disconnection as an 
alternative treatment for portal hy-
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pertension in elderly and high-risk 
patients.
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Multiple Intrahepatic Cholesterol Stones
Juan R. Sanabria, MD; Pierre A. Clavien, MD; Robert Cywes MD; Steven M. Strasberg, MD, FRCS
The authors report a case of multiple intrahepatic cholesterol stones found in an 
asymptomatic patient who had undergone cholecystectomy 12 years before.
Biochemical abnormalities and radiologic and pathologic findings are noted. The 
patient underwent liver resection with Roux-en-Y choledochojejunostomy and 
received ursodeoxycholic acid postoperatively. Recovery was uncomplicated, and the 
patient was well at 1-year follow-up. Intrahepatic cholesterol lithiasis is rare but can 
be diagnosed preoperatively. Treatment depends on the presence of complications 
and the distribution of the stones.
Les auteurs decrivent un cas de calculs de cholesterol intrahepatiques multiples 
decouverts chez une patiente asymptomatique qui avait subi une cholecystectomie 
12 ans plus tot. Ils signalent les irregularites biochimiques, radiologiques et 
pathologiques observees. La patiente subit une resection hepatique avec 
choledochojejunostomie de Roux-en-Y et re?ut 1’acide ursodeoxycholique en periode 
postoperatoire. La guerison se fit sans complication et la patiente se portait bien un 
an apres l’operation. La lithiase intrahepatique due au cholesterol est rare mais elle 
peut etre diagnostiquee avant l’intervention chirurgicale. Le traitement depend des 
complications et de la repartition des calculs.
Intrahepatic gallstones may be produced in the gallbladder and 
migrate into the bile duct or may 
arise primarily in the bile ducts. 
Duct stones originating in the gall­
bladder may be of the pigment or 
cholesterol type, depending on the 
nature of the stones in the gallblad­
der, although cholesterol stones in 
the bile duct may lead to the forma­
tion of brown pigment stones later 
by inducing stasis and bacterial 
overgrowth in the bile ducts.1 In­
trahepatic stones originating in the 
gallbladder are usually few in num­
ber and are found in association 
with extrahepatic choledocholithia- 
sis. Among patients with gallstone 
disease in Western countries, Simi 
and colleagues2 and Lindstrom3 
have reported frequencies of in­
trahepatic stones of 0.6% and 1.3%, 
respectively. This frequency may 
reach 24% in patients with choledo- 
cholithiasis.4 Primary duct stones 
are almost always of the pigment 
type. They are usually caused by a 
parasitic infection of the biliary 
tree.5 In East Asia, where this prob­
lem is most common, the occur­
rence of intrahepatic stones is al­
most 10%,67 and it is not unusual 
to find patients with hundreds of 
intrahepatic pigment gallstones.89 
Cholelithiasis may coexist.
Reports of large numbers of in­
trahepatic gallstones of the choles­
terol type are rare. To our knowl­
edge there has only been one such 
case documented by detailed chemi­
cal analysis of the stones and de­
scription of the clinical presentation
and treatment.10 Several other case 
reports from Japan have reported 
on patients who almost certainly 
had multiple intrahepatic stones, 
but either the stone type was diag­
nosed on morphologic grounds or 
the method of analysis was not 
given.1112 We present another case 
of multiple intrahepatic cholesterol 
gallstones and discuss the manage­
ment of this rare condition.
Case Report
A 38-year-old woman, born in 
Greece, was referred because of 
abnormal findings on liver function 
testing, which was performed be­
cause she complained of lack of 
energy. In Greece, 22 years earlier,
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she had been hospitalized for 10 
days for an acute episode of icteric 
hepatitis. Twelve years before she 
had had an attack of biliary colic 
complicated possibly by mild acute 
pancreatitis. A cholecystectomy was 
done, but operative cholangiogra­
phy was not performed. The gall­
bladder contained a single, yellow, 
strawberry-like calculus, and cho- 
lesterolosis and chronic cholecysti­
tis were present. The patient be­
came asymptomatic postoperatively.
On examination the patient was 
well nourished (she weighed 69 kg 
and was 170 cm tall), and aside 
from a well-healed subcostal chole­
cystectomy scar, findings on physi­
cal examination were normal. The 
serum bilirubin level was normal. 
Liver enzyme levels were moderate­
ly elevated, the aspartate amino­
transferase level was 73 U/L (nor­
mal less than 35 U/L), the alanine 
aminotransferase level was 168 
U/L (normal less than 55 U/L) and 
the gamma glutamyl transferase 
level was 179 U/L (normal 8 to 80 
U/L). The alkaline phosphatase 
level and complete blood count 
were within normal limits. Hepati- 
tis-B markers, as well as examina­
tion of stools for ova of parasities, 
were negative.
On ultrasonography, multiple 
shadowing lesions compatible with 
gallstones were seen in the common 
bile duct and in the left lobe of the 
liver (Fig. 1A). Abdominal comput­
ed tomography (CT) showed sub­
stantial dilatation of the intrahepat- 
ic biliary tree, particularly on the 
left side, with no sign of external 
compression or stricture of ducts 
but with numerous large stones in 
the common bile duct (Fig. IB). 
Percutaneous transhepatic cholan­
giography (PTC) confirmed dilated 
ducts, which contained hundreds of 
stones of varying sizes within the 
large and small ducts of the left 
lobe of the liver and extending into 
the common bile ducts (Fig. 1C). A
fever developed after this proce­
dure. A diagnosis of cholangitis was 
made, and the patient was operated 
on electively after the cholangitis 
had responded to antibiotics.
Operation
At operation the bile duct was 
found to be dilated to about 2 cm in 
diameter, and stones could be pal­
pated along its length. Through a 
choledochotomy, multiple large 
stones were removed from the com­
mon bile duct, common hepatic 
duct and left hepatic ducts and 
perhaps the main right duct. Chole­
dochoscopy revealed a clear ductal 
system in the right lobe and stones 
blocking the left main duct. A left 
lateral segmentectomy was per­
formed. The left lateral segmental 
duct was very large (2 cm) as were 
its branches, and several hundred 
stones were removed from it. These 
stones, as well as those in the 
extrahepatic bile ducts, were 
smooth, facetted and white, and 
spilled out of the ductal system. 
Once the segment was resected it 
was possible to remove additional 
stones from the left medial seg­
ment. Repeat choledochoscopy re­
vealed that the residual biliary tree 
was free of stones. Particular care 
was taken to evaluate the patency 
of the ductal system, and there was 
no evidence of strictures in the 
biliary tree. The left segmental duct 
was oversewn. A side-to-side Roux- 
en-Y choledochojejunostomy was 
performed in such a way that the 
anastomosed intestine was carried 
slightly onto the right hepatic duct, 
so that the left duct orifice opened 
directly into the loop. To provide 
easy access should recurrent stones 
develop, the side of the efferent 
limb was sewn to the anterior ab­
dominal wall about 15 cm from the 
anastomosis.
When the patient was discharged 
9 days after operation, she tolerated
a full diet. She was started on 
ursodeoxycholic acid, 250 mg/d. 
No complications were recorded 
during her hospitalization.
Pathological Findings and 
Biochemical Analysis
Liver sections showed prominent 
intrahepatic biliary dilatations lined 
with cuboidal epithelium that did 
not exhibit excessive proliferative 
activity and in some areas contained 
inspissated bile. Cell infiltration in 
periportal areas by granulocytes 
was common (Fig. 2A). Liver cells 
appeared compressed by periductal 
tissue with concentric “onion-skin” 
fibrosis (Fig. 2B). Despite some in­
crease in periportal fibrous tissue, 
the delicate reticulin framework of 
the liver parenchyma was intact 
with no changes indicative of cir­
rhosis (Fig. 2C). Stone analysis was 
performed by standard techniques. 
Stones were weighed, crushed and 
placed in hexane. Cholesterol was 
measured by gas-liquid chromatog­
raphy. The stones were found to be 
99% cholesterol by weight.
Follow-up
The clinical course was uncompli­
cated. Five months after surgery, 
signs and symptoms of a duodenal 
ulcer developed. The ulcer was suc­
cessfully treated with H2-receptor 
blocking agents. An abdominal CT 
scan revealed no abnormalities and 
all liver function test results were 
normal. The patient was well 1 year 
after surgery.
Discussion
Intrahepatic cholesterol stones 
may originate from the gallbladder 
and be missed at cholecystectomy, 
especially if cholangiography is not 
performed. It is also possible that 
cholesterol stones rarely form in the
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FIG. 1. Radiologic findings in patient with multiple intra- 
hepatic cholesterol stones. (Top) Ultrasonogram of left hepatic 
lobe shows dilated bile ducts which contain multiple acoustic 
shadows (AS) of various sizes. (Middle) Computed tomography 
scan confirms dilatation of intrahepatic biliary tree, particular­
ly on left (arrow), with no sign of external compression. 
(Bottom) Percutaneous transhepatic cholangiogram demon­
strates hundreds of stones of many sizes within large and 
small ducts of left hepatic lobe, extending into common bile 
ducts (arrow).
FIG. 2. (A) Liver section shows prominent biliary dilatations 
(BD) with cell infiltration by granulocytes around portal area 
(PV) (hematoxylin-eosin, original magnification X 125). (B) 
“Onion-skin” fibrosis of periductal tissue (arrow) which 
appears to compress adjacent liver cells (hematoxylin-eosin, 
original magnification X 750). (C) Staining for fibrous tissue 
shows intact reticulin framework of liver parenchyma (Mallo­
ry’s triple stain, original magnification X 250).
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ductal system or that they increase 
in size in the ductal system. Al­
though one cannot deny conclusive­
ly that stones were missed at the 
original operation, the bulk of the 
cholesterol stones must have 
formed in the bile ducts. In the left 
ductal system small stones filled the 
smaller ducts and large stones filled 
the main ducts. The mass of stones 
recovered was large, and the chole- 
dochus was very wide and stuffed 
with large and easily palpated 
stones. It seems inconceivable that 
before cholecystectomy this mass of 
stones emptied itself from the gall­
bladder, leaving only one stone be­
hind, that it distributed itself ac­
cording to size exclusively in the 
left ductal system and that a sur­
geon missed the very obvious ductal 
findings at the initial operation. On 
the other hand one cannot com­
pletely rule out the possibility that a 
myriad of tiny stones that were 
originally in the gallbladder passed 
into the ductal system and grew in 
it. In the latter case, finding these 
large, exclusively cholesterol stones 
is still remarkable because they 
grew in the ductal system as choles­
terol and not pigment calculi.
Cholesterol gallstones do not 
form normally in the bile ducts. 
Although hepatic bile is super­
saturated with cholesterol and is 
usually more supersaturated than 
gallbladder bile, the supersaturation 
is due to the dilute state of the bile 
as opposed to the presence of great­
er amounts of cholesterol.1314 The 
supersaturated but dilute hepatic 
bile usually takes several days to 
nucleate cholesterol crystals.14 This 
is much slower than the less satu­
rated but more concentrated gall­
bladder bile.14 Even within the gall­
bladder it has been shown that 
concentration favours nucleation.15 
The stability of hepatic bile is likely 
owing to the fact that at the con­
centration of lipids present in hepat­
ic bile most cholesterol is carried in
vesicles with a low cholesterol-to- 
phospholipid ratio.16 As bile be­
comes concentrated, lipid shifts 
from vesicle to micelle, resulting in 
vesicles with high cholesterol-to- 
phospholipid ratios that are prone 
to nucleate cholesterol crystals.
There are several reasons why 
cholesterol stones might form in 
the bile ducts. The bile duct system 
is capable of water absorption,17 
although normally this is offset by 
secretion, especially after meals. It 
seems possible that rarely, perhaps 
particularly after cholecystectomy, 
duct reabsorption might be in­
creased to a point where hepatic 
bile reaches a concentration at 
which nucleation of cholesterol is 
possible. Another less likely possi­
bility is that hepatic lipid secretion 
rates may result in bile so super­
saturated with cholesterol that nu­
cleation from dilute bile will occur. 
Finally, it is possible that pronu- 
cleating substances might induce 
lipid shifts at dilute concentrations 
that are only found normally in 
concentrated bile or induce nucle­
ation in dilute bile by some other 
mechanism. Stricture formation and 
infection are common etiologic 
events in the much more common 
problem of multiple intrahepatic 
pigment gallstones.151819 There 
were no strictures in the ductal 
system nor was there evidence of 
infection, although there was fi­
brous reaction in the ducts. The 
ease with which the stones fell out 
of the ductal system was much 
different from what is found in 
pigment intrahepatic lithiasis, in 
which the stones seem almost to 
adhere to the duct walls.
Our patient was either asymp­
tomatic or had very mild symptoms. 
The cholangitis that occurred fol­
lowed investigation by PTC and 
resolved. The decision to treat was 
based on the belief that such multi­
ple intrahepatic stones are likely to 
cause complications. The preopera­
tive diagnosis was multiple pig­
ment-stone lithiasis, possibly associ­
ated with a degree of stricture for­
mation. At operation it was not 
possible to clear the ductal system 
from below. Resection of the left 
lateral segment (Couinaud seg­
ments 2 and 3) was accomplished 
easily at very little risk and achieved 
several goals. It removed the bulk 
of the stones and the damaged por­
tion of the liver and the probable 
site of stone formation. It provided 
excellent access to the ductal sys­
tem of the left medial segment from 
above and below. The choledochoje- 
junostomy with percutaneous ac­
cess was precautionary, and the pa­
tient was maintained on a night­
time dose of ursodeoxycholic acid, 
250 mg/d.
This is the second case of multi­
ple intrahepatic stones in which the 
clinical course, biochemical compo­
sition and treatment is described in 
detail. Strichartz and associates10 
recently presented a case in which 
sequential biliary biochemical analy­
ses were performed after surgical 
treatment complemented with oral 
dissolution agents. Chenotherapy 
decreased the cholesterol saturation 
index from hepatic bile, probably 
preventing further stone formation. 
These two cases are remarkably 
similar. Another recent report from 
Japan documented multiple choles­
terol stones in one patient at autop­
sy in association with cholangiocar- 
cinoma.12 Saito and colleagues11 re­
ported three cases treated by resec­
tion; the method of chemical analy­
sis and the outcome of treatment 
were not stated.
The diagnosis of multiple in­
trahepatic cholesterol gallstones 
should be considered especially 
when multiple intrahepatic stones 
are seen in occidentals and when 
the usual history of repeated bouts 
of cholangitis are absent. Obtaining 
a stone at endoscopic retrograde 
cholangiopancreatography would
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allow assay of cholesterol content 
of the stone and make the diagno­
sis. It is even possible that the 
disease might be amenable to ur- 
sotherapy.
Intrahepatic stones can be found 
in as many as 24% of patients with 
choledocholithiasis.4 The incidence 
of intrahepatic stones has not 
changed significantly through the 
last century although there is a 
declining trend in the most recent
reports (Table 12-4.6-8,20-28) We have 
calculated that about 5% of symp­
tomatic patients with gallstones 
have intrahepatic calculi, although 
the incidence of primary and multi­
ple cholesterol intrahepatic stones 
is not known. There are a number 
of reports of intrahepatic stones 
treated by liver resection with low 
death rates and reduced complica­
tions during the follow-up (Table
JJ2.8.9.27-31)
Conclusions
Intrahepatic cholesterol lithiasis 
is rare but may be recognized pre- 
operatively. Treatment depends on 
the presence of complications and 
the distribution of the stones.
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NOTICES
AVIS
Fourth Annual Rush Symposium 
on Transplantation
“Broaching the Biological Barriers to 
Transplantation” will be the topic of 
the Fourth Annual Rush Symposium on 
Transplantation. The symposium will be 
held at Rush-Presbyterian-St. Lukes’s 
Medical Center in Chicago on June 26, 
1993. Specific attention will be given to 
the features of immune function that 
offer a common barrier to the success­
ful transplantation of both solid organs 
and bone marrow. The registration fee 
is $150 US. To register for the sympo­
sium or for more information contact: 
The Transplant Program Physician Re­
lations Coordinator at (312) 942-6242.
GI Tract Laparoscopic Surgery 
International Meeting
The third international meeting on gas­
trointestinal tract laparoscopic surgery 
will be held in Liege, Belgium, on Sept. 
9 and 10, 1993. The morning sessions 
will feature operative demonstrations. 
The afternoons sessions will concen­
trate on two themes: the presentation of 
the most recent techniques and the 
evolution of surgical techniques in well- 
tried operations. Each speaker will pres­
ent his or her own experience and initial 
and latest results. For more information 
contact: Catherine Marissaux, Clinique 
Saint-Joseph, rue de Hesbaye 75, B- 
400, Liege, Belgium.
Cutaneous Malignancies:
1994 Skin Cancer Update
This course, designed for physicians 
with an interest in skin cancers, will 
take place from Jan. 21 to 23, 1994, at 
the Sheraton Grande Torrey Pines 
Hotel in La Jolla, Calif. Sponsored by 
Scripps Clinic and Research Founda­
tion, the course is designed for derma­
tologists, oculoplastic surgeons, oph­
thalmologists, head and neck surgeons, 
plastic surgeons and other physicians 
with an interest in skin cancers. The 
course will provide an update on cuta­
neous neoplasms, melanoma and facial
continued on page 275
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Value of Cultures of Tissue Samples Taken 
at Operation for Lower Intestinal Perforation
Frankie O.G. Fraulin, MD; Olin G. Thurston, MD, FACS, FRCSC
Tissue cultures from perforations of the lower intestinal tract commonly yield both 
aerobes (coliform organisms) and anaerobes (Bacteroides sp. and Clostridium sp.).
To determine the consistency of this pattern and the value of intraoperative 
cultures, the authors reviewed the hospital records of 115 patients with perforation 
of the appendix (100 patients) or colon (15 patients), treated between 1987 and 
1990, in whom organisms were cultured from tissue samples taken intraoperatively.
Attention was paid to the organisms cultured, their distribution and antibiotic 
sensitivity in initial samples and in subsequent samples obtained when there were 
septic complications.
On average, 4.7 bacterial isolates per patient were obtained. The common 
organisms were as expected: Bacteroides fragilis, Escherichia coli and Clostridium 
sp. Although the culture results did not affect the management of these patients, the 
sensitivity of Bacteroides fragilis to cefoxitin was found to be lower than expected, 
indicating a shift in sensitivity.
Les cultures des tissus adjacents a une perforation des voies intestinales inferieures 
revelent generalement la presence d’aerobies (des coliformes) et d’anaerobies 
(Bacteroides sp. et Clostridium sp.). Afin de verifier la Constance de cette 
observation et l’utilite des prelevements effectues en cours de chirurgie pour fins de 
culture, les auteurs ont etudie les dossiers de 115 patients souffrant d’une 
perforation de l’appendice (100 patients) ou du colon (15 patients) qui furent traites 
entre 1987 et 1990, et dont des microorganismes furent cultives a partir des 
echantillons tissulaires preleves durant la chirurgie. On a recherche les types 
d’organismes isoles, leur distribution, leur sensibilite initiale aux antibiotiques et 
celle qu’ils exhiberent subsequemment lorsqu’il y eut des complications infectieuses.
Une moyenne de 4,7 isolats bacteriens furent obtenus par patient. Les 
microorganismes les plus frequents furent ceux auxquels on s’attendait: Bacteroides 
fragilis, Escherichia coli et Clostridium sp. Bien que les cultures bacteriennes 
n’aient pas influence le traitement des patients, la sensibilite du Bacteroides fragilis 
a la cefoxitine s’est averee plus faible qu’anticipe, ce qui indique un deplacement de 
la sensibilite de ce microorganisme.
The bacteria encountered in per­forations of the lower intestinal 
tract have been well characterized; 
they represent a mixture of the 
normal aerobic and anaerobic enter­
ic flora.1-2 For example, the most 
common groups isolated include co­
nforms or gram-negative aerobes 
(e.g., Escherichia coli), gram-nega­
tive anaerobes (e.g., Bacteroides
fragilis), gram-positive anaerobes 
(e.g., Peptostreptococcus and Clos­
tridium sp.) and, less commonly, 
gram-positive aerobes (e.g., a- 
hemolytic Streptococcus).
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In practice, when a patient is 
operated on for bowel perforation, 
it is almost routine for samples of 
peritoneal fluid to be taken for 
culture; and it is often taken for 
granted that the results will influ­
ence the choice of antibiotics to be 
given postoperatively. Furthermore, 
many studies3 6 have compared vari­
ous combinations of antibiotics in 
the treatment of appendiceal perfo­
rations. The common conclusion 
from these studies is that the pa­
tient requires broad-spectrum anti­
biotics to cover both the aerobic 
and anaerobic flora.3-6 Therefore, if 
we know that polymicrobial organ­
isms will be cultured and that the 
antibiotics needed to treat them 
must be broad spectrum, we must 
question the value of tissue culture 
in the first place.
To determine if there is any need 
for tissue culture at operation in 
cases of perforation of the lower 
intestinal tract, we set out to an­
swer two questions: (a) Does culture 
of peritoneal fluid obtained at oper­
ation ever yield organisms other 
than the ones expected? and (b) Do 
the results of these cultures actual­
ly influence patient management 
postoperatively?
Method
We reviewed the hospital records 
of 115 patients (70 males, 45 fe­
males), treated between July 1987 
and April 1990 at the Walter C. 
Mackenzie Health Sciences Centre, 
University of Alberta, who met the 
following criteria: (a) had perfora­
tion of the appendix (100 patients) 
or colon (15 patients); (b) had sam­
ples of peritoneal fluid taken in- 
traoperatively for culture; and (c) 
had positive culture results, and the 
organisms were identified.
The hospital courses of these 
patients were reviewed with particu­
lar attention to the organisms cul­
tured, their antibiotic sensitivity, 
the antibiotics chosen and the sep­
tic complications. In our hospital, 
aerobic cultures are taken with cot­
ton swabs (Starswab; Starplex Sci­
entific, Etobicoke, Ont.); anaerobic 
cultures are taken with cotton 
swabs and transported in anaerobic 
culture media (Port-a-cul tube; 
Beckon Dickinson Microbiology 
Systems, Cockeysville, Md.). Antibi­
otic sensitivities were not reported 
for all organisms cultured; if sensi­
tivities were measured, they were 
reported as sensitive, moderately 
sensitive, or resistant.
Results
Epidemiologic Findings
The patients ranged in age from 
8 months to 88 years (mean 38 
years). On average 4.7 different
Table 1. Type of Aerobes Isolated and 
Number of Isolates
Organism No. of isolates
Escherichia coli 
a-hemolytic
85
Streptococcus 32
Pseudomonas sp 15
Klebsiella sp 12
Eikenella corrodens 10
Group D Streptococcus 
/7-hemolytic 
Streptococcus (not
8
group A, B, C or G) 
Group C /3-hemolytic
8
Streptococcus 
Group F ^-hemolytic
6
Streptococcus
Staphylococcus
5
epidermidis 5
Diphtheroids 3
Haemophilus sp 3
Proteus sp 2
Citrobacter sp 2
Salmonella sp 
Streptococcus
2
pneumoniae 1
Corynebacterium sp 1
Enterobacter cloacae 1
Morganella morganii 
Gram-positive cocci, not
1
specified
Gram-negative bacilli, not
8
specified 5
Total 215
species of bacteria, both aerobes 
and anaerobes, were isolated per 
patient from the cultures. Tissue 
cultures yielded aerobic and anaero­
bic organisms in 99 of the 115 
patients (86%), aerobes only in 12 
(10%) and anaerobes only in 4 (3%).
Organisms Cultured
Out of a total of 537 bacterial 
isolates, 215 (40%) were aerobes 
and 321 (60%) were anaerobes; 1 
was a yeast. The commonest organ­
isms isolated were the ones we 
expected to find (Tables I and II).
For aerobes, E. coli predominated 
(85 isolates), followed by a- 
hemolytic Streptococcus (32 iso­
lates) and Pseudomonas sp. (15 
isolates). For anaerobes, Bacter- 
oides sp. (108 isolates) predominat­
ed (the most common being Bacter- 
oides fragilis), followed by Clostridi­
um sp. (54 isolates) and Peptostrep- 
tococcus sp. (31 isolates).
Bacterial Sensitivity
For 92 (80%) of the 115 cultures, 
antibiotic sensitivities were report­
ed, most commonly for Bacteroides 
sp. and E. coli.
For the 108 Bacteroides isolates,
Table II. Type of Anaerobes Isolated and 
Number of Isolates
Organism No. of isolates
Bacteroides fragilis 61
Bacteroides sp 47
Clostridium sp 54
Peptostreptococcus sp 31
Eubacterium lentum 19
Microaerophilic
Streptococcus 16
Fusobacterium sp 12
Veillonella sp 2
Lactobacillus sp 2
Gram-positive cocci, not
specified 23
Gram-positive bacilli,
non-spore forming, not
specified 39
Gram-negative bacilli, not
specified 15
Total 321
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74 (69%) had antibiotic sensitivities 
reported; 20 (27%) of these isolates 
were resistant, and 21 (28%) were 
only moderately sensitive to cefox­
itin. All were sensitive to met­
ronidazole.
For the 85 E. coli isolates, 77 
(91%) had antibiotic sensitivities re­
ported; 19 (25%) were resistant and 
22 (29%) were only moderately sen­
sitive to ampicillin. One isolate was 
resistant to gentamicin.
Patient Management
All but two patients received anti­
biotics preoperatively, and all pa­
tients received them postoperative- 
ly. The average length of antibiotic 
therapy for patients with appen­
diceal perforation was 6.6 days, 
compared with 19.5 days for pa­
tients with colonic perforations.
Culture results appeared to influ­
ence the addition or deletion of 
antibiotics in only eight patients 
(7%). For example, if a patient was 
given cefoxitin postoperatively and 
the culture grew Bacteroides sp. 
resistant to cefoxitin, therapy would 
appear to have been influenced by 
the culture results only if a change 
in antibiotics was made.
In contrast, culture results did 
not appear to influence therapy in 
107 (93%) patients. The majority of 
these (61 patients [57%]) were 
placed on “triple” antibiotic therapy 
postoperatively, consisting of met­
ronidazole, gentamicin and either 
penicillin or ampicillin, and no ad­
justment was made in the antibiot­
ics despite the culture results. (Oth­
er frequent combinations included 
cefoxitin and metronidazole or ce­
foxitin alone.)
Antibiotics and Antibiotic 
Sensitivity
We also compared the relation­
ship of the antibiotics the patient 
was receiving with the antibiotic
sensitivity of the organisms in cul­
ture. If a patient was receiving 
antibiotics that covered the organ­
isms cultured according to the sen­
sitivity data, the situation was con­
sidered “ideal” (64 patients). If the 
antibiotic therapy and sensitivity 
data did not coincide, the situation 
was considered “non-ideal” (16 pa­
tients) (Because of a lack of sensi­
tivity data or because the sensitivi­
ties given were not to any antibiot­
ics the patient was receiving, 35 
patients were excluded from these 
two groups.) Patients in the “non­
ideal” group would be expected to 
have a higher complication rate 
because they were receiving inap­
propriate treatment. However, we 
found no difference in the septic 
complication rate between the two 
groups. Thirteen (20%) of the "ide­
al” cases had septic complications 
compared with 3 (19%) of the “non- 
ideal” cases.
Septic Complications
Twenty-two patients suffered sep­
tic complications related to the 
original perforation. These complb 
cations can be categorized as fol­
lows; wound infection (10); intra­
abdominal abscess (4); wound de­
hiscence (2); septic shock (2); pul­
monary infection (2); perforation at 
another intestinal site (1); and 
thrush (1). Four of these patients 
died (one patient with wound dehis­
cence, both patients with septic 
shock and one patient with pulmo­
nary infection).
Of those who had an original 
diagnosis of perforated appendix, 
14% had septic complications. Of 
those who had an original diagnosis 
of perforated colon, 53% had septic 
complications.
Samples of tissue were taken 
from the complication site for cul­
ture in 18 of the 22 patients. The 
most common organisms cultured 
were again representative of the
normal enteric flora. Again, the 
culture results did not appear to 
have influenced therapy. The major­
ity of these patients were placed on 
triple antibiotic therapy or imipe- 
nem.
Discussion
In answer to the first of the two 
questions we posed — Does culture 
of peritoneal fluid obtained at oper­
ation for perforation of the lower 
intestinal tract ever yield organisms 
other than the ones expected? — 
we found that the organisms cul­
tured were predictable in samples 
obtained at the first operation and 
in subsequent complications and 
were usually a combination of aero­
bic and anaerobic organisms.
The relationship between aerobes 
and anaerobes in intra-abdominal 
infection has been shown to be 
synergistic in animal models.78 
Brook, in 19801 and 19892, de­
scribed the variety of possible or­
ganisms cultured. He found B. fra- 
gilis, E. coli and Peptostreptococ- 
cus to be the predominant patho­
gens. Our results contrast only in 
that Clostridium sp. was the third 
most common isolate, closely fol­
lowed by Peptostreptococcus and 
a-hemolytic Streptococcus.
We did not find any unusual 
organisms. We had only one yeast 
isolate, which bore no relation to 
the severity of illness or subsequent 
complications. In a recent study of 
tissue samples taken at operation 
for perforation of the upper intesti­
nal tract, several isolates of yeast 
were cultured and were associated 
with an increased septic complica­
tion rate and mortality.9 Three pa­
tients in our study had chronic 
renal failure but the organisms cul­
tured were not unusual. None of 
our patients had acquired im­
munodeficiency syndrome (AIDS).
There have been infrequent re-
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ports of unusual organisms cul­
tured; Salmonella newport and Shi­
gella flexneri have both been associ­
ated with toxic megacolon and co­
lonic perforation.1011 A toothpick 
perforation of the sigmoid colon 
associated with Erysipelothrix rhu- 
siopathiae septicemia has been re­
ported.12 A patient with AIDS who 
had colonic perforation and cytome­
galovirus vasculitis has also been 
reported.13
Unusual organisms often require 
special culture media to grow, 
which may explain why certain or­
ganisms were not cultured. More 
important, in terms of virulence and 
frequency, are the anaerobes and 
the difficulty in culturing them. 
Improper collection techniques and 
prolonged exposure to oxygen can 
decrease the number of strains iso­
lated.14 It has also been suggested 
that the number and variety of 
organisms cultured depend on pre­
operative antibiotic therapy.215
In answer to the second question 
we posed — Do the results of these 
cultures actually influence patient 
management postoperatively? — we 
found that cultures and antibiotic 
sensitivity data added little to the 
management of these patients. Cul­
ture results influenced antibiotic 
therapy in only 7% of patients after 
the initial operation and in none of 
the patients who had septic compli­
cations.
Dougherty and associates16 re­
ported a similar percentage in their 
review of bacterial cultures in perfo­
rated or gangrenous appendicitis. 
They also tried to identify predic­
tors of culture influence on antibi­
otic management. The three most 
important predictors, according to 
Dougherty and associates, were the 
occurrence of infectious complica­
tions postoperatively, isolation of 
organisms resistant in vitro to pre­
vious antibiotic therapy and pro­
longed courses of antibiotics. How­
ever, because of the low number of
patients whose culture results actu­
ally influenced management (7 of 
104 patients), the value of these 
predictors is questionable.
As already mentioned, most pa­
tients in our study received triple­
antibiotic therapy postoperatively. 
However, some were placed on ce­
foxitin alone. We found that Bacter- 
oides sp. were more resistant than 
expected (27%) and had only mod­
erate sensitivity (28%) to cefoxitin 
in in-vitro culture. These figures 
agree with the low sensitivity rate 
of B. fragilis to cefoxitin (only 50%) 
reported by the Department of Med­
ical Microbiology at the University 
of Alberta Hospitals in their Janu­
ary to June 1991 antibiogram.17 A 
nationwide study done in the United 
States in the early 1980s also 
showed increasing resistance of this 
organism to cefoxitin, although to a 
lesser degree at that time (10% 
resistance in 1982, 16% resistance 
in 1983).18 Both in our hospital and 
in the United States study, there 
has been 100% sensitivity of B. 
fragilis to metronidazole and chlor­
amphenicol. The authors of the 
United States study suggested that 
the reasons for increased resistance 
may be epidemiologic factors that 
result in a decrease in the perme­
ability of the outer membrane or an 
increase in the /3-lactamase content. 
Changing sensitivity rates is a good 
indication for continued monitoring 
to detect the emergence of out­
breaks due to resistant organisms.
Conclusions
We found that routine bacterial 
cultures were not useful in the 
clinical management of patients 
with perforations of the lower intes­
tinal tract. However, the cultures 
were of some “value” in that they 
showed a lower than expected sen­
sitivity of Bacteroides sp. to cefox­
itin. This has resulted in a de­
creased use of cefoxitin by the 
general surgeons in our hospital 
and an increased use of met­
ronidazole.
The value of routine cultures of 
tissue samples obtained intraopera- 
tively in perforations of the lower 
intestinal tract must be questioned, 
except in regard to detection of 
long-term shifts in antibiotic sensi­
tivity.
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BOOK REVIEWS
continued from page 207
Francisco and the University of Queens­
land, this beautifully illustrated atlas 
covers the whole range of vascular 
complications.
The book has a number of shortcom­
ings. The chapters on imaging tech­
niques are good but contain little dis­
cussion of graft surveillance. No men­
tion is made of cost effectiveness, the 
frequency of graft failure and time 
elapsed before graft failure occurs. The 
use of magnetic resonance imaging in 
diagnosing infected grafts is also dealt 
with briefly. Discussion of the relative 
merits of arteriography, including intra­
venous and intra-arterial digital subtrac­
tion angiography, which is invaluable in 
defining specific problems, would have 
been helpful. The use of vein grafts 
after failed autogenous renal recon­
struction or visceral reconstruction is 
dismissed without discussion.
The chapter on failed vein grafts 
makes no mention of the use of duplex 
scanning and whether this procedure is 
more helpful than measurement of the 
ankle-brachial pressure. No reference is 
made to the use of thrombolytic therapy 
as an adjunct before surgical interven­
tion. In the chapter on graft-limb 
thrombosis, crossover femoral bypass 
and profundaplasty are not mentioned 
as alternative forms of management. 
Furthermore, discussion of alternatives 
to some of the reoperative procedures 
described would have strengthened the 
book. The addition of references would 
have been helpful.
Despite these shortcomings, this is 
an excellent atlas. It is clearly laid out
and contains superb illustrations. I 
would recommend it to any resident in 
vascular surgery or vascular surgeon as 
a useful addition to their library.
F. Michael Ameli, MB, ChB, FRCSC
Vascular surgeon 
Suite 313
The Wellesley Hospital 
160 Wellesley St. E 
Toronto, ON 
M4Y 1E3
DIAGNOSIS OF COLORECTAL AND 
OVARIAN CARCINOMA. APPLICA­
TION OF IMMUNOSCINTIGRAPHIC 
TECHNOLOGY (TARGETED DIAG­
NOSIS AND THERAPY SERIES/6). 
Edited by Robert T. MacGuire and 
Douglas Van Nostrand. 260 pp. Illust. 
Marcel Dekker, Inc., New York. 1992. 
$99.75 (US). ISBN 0-8247-8648-7
This multiauthored book summarizes 
the experience of several institutions 
with a labelled monoclonal antibody 
(MAb) B72.3 (also known as 
CYT-103-111 In or OncoScint), which 
is reactive against an antigen frequently 
found in adenocarcinomas.
This book is the sixth in a series 
published under the auspices of the 
Cytogen Corp., the manufacturer of 
this MAb kit for radiolabelling. One of 
the editors, R.T. MacGuire, is the direc­
tor of clinical investigations at Cytogen. 
I approached this text with scepticism, 
fearing that it would be a self-serving
product monograph, but I found it to be 
objective and to have broad application.
The authors document the difficul­
ties encountered in radioimmunoimag- 
ing as well as the benefits from the use 
of this product. MAb B72.3 is only one 
of an almost limitless number of poten­
tial MAbs that might be introduced for 
clinical trials. This particular product 
appears to complement other diagnostic 
modalities for the staging of metastatic 
disease. It was able to demonstrate 
additional focal or diffuse lesions that 
were not detectable by computed to­
mography or ultrasonography. False­
positive results were not common but 
were seen in inflammatory lesions and 
in some uninvolved lymph nodes drain­
ing the primary site. The MAb was not 
particularly sensitive for primary colon­
ic carcinomas and is thus not useful for 
initial diagnosis. There are sufficient 
data in this volume and in the extensive 
references for the reader to decide 
whether this product has a potential 
use in a given clinical practice.
Aside from the specifics of MAb, 
readers with an interest in the use of 
labelled MAbs for research, clinical di­
agnosis or possible therapy will find a 
considerable amount of useful general 
information for any MAb application. 
This includes an overview of radioim- 
munoimaging, a review of the method­
ology for production and labelling of 
MAbs, immunopharmokinetics and fu­
ture directions for improvement in MAb 
production and imaging.
continued on page 270
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VASOTEC
(enalapril maleate, Frosst Std.) 
Tablets 2.5, 5,10, 20 mg"VASOTEC
(enalaprilat)
1.25 mg/mL
Angiotensin Converting Enzyme Inhibitor
INDICATIONS AND CLINICAL USE
VASOTEC® is indicated in the trea tm ent of 
essential or renovascular hypertension; usually 
adm inistered in association with other drugs, 
particularly thiazide diuretics. Consider the risk of 
angioedema (see WARNINGS). Normally used 
when a diuretic or beta-blocker was ineffective or 
associated with unacceptable adverse effects. 
Can also be tried as initial agent where a diuretic 
and/or beta-blocker is contraindicated or could 
cause serious adverse effects.
Oral enalapril is also indicated in the treatment of 
congestive heart failure, as adjunctive therapy in 
patients not responding adequately to digitalis and 
diuretics.
Use of ACE inhibitors during the second and 
third trimesters of pregnancy can cause injury 
or death of a developing fetus. When pregnancy 
is detected, discontinue VASOTEC’ as soon as 
possible (see WARNINGS; Use in Pregnancy).
VASOTEC® I.V. (enalaprilat) is an active meta­
bolite of enalapril; the onset of action after admin­
istration occurs within 15 minutes, with the maximum 
effect within 1 to 4 hours.
VASOTEC® I.V. is indicated for the treatment of 
hypertension when oral therapy is not practical. 
VASOTEC® I.V. has been studied with only one 
other antihypertensive agent, furosemide, which 
showed additive effects on blood pressure. Due to 
insufficient experience in the treatment of acceler­
ated or malignant hypertension, VASOTEC® I.V. is 
no t recom m ended in such s itu a tio n s  (see 
DOSAGE and ADMINISTRATION).
CONTRAINDICATIONS
H ypersensitiv ity to any component; history of 
angioneurotic edema related to ACE inhib itor 
therapy.
WARNINGS
Angioedema, with laryngeal edema and/or shock, 
have been reported and may be fatal. In such 
cases, discontinue drug promptly and observe 
patient until swelling subsides. Swelling confined 
to the face, lips, and mouth usually resolves 
without treatment, although antihistamines may be 
useful in relieving symptoms. However, where 
there is involvement of the tongue, glottis and 
larynx, likely to cause airway obstruction, prompt 
administration of subcutaneous adrenaline (0.5 mL 
1:1000) may be indicated. Patients with a history of 
angioedema, unrelated to ACE inhibitor use, may 
be at increased risk (see CONTRAINDICATIONS). 
Symptomatic hypotension has occurred, usually 
du ring  in itia l therapy or when the dose was 
increased, and is more likely in patients who are 
vo lum e-d ep le ted . In pa tien ts  w ith seve re  
congestive heart failure, excessive hypotension 
m ay be associated w ith o ligu ria  and/or p ro ­
g ress ive  azotemia. For patients in whom the 
excessive hypotension could result in severe or 
fa ta l com p lica tions, i.e . those  w ith seve re  
co n g e s tive  heart fa ilu re , ischem ic heart or 
cerebrovascular disease -  start therapy under 
close medical supervision, usually in a hospital. 
Such patients should be followed closely for the 
potential fall in blood pressure during first two 
weeks of therapy or when enalapril or a diuretic is 
increased. If hypotension occurs, place patient in 
sup ine  position and if needed, adm inister IV 
infusion of normal saline. A transient hypotensive 
response is not a contraindication to further doses 
of enalapril or enalaprilat.
•Trademark Merck & Co., Inc. 
Merck Frosst Canada Inc., R.U.
Neutropenia/agranulocytosis and bone marrow 
depression have been caused by ACE inhibitors. 
Current experience with enalapril shows incidence 
to be rare. Consider periodic monitoring of white 
blood cell counts in patients with collagen vascular 
disease and renal disease.
Use of ACE inhibitors in pregnancy can cause 
fetal and neonatal morbidity and mortality. When 
pregnancy is detected, discontinue VASOTEC® 
as soon as possible. Rarely, no alternatives to an 
ACE inhibitor will be found and mothers should be 
apprised to the potential hazards to the fetus. 
Ultrasound should be performed to assess fetal 
development, well-being and volume of amniotic 
fluid. If oligohydramnios is observed, discontinue 
VASOTEC® unless lifesaving for the mother. 
A non-stress test and/or a biophysical profiling 
may be appropriate however, if concerns persist, a 
contraction stress testing should be considered. 
Oligohydramnios may only appear after fetus has 
sustained irreversible injury.
Closely observe infants exposed in utero to ACE 
inhibitors for hypotension, oliguria and hyper­
ka lem ia , and in itia te  appropria te  corrective  
medical procedures.
Human Data: Exposure to ACE inhibitors during 
second and third trimesters has been associated 
w ith hypotension, neonatal skull hypoplasia, 
anuria, reversible or irreversible renal failure and 
death of the fetus. Oligohydramnios, associated 
with fetal limb contractures, craniofacial defor­
mation, and hypoplastic lung development also 
has been reported. Prematurity and patent ductus 
arteriosus also reported but unknown if due to 
ACE inhibitor use. It is not known whether expo­
sure limited to the first trimester can adversely 
affect fetal outcome.
PRECAUTIONS
Impaired renal function: Renal function should 
be assessed before initiating therapy with enalapril 
or enalaprilat. Patients with renal insufficiency may 
require reduced or less frequent doses, and their 
renal function must be monitored appropriately (see 
DOSAGE). Renal failure, which has been reported 
mainly in patients with severe congestive heart failure 
or underlying renal disease including renal artery 
stenosis, is usually reversible when treated promptly. 
Some hypertensive patients with no apparent 
renal disease have developed increases in BUN 
and creatin ine w hile  on concurrent d iu re tic / 
enalapril therapy. Dosage reduction or discontin­
uation of one or both drugs may be required. 
Hyperkalemia: In clinical trials, hyperkalemia 
(>5.7 mmol/L) was observed in approximately 1% 
of hypertensive patients, and caused discontin­
uation of therapy in 0.28% of such patients. Risk 
factors for hyperkalemia development may include 
renal insufficiency, diabetes mellitus, and con­
comitant use of agents to treat hypokalemia (see 
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with 
aortic stenosis, who do not develop as much 
afterload reduction, might be at risk of decreased 
coronary perfusion when treated with vasociilators. 
Surgery/Anaesthesia: During major surgery or 
anaesthesia with hypotensive agents, enalapril 
blocks angiotensin II formation secondary to 
compensatory renin release. Hypotension that 
develops due to this mechanism can be corrected 
by volume expansion.
Im paired liver function: Hepatitis, jaundice 
(hepatocellular and/or cholestatic),elevation of 
liver enzymes and/or serum bilirubin, which have 
occurred in patients with or without pre-existing 
liver abnormalities, were usually reversed on 
discontinuation of enalapril or enalaprilat. For any 
unexplained symptoms, particularly within the first 
months of treatment, a full set of liver function tests 
and other necessary investigations are recom­
mended. Consider discontinuation of enalapril or 
ena laprila t when appropriate . Use ena lapril 
or enalaprilat with particular caution in patients with 
pre-existing liver abnormalities. Obtain baseline 
liver function tests before in itiating drug and 
monitor response and metabolic effects closely. 
Cough: A dry, persistent cough has been report­
ed, which usually disappears after withdrawal or 
lowering the dose of enalapril or enalaprilat. 
Nursing mothers: Enalapril and enalaprilat are 
secreted in human m ilk in tra ce  am ounts 
therefore, nursing should be interrupted.
Pediatric use: This use is not recommended 
because enalapril and enalaprilat have not been 
studied in children.
Hemodialysis patients: Anaphylactoid reactions 
have been reported with high-flux membranes (eg.
polyacrylonitrile [PAN]) and treated concomitantly 
w ith an ACE inhib itor. If symptoms such as 
nausea, abdominal cramps, burning, angioedema, 
shortness of breath and severe hypotension 
occur, stop dialysis immediately. The symptoms 
are not relieved by antihistamines and the use of a 
different type of dialysis membrane or class of 
antihypertensive agent should be considered. 
Drug Interactions
Hypotension - Patients on Diuretic Therapy:
Particu larly when diuretics recently initiated, 
patients occasionally experience hypotension 
after initiating therapy with enalapril or enalaprilat. 
To minimize the hypotensive effects, discontinue 
the diuretic or increase the salt intake prior to 
starting the drug. If the diuretic cannot be dis­
continued, patients should be placed under close 
medical supervision for at least one hour after the 
initial dose of enalaprilat (see WARNINGS).
Agents Increasing Serum Potassium: Since 
enalapril and enalaprilat decrease aldosterone 
production, elevation of serum potassium may 
occur. D iu re tics  such as sp iro no la c tone , 
triamterene or amiloride, or potassium supple­
ments should be given cautiously for documented 
hypokalem ia only and should be m onitored 
frequently. Potassium containing salt substitutes 
should be used with caution.
Agents Causing Renin Release: Diuretics, for 
example, augment the antihypertensive effect of 
enalapril and enalaprilat.
Agents A ffecting Sym pathetic  A ctiv ity :
Ganglionic blocking agents or adrenergic neuron 
blocking agents, for example, may be used with 
caution. Beta-adrenergic blockers add some 
further antihypertensive effect to enalapril.
Lithium  S alts : Lith ium  c learance may be 
reduced; therefore, monitor serum lithium levels 
carefully if they are administered.
ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving 
2314 hypertensive patients and 363 heart failure 
patients, the most severe adverse reactions were: 
angioedema (0.2%), hypotension (2.3%) and renal 
fa ilu re  (5 cases). In hypertensive  pa tients, 
hypotension occurred in 0.9% and syncope in 
0.5%, with a discontinuation rate of 0.1%. In heart 
failure patients, hypotension occurred in 4.4% and 
syncope in 0.8%, with a discontinuation rate of 
2.5%. The most frequent clinical adverse reactions 
in controlled clinical trials were: headache (4.8%), 
dizziness (4.6%) and fatigue (2.8%). Discontin­
uation of therapy was required in 6.0% of the 
2677 patients.
H y p e rte n s io n H e a r t  F a ilu r e
% %
(2 3 1 4  P a tie n ts ) (3 6 3  P a t ie n ts )
C A R D IO V A S C U L A R
Hypotension 0.9 4.4
Chest Pain 0.9 1.7
Palpitations 0.6 0.3
Myocardial Infarction,
Acute 0.2 0.6
Myocardial Infarction,
Recurrent — 0.3
G A S T R O IN T E S T IN A L
Nausea 1.4 1.1
Vomiting 0.8 1.7
Dysphagia 0.1 —
Diarrhea 1.4 3.0
Abdominal pain 0.7 1.4
R E N A L
Renal failure 0.1 0.6
Oliguria 1 case
Proteinuriat 0.1 —
D E R M A T O L O G IC
Rash 1.4 1.9
Pruritus 0.4 1.4
N E R V O U S  S Y S T E M
Headache 5.2 2.2
Dizziness 4.3 6.6
Insomnia 0.5 0.3
Nervousness 0.6 __
Somnolence 0.6 __
Paresthesia 0.6 —
A L L E R G IC
Cough 1.3 1.4
Angioedema 0.2 —
H E M A T O L O G IC
Anemia 0.1 __
Leukopenia 1 case —
M IS C E L L A N E O U S
Muscle cramps 0.6 0.3
Dyspnea 0.6 1.1
Hyperhidrosis 0.7 —
Impotence 0.4 0.3
Fatigue 3.0 1.4
Taste disturbance 0.4 0.3
t  Defined as >1g/24h or >0.5g/12h on two consecutive 
measurements, at least one month apart.
ABNORMAL LABORATORY FINDINGS 
Hyperkalemia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were 
reported in about 20% of patients with renovascular 
hypertension and about 0.2% of patients with 
essential hypertension on enalapril alone, in­
creases, which usually were reversible upon 
discontinuation of enalapril or concomitant therapy, 
were reported in 9.7% of heart failure patients who 
were receiving diuretics and/or digitalis.
Hemoglobin and Hematocrit: Decreases (mean 
approximately 0.34 g% and 1.0 vol%, respectively) 
occurred frequently, but were rarely of clinical 
importance. In clinical trials, less than 0.1% of 
patients discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum 
bilirubin have occurred (see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UN­
CONTROLLED TRIALS AND/OR MARKETING 
EXPERIENCE
With an incidence of 0.5 to 1%: Insomnia, im­
potence, renal dysfunction, renal failure and 
oliguria.
With an incidence < 0.5%:
Cardiovascular: Myocardial infarction or 
cerebrovascular accident, possibly secondary to 
excessive hypotension in high risk patients (see 
WARNINGS); cardiac arrest; pulmonary em­
bolism; rhythm disturbances; angina pectoris. 
Gastrointestinal: Anorexia; ileus; pancreatitis; 
dyspepsia; constipation. Hemopoeitic: Neutro­
penia; thrombocytopenia; bone marrow depres­
sion. Hepatic: Liver function abnormalities; 
hepatitis; jaundice (hepatocellular and/or 
cholestatic). Nervous System/Psychiatric: Vertigo; 
depression; confusion; ataxia. Respiratory: 
Bronchospasm/asthma; rhinorrhea. Other: Ery­
thema multiforme; exfoliative dermatitis; Stevens- 
Johnson syndrome; toxic epidermal necrosis; 
urticaria; photosensitivity; alopecia; flushing; tin­
nitus; hearing impairment; glossitis; blurred vision. 
A symptom complex has been reported which may 
include fever, serositis, vasculitis, myalgia, 
arthralgia/arthritis, a positive ANA, elevated 
erythrocyte sedimentation rate, eosinophilia and 
leukocytosis. Rash, photosensitivity or other 
dermatologic manifestations may occur. These 
symptoms have disappeared after discontinuation 
of therapy.
LABORATORY TEST FINDINGS: Hyponatremia
VASOTEC® I.V.: Since enalapril is converted to 
enalaprilat, those adverse reactions associated 
with VASOTEC® tablets might also be expected to 
occur with VASOTEC® I. V. The incidence of symp­
tomatic hypotension is 3.4% with VASOTEC® I.V. 
Other adverse experiences occurring in greater 
than 1% of patients were headache (2.9%) and 
nausea (1.1%). Adverse reactions occurring in 0.5 
to 1.0% of patients in controlled clinical trials 
include myocardial infarct, fatigue, dizziness, 
fever, rash and constipation.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
Limited human data are available. The most likely 
manifestation of overdosage would be hypo­
tension, which can be treated by I.V. infusion of 
normal saline solution. Enalaprilat may be 
removed from the general circulation by 
hemodialysis.
DOSAGE AND ADMINISTRATION
VASOTEC®
FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of 
enalapril maleate is not affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of 
extent of blood pressure elevation, salt restriction 
and recently used antihypertensive agents, the 
dosage of which may need to be adjusted.
The recommended initial dose of enalapril maleate 
in patients not on diuretics is 5 mg once a day. 
Adjust dosage according to blood pressure 
response; the usual range is 10 to 40 mg daily, in 
a single dose or divided in two doses. Some 
patients on once-daily dosage may have 
diminished antihypertensive effect toward the end 
of dosing interval and require an increase in 
dosage, or twice daily administration. If blood 
pressure is not controlled, a diuretic may be 
added. Raising the daily dose above 40 mg is not 
recommended because adverse reactions may be 
increased.
Occasionally symptomatic hypotension may occur 
following the initial dose, more likely in patients 
currently taking a diuretic. Therefore, if possible, 
discontinue the diuretic two to three days before 
initiating enalapril therapy (see WARNINGS). If 
the diuretic cannot be discontinued, use an initial 
dose of 2.5 mg.
In the absence of sufficient experience in the 
treatment of accelerated or malignant hyper­
tension, enalapril is not recommended in such 
situations.
Dosage in the Elderly (over 65 years): Start at 
2.5 mg daily. Some elderly patients may be more 
responsive than younger patients.
Dosage Adjustment in Renal Impairment: (see 
PRECAUTIONS - Hemodialysis patients)
Guidelines for reducing doses in hypertensive 
patients:
Renal Status
Creatinine
Clearance
mL/min(mL/s)
Initial Dose 
mg/day
Normal renal 
function
>80 mL/min 
(>1.33 mL/s)
5 mg
Mild impairment <80 >30 mL/min 
(<1.33 >0.50 mL/s)
5 mg
Moderate to 
severe impairment
<30 mL/min 
(<0.50 mL/s)
2.5 mg
Dialysis patients 2.5 mg on 
dialysis days*
Enalaprilat is dialysable. Dosage on nondialysis days 
should be adjusted depending on the blood pressure 
response.
CONGESTIVE HEART FAILURE
Use in conjunction with a diuretic and digitalis. 
Initiate therapy under close medical supervision, 
usually in a hospital. Monitor blood pressure and 
renal function before and during treatment with 
enalapril, because severe hypotension, and more 
rarely, consequent renal failure have been 
reported (see WARNINGS and PRECAUTIONS). 
When initiating enalapril consider the recent 
diuretic therapy and possibility of severe salt/ 
volume depletion. Before beginning enalapril 
reduce diuretic therapy if possible.
The recommended initial daily dose is 2.5 mg. 
While managing symptomatic hypotension, 
increase dose gradually, depending on individual 
response, to the usual maintenance dose of IQ- 
20 mg daily, given in a single dose or divided in 
two doses. This dose titration may be performed 
over a two- to four-week period, or more rapidly if 
indicated by residual signs and symptoms of heart 
failure. The maximum daily dose is 40 mg.
VASOTEC® I.V. FOR INTRAVENOUS 
ADMINISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually 
and should not be used if particulate matter or 
discoloration is observed.
VASOTEC® I.V. may be administered intra­
venously as supplied, or mixed with up to 50 mL of 
one of the following diluents:
5% Dextrose Injection
0.9% Sodium Chloride Injection 
0.9% Sodium Chloride Injection in 5% Dextrose 
5% Dextrose in Lactated Ringer's Injection 
Diluted solutions should be used within 24 hours.
The dose is 1.25 mg every 6 hours administered 
intravenously over at least 5 minutes. A clinical 
response is usually seen within 15 minutes. Peak 
effects after the first dose may not occur for up to 
four hours after dosing. The peak effects of the 
second and subsequent doses may exceed those 
of the first.
No dosage regimen for VASOTEC® I.V. has been 
clearly demonstrated to be more effective in 
treating hypertension than 1.25 mg every 6 hours. 
However, in controlled clinical studies in 
hypertension, doses as high as 5 mg every 
6 hours were well tolerated for up to 36 hours. 
There has been inadequate experience with doses 
greater than 20 mg per day.
In studies of patients with hypertension, 
VASOTEC® I.V. has not been administered for 
periods longer than 48 hours. In other studies, 
patients have received VASOTEC® I.V. for as long 
as 7 days.
The dose for patients being converted to 
VASOTEC® I.V. from oral therapy for hypertension 
with enalapril maleate is 1.25 mg every 6 hours 
administered intravenously over at least 
5 minutes. For conversion from intravenous to oral 
therapy, the recommended in itial dose of 
VASOTEC® tablets is 5 mg once a day with 
subsequent dosage adjustments as necessary.
Patients on Diuretic Therapy
For patients on diuretic therapy, the recommended 
starting dose for hypertension is 0.625 mg admin­
istered intravenously over at least 5 minutes. 
A c lin ica l response is usually seen w ith in 
15 minutes. Peak effects after the first dose may 
not occur for up to 4 hours after dosing, although 
most of the effect is usually apparent within the 
first hour. If after 1 hour there is an inadequate 
c lin ica l response, the 0.625 mg dose may 
be repeated. Additional doses of 1.25 mg may be 
administered at 6 hour intervals.
For conversion from intravenous to oral therapy, 
the recommended initial dose of VASOTEC® 
tablets for patients who have responded to 
0.625 mg of enalaprilat every 6 hours is 2.5 mg 
once a day with subsequent dosage adjustment 
as necessary.
Dosage Adjustment in Renal Impairment
The usual dose of 1.25 mg of enalaprilat every 
6 hours is recommended for patients with a 
creatinine clearance >30 mL/min [>0.50 mL/s] 
(serum creatinine up to approximately 3 mg/dL 
[265.2 pmol/L]). For patients with creatinine 
clearance <30 mL/min [<0.50 mL/s] (serum 
creatinine >3 mg/dL [>265.2 pmol/Lj), the initial 
dose is 0.625 mg (see WARNINGS).
If after 1 hour, there is an adequate clinical re­
sponse, the 0.625 mg dose may be repeated. 
Additional doses of 1.25 mg may be administered 
at 6 hour intervals.
For dialysis patients, the initial dose should be 
0.625 mg every 6 hours, (see PRECAUTIONS - 
Hemodialysis patients).
For conversion from intravenous to oral therapy, 
the recommended initial dose of VASOTEC® is 
5 mg once a day for patients with creatinine 
clearance >30 mL/min [>0.50 mL/s] and 2.5 mg 
once daily for patients with creatinine clearance 
<30 mL/min [<0.50 mL/s]. Dosage should then be 
adjusted according to blood pressure response.
AVAILABILITY OF DOSAGE FORMS
Barrel-shaped, biconvex tablets, engraved with 
code number on one side and VASOTEC on other. 
VASOTEC® 2.5 mg - yellow, scored, engraved 14. 
VASOTEC® 5 mg - white, scored, engraved 712. 
VASOTEC® 10 mg - rust-red, engraved 713. 
VASOTEC® 20 mg - peach, engraved 714.
All strengths available in bottles of 100 tablets. 
VASOTEC® I.V. 1.25 mg per mL, is a clear, 
colourless solution and is supplied in vials 
containing 2 mL.
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Is a Long Delay Necessary
Before Appendectomy After Appendiceal
Mass Formation? A Preliminary Report
S.K.S. Marya, MD, FICS; Pradeep Garg, MS, DNB; Multan Singh, MS, DNB; Ashok K. Gupta, MS; 
Yogender Singh, MB, BS
The standard treatment for an appendiceal mass is conservative therapy followed by 
appendectomy after 6 to 10 weeks. With the advent of antibiotics designed to 
prevent the growth of anaerobes, early appendectomy can now be carried out 
without complication. The authors studied 56 patients with appendiceal mass 
formation, 26 (group A) treated conventionally and 30 (group B) treated by early 
appendectomy. In group B, the infection rate was 17%, the mean operating time was 
38.7 minutes, the mean hospital stay was 15 days and there was an early return to 
work. The corresponding parameters for group A were an infection rate of 8%, a 
mean operating time of 35.2 minutes, a hospital stay of 19.1 days and a late return 
to work. Furthermore, 15% of the patients in group A had a recurrent acute episode 
during the waiting period. Overall, early appendectomy appears to be a safe and 
cost-effective treatment for appendiceal mass formation.
Le traitement classique d’une masse appendiculaire est tout d’abord conservateur, 
puis suivi d’une appendicectomie, de 6 a 10 semaines plus tard. Avec la venue des 
antibiotiques destines a prevenir la croissance des anaerobies, une appendicectomie 
precoce peut maintenant etre pratiquee sans complication. Les auteurs ont etudie 56 
patients porteurs d’une masse appendiculaire. Vingt-six (le groupe A) furent traites 
de fa?on conventionnelle et 30 (le groupe B) subirent une appendicectomie precoce. 
Le taux d’infection dans le groupe B fut de 17 %, la duree d’intervention de 38,7 
minutes, l’hospitalisation moyenne de 15 jours et les patients reintegrerent leur 
travail rapidement. Les parametres correspondants pour le groupe A furent de 8 % 
pour le taux d’infection, de 35,2 minutes pour la duree d’intervention, de 19,1 jours 
d’hospitalisation et le retour au travail fut retarde. De plus 15 % des patients du 
groupe A subirent une rechute aigue pendant qu’ils attendaient l’operation. Dans 
l’ensemble, l’appendicectomie precoce parait etre un traitement sur et rentable des 
masses appendiculaires.
U nlike acute cholecystitis, there is no good alternative to ap­
pendectomy for the treatment of 
acute appendicitis. Reluctance to 
accept early operation prompted 
Murphy to observe “the responsibil­
ity lies with the first doctor called in 
to see these patients.”1 The conven­
tional management of an appen­
diceal mass (a phlegmon of adher­
ent omentum or small-bowel loops 
or an abscess) deviates from the
principle of early operation. It in­
volves localizing the infection and 
inflammation by conservative thera­
py followed by appendectomy after 
an interval of 6 to 10 weeks. In the 
present study, we implemented
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APPENDICEAL MASS AND APPENDECTOMY
Murphy’s principles as soon as the 
appendiceal mass was conducive to 
operative manipulation.
Patients and Methods
Of 61 patients who had an appen­
diceal mass and were seen by the 
authors between 1989 and 1991, 
29 were managed conservatively 
(group A) and 32 were managed by 
early appendectomy (group B). 
There was no follow-up for three 
patients in group A, and conserva­
tive therapy was abandoned for 
drainage of an appendiceal abscess 
in two patients from group B. 
These patients were excluded, leav­
ing 26 patients in group A and 30 
patients in group B for study.
After the clinical diagnosis was 
established, conservative treatment 
was continued for group A patients 
(Oschner-Sherren regimen) who 
were discharged after resolution of 
the mass. Patients were given a 
tentative date fointerval appendec­
tomy (a minimum of 6 weeks after 
discharge).
Group B patients had appendec­
tomy as soon as the lump became 
impalpable. They were discharged 
after removal of the stitches on the 
7th or 8th postoperative day. Pa­
tients in both groups received com­
binations of gentamicin, ampicillin 
and metronidazole for as long as 
tenderness, tachycardia and high 
temperature persisted. After stabili­
zation, ampicillin only was given to 
group A patients until 5 days after
discharge and to group B patients 
until the 5th postoperative day. 
Metronidazole (500 mg) was given 
to group B patients on the day of 
the operation.
The two groups of patients were 
compared with respect to the oper­
ating time, the complications of 
appendectomy, the rate of wound 
infection, the duration of hospital­
ization and the time of return to 
work.
Results
The results of our study are 
shown in Table I. During the wait­
ing period between diagnosis of the 
appendiceal mass and appendecto­
my, four group A patients had 
acute exacerbation of their condi­
tion and were operated on immedi­
ately.
The operating time was similar in 
both groups, and there were no 
complications of operation, such as 
fistula formation or spread of infec­
tion, ineither group. Group B pa­
tients had a higher infection rate, 
but the duration of hospitalization 
was longer in group A patients.
In the interval from conservative 
treatment to appendectomy in 
group A patients, 42% did not go to 
work. The remaining 58% preferred 
light work, but all patients in this 
group shared a common fear that 
resumption of normal work habits 
might precipitate an episode of 
acute appendicitis. After appendec­
tomy for acute appendicitis, group
T a b le  1. Parameters Associated With the Treatment of an Appendiceal Mass
G roup A Group B
P aram ete r (o = 2 6 ) (n =  30)
Wound infection, no. (%) 2(8) 5(17)
Mean operating time, min. 35.2 38.7
Mean hospital stay, d 19.1* 15
Recurrence during resting
period, no. (%) 4(15) —
Return to work Late Early
‘ Mean stay for both conservative treatment and elective appendectomy
B patients returned to work earlier 
than group A patients (3 to 4 weeks 
versus 8 to 10 weeks).
Discussion
The management of appendiceal 
mass formation is controversial. 
Most medical centres practise initial 
conservative therapy, followed in 6 
to 10 weeksby appendectomy. Few 
centres advocate immediate appen­
dectomy and drainage.2
Proponents of conservative treat­
ment fear that more aggressive 
therapy may spread an already lo­
calized peritonitis or may injure 
adherent intestine, causing fecal fis­
tula formation. Patients treated 
conservatively require a seconhospi- 
talization for appendectomy to pre­
vent the 10% to 20% risk of recur­
rent appendicitis.2 The second hos­
pitalization itself exposes the pa­
tient to a 19% complication rate.3 
Furthermore, during the “resting 
period” of 6 to 10 weeks, a recur­
rent acute episode can occur, rang­
ing in frequency from 7% to 46% in 
different series.4 In our study there 
was an acute episode in 15% of 
patients.
In contrast, an aggressive ap­
proach such as appendectomy with 
drainage carries a complication rate 
of 36%, which is almost comparable 
to that for perforated appedicitis 
presenting without palpable mass.2 
Our approach to early appendecto­
my adopts a middle course: the 
mass is rendered subacute to 
“cold,” and free of edema and pos­
sible adhesions, so that operation 
invites few or no local complica­
tions. The only complication seen 
with this approach in our series was 
a parietal wound infection in five 
patients
Early operation with an almost 
negligible complication rate has 
been made possible by modern anti­
biotics. Nonavailability of a broad
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spectrum of effective antibiotics, es­
pecially those designed to combat 
anaerobes, was likelya major factor 
preventing surgeons from carrying 
out early operation. The conserva­
tive approach does not keep pace 
with modern therapeutics. Further­
more, exploration of the appendix 
when the mass becomes impalpable 
seems no more hazardous than re­
moval of an inflamed turgid appen­
dix in acute episodes.
Early operation is highly cost- 
effective with respect to operating 
time, total hospital stay and the 
patient's return to work. It provides 
early confirmation of the diagnosis 
(the only way to confirm appendici­
tis is by operation) and ensures 
complete resolution of the patient’s 
condition by circumventing any 
chance of missed follow-up dur­
ing the resting period of 6 to 10 
weeks.
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continued from page 265
Numerous problems in the current 
technology must be overcome. A mouse 
source for the MAb results in the 
production of human antibodies against 
mouse antigen (HAMA) in about 50% of 
patients. This may prevent a second use 
of murine antibodies in those patients. 
More specificity is required to improve 
targeting and reduce unwanted back­
ground activity in the liver, bone mar­
row and blood pool. This may be 
achieved by more specific MAb produc­
tion, MAb fragmentation, enhancement 
with drugs such as Interferon and im­
proved labelling efficiency. At present, 
the technology is expensive for the 
relatively small improvement in diag­
nostic yield, although for some patients 
radioimmunoscintigraphy may affect 
staging and surgical management.
Manufacturers need to recover the 
costs of research and development, but 
the production and clinical trials of 
MAb are expensive and so is the pro­
duction of indium 111 and iodine 123, 
the radiotracers used to label the MAb. 
Furthermore, the high price may limit 
clinical use, causing a vicious circle that 
may further inhibit innovation and ar­
rest progress in what ultimately will 
likely be a valuable clinical tool.
However, for the clinician, wide­
spread use Of this “magic bullet” is still 
a long way off. Like a cannon firing at a 
distance, we can see the flash and 
smoke but have not yet heard the
significant bang of its impact on our 
routine practice.
N.D. Greyson, MD, FRCPC
Head
Division of Nuclear Medicine 
St. Michael’s Hospital. 
Associate professor 
Department of Radiology 
University of Toronto 
Toronto, Ont.
SURGERY: SCIENTIFIC PRINCI­
PLES AND PRACTICE. Edited by 
Lazar J. Greenfield. 2208 pp. Illust. 
J.B. Lippincott Co., Philadelphia. 
1992. $92 (US). ISBN 0-397-51121- 
3
This large textbook attempts to address 
the entire spectrum of the current prac­
tice of surgery. This has necessitated 
contributions from 155 individuals from 
diverse areas of surgical specialization.
The first quarter of the book is 
devoted to the scientific principles un­
derlying surgical practice. These cover 
not only the usual topics of cell struc­
ture, metabolism and hemostasis but 
also more current basic science chap­
ters on anesthesia, tumour biology and 
transplantation immunology.
The remainder of the book is divided 
into 21 sections primarily according to
anatomic region. This leads to a signifi­
cant imbalance in terms of prevalence of 
disease or surgical intervention; for ex­
ample, the number of pages devoted to 
diseases of the pancreas is approximate­
ly five times the number devoted to the 
entire specialty of orthopedic surgery 
and five times the number devoted to 
the specialty of urology.
The book would more correctly be 
titled General Surgery: Scientific Princi­
ples of Practice because that would 
reflect the editor’s intent.
Some surgical specialties are well 
covered especially surgical endocrinolo­
gy, the cardiovascular system and pedi­
atric general surgery.
This volume would be of value in 
hospital libraries in which students and 
residents demand a comprehensive ref­
erence text for the specialty of general 
surgery. It would also be of value to the 
practising general surgeon and to gen­
eral surgery residents. It will be of 
limited value to residents and practition­
ers in other specialties because it con­
tains inadequate material for their spe­
cialty interest and too much detail re­
garding general surgery for casual ref­
erence. The first quarter of the book, 
however, is excellent and covers the 
basic principles underlying all surgical 
specialties.
A final note regarding the size of the 
continued on page 280
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The Value of Reoperation for Recurrent 
Glioblastoma
Peter Dirks, MD;* Mark Bernstein, MD, FRCSC;* Paul J. Muller, MD, FRCSC;t 
William S. Tucker, MD, FRCSCt
To determine the value of reoperation alone (no further surgical procedures or 
radiotherapy), 43 patients (27 men, 16 women) with recurrent supratentorial 
glioblastomas who underwent a second craniotomy for recurrent tumour were 
reviewed retrospectively. The patients ranged in age from 27 to 66 years (median 53 
years).
All patients were treated initially by surgical resection and external radiation (50 
Gy in 25 fractions through parallel opposed regional fields). In addition, 10 patients 
(23%) received chemotherapy, 3 patients (7%) received photodynamic therapy and 9 
patients (21%) received interstitial brachytherapy postoperatively. Although none of 
the patients had further surgical procedures or radiotherapy after reoperation for 
tumour recurrence, 5 of the 43 did receive single-agent chemotherapy.
The median survival after the first operation was 57 weeks. The median interval 
between first and second operations was 32 weeks. Median survival after reoperation 
was 19 weeks. An interval of more than 50 weeks between the two operations 
correlated with a significant (p < 0.05) increase in survival. The death rate for 
reoperation was 4.6%. The infection rate was 9.3%. The authors conclude that 
reoperation alone confers a modest but valuable increase in survival, especially if the 
interval between operations is greater than 50 weeks.
Afin de mesurer l’apport d’une seconde operation seule (sans autre intervention 
chirurgicale ou radiotherapie), 43 patients (27 hommes, 16 femmes) porteurs d'un 
glioblastome supratentoriel recidivant qui subirent une deuxieme craniotomie lors 
de la recidive tumorale ont ete etudies en retrospective. L’age des patients variait de 
27 a 66 ans (mediane, 53 ans).
Tous les patients avaient ete traites initialement par resection chirurgicale et 
radiation externe (50 Gy, en 25 doses fractionnees par champs regionaux opposes, 
paralleles). De plus, 10 patients (23 %) avaient re?u de la chimiotherapie. Trois 
patients (7 %) avaient eu un traitement photodynamique et neuf patients (21 %) 
avaient reyu une brachytherapie interstitielle postoperatoire. Meme si aucun de ces 
patients n’a subi d’autre intervention chirurgicale ou n’a re?u de radiotherapie apres 
la reoperation pour rechute, 5 des 43 ont eu une monochimiotherapie.
La survie mediane apres la premiere operation a ete de 57 semaines. L’intervalle 
median entre la premiere et la seconde operation a ete de 32 semaines. La survie 
mediane apres la deuxieme intervention a ete de 19 semaines. Un intervalle excedant 
50 semaines entre les deux operations a ete relie a une augmentation significative (p 
< 0,05)) de la survie. La mortality consecutive a la seconde operation a ete de 4,6 %
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et le taux d’infection, de 9,3 %. Les auteurs concluent qu’une reoperation seule 
procure un allongement modeste mais mesurable de la survie, specialement quand 
l’intervalle entre les operations depasse 50 semaines.
The rationale for the surgical treatment of malignant gliomas 
includes the following: to make a 
histologic diagnosis; to alleviate the 
neurologic deficit caused by local 
tumour compression; to reduce ele­
vated intracranial pressure from the 
tumour mass; and to achieve cy- 
toreduction of the tumour to in­
crease the efficacy of adjuvant ther­
apy.1 The rationale for the surgical 
treatment of recurrent malignant 
gliomas is almost the same. The 
goals of reoperation are to prolong 
survival and to maintain or improve 
the patient’s functional status.
Historically, the rate of repeat 
craniotomy for recurrence of malig­
nant primary brain tumours has 
been low (0% to 10%).2 In the past 
10 years, a number of studies on 
the effect of reoperation have been 
carried out.2'8 However, the value 
of reoperation alone, without adju­
vant therapy, for recurrent malig­
nant astrocytoma is unclear.
The purpose of this report was to 
examine the effect of reoperation 
alone in a relatively homogeneous 
group of patients, who had no 
additional antineoplastic therapy 
after the reoperation.
Patients and Methods
Patients who underwent reopera­
tion for malignant astrocytic tu­
mours (glioblastoma multiforme 
and malignant astrocytoma without 
necrosis) between 1978 and 1990 
were reviewed. Patients were taken 
from the services of three neurosur­
geons whose operative approach 
was similar. All patients had their 
initial and repeat operations at hos­
pitals fully affiliated with the Uni­
versity of Toronto.
Inclusion criteria were: histologi­
cally confirmed supratentorial glio­
blastoma multiforme or malignant 
astrocytoma at both first and subse­
quent operations; full course of ex­
ternal radiotherapy completed after 
the initial operation; gross total or 
subtotal resection of tumour at re­
peat operation; reoperation for re­
currence performed at least 1 
month after the completion of post­
operative radiation; and Karnofsky 
performance status of 50 or greater 
at reoperation.
Exclusion criteria were: low- 
grade astrocytoma at first opera­
tion; reoperation other than for re­
section of recurrent tumour (e.g., 
cyst drainage, limited biopsy, cere­
brospinal fluid shunting, wound re­
pair, hematoma evacuation or inser­
tion of devices for intratumoral 
therapy); more than one reoperation 
for recurrence; experimental thera­
py or additional radiotherapy after 
the second operation (e.g., photody­
namic therapy, brachytherapy, in­
tratumoral interferon therapy); and 
failure to confirm recurrence histo­
logically.
Reoperation was performed for 
increasing neurologic deficit or ele­
vated intracranial pressure with evi­
dence on the computed tomography 
(CT) scan of recurrence in an acces­
sible location, or occasionally for 
recurrence (on CT) without further 
symptomatic progression.
Findings
Patient Characteristics
Thirty-eight patients (88%) had 
glioblastoma multiforme and 5 pa­
tients (12%) had malignant as­
trocytoma at initial operation. 
There were 27 men (63%) and 16 
women (37%). The patients ranged
in age from 27 to 66 years at initial 
operation (median 53 years). Twen­
ty-seven patients (63%) had right­
sided tumours, 15 patients (35%) 
had left-sided tumours, and 1 pa­
tient (2%) had a bifrontal tumour.
All patients received a full course 
of external radiotherapy (50 Gy in 
25 fractions through parallel op­
posed regional fields) after initial 
operation. In addition, 10 patients 
(23%) received chemotherapy, 9 pa­
tients (21%) received interstitial 
brachytherapy and 3 patients (7%) 
received photodynamic therapy. 
After reoperation, none of the pa­
tients received additional radiother­
apy or experimental therapy and 
five patients (12%) had single-agent 
chemotherapy.
Morbidity and Mortality After 
Reoperation
Two patients died within 4 weeks 
of reoperation, giving a surgical 
death rate of 4.6%. Four patients 
(9.3%) suffered infectious complica­
tions; three of them had brain ab­
scesses (one died and is included in 
the 4.6% death rate) and one pa­
tient had an infected scalp flap. Two 
patients, one of whom died within 4 
weeks of the operation, had sys­
temic glioblastoma metastases at 
autopsy.
Survival after Reoperation
The median interval between op­
erations was 32 weeks. The median 
survival after reoperation calculated 
by the Kaplan-Meier method was 
19 weeks and the mean total surviv­
al was 57 weeks (Fig. 1). Patients 
with an interoperative interval 
greater than 50 weeks had signifi­
cant prolongation of survival after 
reoperation (Table I).
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Discussion
The role of reoperation for malig­
nant gliomas has been studied in 
several articles.2-8 Young and col­
leagues8 reviewed the role of a 
single reoperation in 24 patients 
from two university centres over an 
8-year period and reported a median 
survival of 14 weeks. Karnofsky 
performance status greater than 60 
correlated with a significant in­
crease in median survival (22 weeks 
versus 9 weeks), and length of 
interoperative interval correlated 
weakly with prolonged median sur­
vival.
Salcman and colleagues5 studied 
prospectively a consecutive series of 
74 patients entered into a multimo­
dality therapy program for malig­
nant astrocytoma. Forty patients 
underwent reoperation for recur­
rence. All patients had previously
1 - A
CO
>
V
> 0 .8 \
=3
c/> 1
S —o
>
0 .6 \
1
_Q 0 .4 \
CO
.Q
(J
CL
0 .2  - 
0 -------------1-------------1----
0 20 40 60 80  100 120 140 160 180
Weeks after reoperation
FIG. 1. Kaplan-Meier representation of probability of survival after reoperation for 
recurrent glioblastoma. Tick marks represent patients who were still alive at time 
of analysis.
Table I. Characteristics and Survival of Patients With Recurrent Glioblastomas
Characteristic
Patients,
no. (%)
Median survival, 
wk p  value
Sex
Male 27 (63) 20 NS
Female 16(37) 21
Tumour location
Right 27 (63) 21 NS
Left 15(35) 20
Bifrontal 1 (  2) —
Tumour type
Malignant astrocytoma 5(21) 8 NS
Glioblastoma multiforme 38 (88) 21
Interoperative interval, 
wk
< 50 31 (72) 17 0.047*
> 50 12(28) 46
Age, yr
< 50 21(49) 21 NS
> 50 22(51) 18
'Significant difference as independent variable by Mann-Whitney test
received chemotherapy and radio­
therapy, and chemotherapy was 
continued after reoperation. The 
median survival after reoperation 
was 37 weeks. Patients younger 
than 40 years who underwent reop­
eration had a significantly increased 
total survival (121 weeks versus 60 
weeks from the time of the first 
operation). Patients with malignant 
astrocytoma had a prolonged but 
insignificant increase in survival (82 
weeks versus 65 weeks). Age, sex, 
Karnofsky performance status and 
interoperative interval did not corre­
late with survival time after reoper­
ation.
Harsh and associates4 reviewed 
retrospectively a consecutive series 
of 70 patients who underwent reop­
eration for malignant astrocytoma 
over a 9-year period. An unspecified 
proportion of these patients had the 
initial operation at another institu­
tion. The median survival after 
reoperation was 36 weeks for glio­
blastoma multiforme and 88 weeks 
for anaplastic astrocytoma. Youn­
ger age correlated with high-quality 
survival after reoperation in both 
tumour groups and in total survival 
in those with glioblastoma mul­
tiforme. The interoperative interval 
correlated with total survival in 
both tumour groups, and higher 
Karnofsky performance status at 
reoperation correlated with high- 
quality survival in glioblastoma 
multiforme. Poor outcome was as­
sociated with a Karnofsky score less 
than 70.
The extraordinary survival after 
reoperation in the group with ana­
plastic astrocytoma may be attribut­
ed in part to the fact that 48% of 
the patients with anaplastic as­
trocytoma at reoperation had a low- 
grade astrocytoma at the time of 
the first operation. Twenty-six per­
cent of patients with glioblastoma 
multiforme had anaplastic as­
trocytoma at initial operation, and 
3% had low-grade astrocytoma. The
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natural history of low-grade as­
trocytomas is associated with a 
more favourable course than that of 
malignant astrocytoma.9 Patients 
with known malignant degeneration 
from low-grade to high-grade as­
trocytoma survived longer than 
those whose initial tumour diagno­
sis was that of high-grade as- 
tocytoma.10
Ammirati and associates3 re­
viewed the role of reoperation over 
11 years in 55 consecutive patients 
with glioblastoma multiforme and 
anaplastic astrocytoma. Eighty per­
cent of the patients had the initial 
operation at other centres, and 20% 
had more than one reoperation. The 
median survival after reoperation 
was 29 weeks for glioblastoma mul­
tiforme and 61 weeks for anaplastic 
astrocytoma. Factors correlating 
with improved median survival after 
reoperation were preoperative Kar- 
nofsky score (more than 70 versus 
less than 70 — survival times of 
48.5 and 19 weeks respectively), 
extent of surgical resection (gross 
resection versus subtotal resection 
—- survival times of 51 weeks and 
23 weeks respectively), pathologic 
grade, and interoperative interval 
(more than 6 months versus less 
than 6 months — survival times of 
62 weeks and 33 weeks respective­
ly). However, varying types of adju­
vant therapy were given at the first 
operation and at reoperation, and 
survival data did not take into ac­
count the role of adjuvant therapy 
on survival. Furthermore, 13% of 
these patients did not receive radio­
therapy after the initial operation.
Wallner and colleagues7 exam­
ined whether the CT scan of recur­
rent malignant astrocytomas at the 
time of reoperation could predict 
survival. Thirty-nine patients who 
underwent reoperation for recurrent 
anaplastic astrocytoma or glioblas­
toma multiforme were examined. 
Eighty-two percent of the patients 
had their initial operations at other
centres. In 26% the tumour at the 
initial operation was of lower grade 
than that at reoperation. All but 
one patient had external radiothera­
py before reoperation. No patient 
had external or interstitial radiation 
after reoperation. Sixty-two percent 
of patients had chemotherapy ini­
tially; however, it is unclear wheth­
er this was continued after reopera­
tion. The median interoperative in­
terval was 10 months and median 
survival after reoperation was 30 
weeks. In patients with glioblas­
toma multiforme (79% of patients), 
there were trends toward increased 
survival with a Karnofsky score 
greater than 90, frontal tumours, 
smaller tumours and tumours with 
less preoperative peritumoral ede­
ma. The authors concluded that the 
perioperative CT scan appearance of 
malignant astrocytomas could not 
be used in predicting survival after 
reoperation and therefore in choos­
ing patients likely to benefit from 
reoperation.
Our study comprised patients 
who underwent a single reoperation 
for recurrent malignant as­
trocytoma. Only 12% of patients 
received adjuvant therapy (chemo­
therapy) after their reoperation. All 
patients had their initial and repeat 
operations at the same centre, usu­
ally done by the same surgeon. All 
patients had an initial diagnosis of 
glioblastoma (88%) or malignant as­
trocytoma (12%). The median sur­
vival in our series of recurrent gli­
omas after second surgery was 19.5 
weeks; this survival time is similar 
to that of the 14 to 16 weeks found 
in the surgery-only control group of 
the second Brain Tumor Study 
Group protocol.11 From a survey of 
11 papers on the results of therapy 
for glioblastoma, Mineura12 found 
that in 1462 patients treated with 
surgery alone the average median 
survival time was 19.9 weeks.
In our study, patients with a 
longer interoperative interval had
significantly prolonged survival, a 
finding similar to that of previous 
studies.4'8
Functional status has been 
shown to be an important factor in 
survival in several other studies.3'48 
In the two most recent studies,2'4 a 
Karnofsky performance score of 
less than 70 was associated with a 
poorer outcome.
Previous studies stated that reop­
eration for recurrent malignant as­
trocytoma was a reasonably safe 
therapeutic manoeuvre with low 
morbidity and mortality. The opera­
tive death rate (within the first 4 
weeks after operation) ranged from 
0% to 5.1% in the recent studies on 
reoperation.2-46-8 These rates are 
similar to our operative death rate 
of 4.6% (one death from disseminat­
ed intravascular coagulation in a 
patient found to have metastatic 
glioblastoma at autopsy and one 
death from brain abscess). In a 
recent prospective analysis of 104 
consecutive patients who under­
went craniotomy for excision of 
supratentorial glioma, the death 
rate in the first 30 days was 3.3%.13 
The death rate for reoperation was 
stated to be the same as for initial 
operation. Reoperation seems to be 
a relatively safe therapeutic option.
The rate of infectious complica­
tions in our series was 9.3%. There 
were three deep infections (abscess­
es) and one superficial infection. 
Only one patient received antibiotics 
prophylactically at the time of reop­
eration. Our wound infection rate 
for reoperation is similar to that 
reported in the literature — 0% to 
2i%.3-5-8 Tenney and colleagues,14 
in a review on wound infections in 
clean neurosurgical cases, reported 
rates of infectious complications in 
patients with gliomas of 4% for 
initial operation and 13% for reop­
eration.
Reoperation for recurrent malig­
nant astrocytoma is reasonably safe. 
Modestly prolonged survival can be
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expected after surgical treatment 
alone. Patients considered for reop­
eration for glioblastoma or malig­
nant astrocytoma should also be 
considered for adjunctive experi­
mental therapy whenever possible.
We thank Urs. L. Resch and J. Bilbao 
for help with neuropathological review 
of all the cases, and Denise Best and 
Dina Evans for preparing the manu­
script.
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Correction
The title of the article by Paterson 
and colleagues in the April 1993 
issue of the journal, pages 162 to 
164 was incorrect. The title should 
read “Late anastomotic ulceration 
after ileocolic resection in child­
hood."
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clinical tria ls and subsequent post-marketing surveillance are as follows:
Gastro-lntestinal: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis, 
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration, 
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal 
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis. The following have been reported very rarely: hypertension, hot flashes, 
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris, 
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion, 
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal 
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine, increase of intracranial 
pressure. In some instances these reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has 
to  be discontinued and the doctor should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice 
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis, 
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, corneal 
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute 
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions 
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with 
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis: very rarely, 
major liver disorders including hepatic necrosis, joint pain, Lyell Syndrome.
Blood and Blood constituents: eosinophilia, leukocytopenia, leukocytosis, anaemia, granulocytopenia. Very rarely: haemolytic 
anaemia, thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase, 
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubinemia, hyperuricemia, increased 
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis, 
crystalluria and haematuria.
Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in severity .There have been 54 reports of 
arthropathies with CIPRO®. Ten of these reports involved children. Arthralgia was usually the firs t symptom which led to rapid 
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). 
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be 
carefully observed and given supportive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the 
susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function. 
Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before or after meals. Absorption is faster on an empty stomach. 
Patients should be advised to  drink fluids liberally and not take antacids containing magnesium or aluminum.
Adult The recommended dosages of oral CIPRO® are:___________________________________________________________
Location of Infection Type/Severity Unit Dose Frequency Daily Dose
Urinary Tract Mild/Moderate 250 mg q 12h 500 mg
Severe/Complicated 500 mg q 12h 1000 mg
Lower Respiratory Tract 
Bone & Joint Mild/Moderate 500 mg q 12h 1000 mg
Skin & Soft Tissue Severe/Complicated5 750 mg q 12h 1500 mg
Infectious Diarrhea Mild/Moderate/Severe 500 mg q 12h 1000 mg
*  e.g. hospital-acquired pneumonia, osteomyelitis
Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period 
should be approximately 7 to  14 days. Generally, treatment should last 3  days beyond the disappearance of clinical symptoms or 
until cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 to  8  weeks and up to 3 months. 
W ith acute cystitis, a five-day treatment may be sufficient.
Intravenous Administration
Adult The recommended adult dosages of CIPRO® I.V. (ciprofloxacin injection) are:
Location of Infection Type/Severity Unit Dose Frequency Daily Dose
Urinary Tract Moderate/Severe/
Complicated
200 mg to 
400 mg
q 12h 400 mg to 
800 mg
Lower Respiratory Tract 
Skin or Skin Structure 
Blood 
Bone
Moderate 400 mg q 12h 800 mg
Definitive clinical studies have not been completed in severe respiratory tract and other infections.
The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for a t least 3 days 
after the signs and symptoms of infection have disappeared. The usual duration is 7 to 14 days. However, for severe and 
complicated infections more prolonged therapy may be required. Bone and joint infections may require treatment for 4 to 6 
weeks or longer
Sequential IV/PO Therapy
In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated a t the discretion of 
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed. 
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the 
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to  compensate for the 
reduced renal excretion of patients w ith renal impairment. Nonetheless, some modification of dosage is recommended, 
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However, 
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin 
(<1Q%) is removed from the body after haemodialysis or peritoneal dialysis.
Creatinine Clearance 
ml/s (mL/min)
Dose
> 0 .5  (30) No Dose adjustment
< 0 .5  (30)
and patients on haemodialysis or 
peritoneal dialysis
Use recommended dose once daily or 
half usual dose twice daily
When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient) 
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal 
function:
Creatinine Clearance mL/sec In traditional units mL/min
Males: Weight (kg) x (140 - age)
49 x serum creatinine (pmol/L)
Males: Weight (kg) x (140 - age)
72 x serum creatinine m g/100 mL
Females: 0.85 x the above value Females: 0.85 x the above value
Children
The safety and efficacy of CIPRO® and CIPRO® I.V. in children have not been established.
CIPRO® and CIPRO® I.V. should not be used in prepubertal patients (see WARNINGS).
AVAILABILITY OF DOSAGE FORMS
Tablets:
Cipro 9 250 Each tablet is engraved MILES on one side and 512 on the other and contains ciprofloxacin hydrochloride 
equivalent to 250 mg ciprofloxacin. Bottles of 100.
Cipro ® 500 Each tablet is engraved MILES on one side and 513 on the other and contains ciprofloxacin hydrochloride 
equivalent to 500 mg ciprofloxacin. Bottles of 100 and unit dose packages of 100.
Cipro ’ 750 Each tablet is engraved MILES on one side and 514 on the other and contains ciprofloxacin hydrochloride 
equivalent to 750 mg ciprofloxacin. Bottles of 50 and unit dose packages of 100.
Injection:
Cipro ® I.V. Each mL contains 10  mg of ciprofloxacin, in vials of 20  mL and 40 mL.
Product Monograph available upon request.
©  MILES CANADA INC., 1993
®  Registered Trademark. MILES CANADA INC., is the Registered User of the Trademark CIPRO®, the original brand of 
ciprofloxacin hydrochloride.
™ The trademark of the Cipro tablet, consisting of it's colour, shape and size, is a trademark of MILES CANADA INC.
References: 1. Cipro /  Cipro I.V. Canadian Product Monograph, MILES CANADA INC., September 1991. 
2. Current manufacturers' prices as of Jan., 1993.
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HISTORY OF SURGERY 
HISTOIRE DE CHIRURGIE
Coat of Arms of the Canadian Association 
of General Surgeons
Robert H. Thorlakson, MD, FRCS, FRCSC, FACS
The background to the granting of a coat of arms for the Canadian Association of 
General Surgeons is described. To help the reader understand the process, the 
author details how he applied the basic rules and philosophies of the art of heraldry 
to his design. He hopes this description will stimulate other societies and 
associations to create their own coats of arms.
Le contexte de l’octroi du blason de TAssociation canadienne des chirurgiens 
generaux est decrit. Pour aider le lecteur a comprendre le processus, l’auteur decrit 
en detail comment il a applique les regies fondamentales et les philosophies de 
Theraldique a son motif. II espere que cette description incitera d’autres societes et 
associations a creer leurs propres blasons.
T he Royal College of Physicians and Surgeons of Canada 
(RCPSC) was founded in 1929 by 
an act of the Canadian parliament. 
Initially, the College offered two 
specialty qualifications: fellowship 
in general medicine and fellowship 
in general surgery. In 1937, at the 
request of the Canadian Medical 
Association, the College offered 
qualifications in seven other special­
ties. Over the years additional spe­
cialties have been added. This was 
particularly so after the war when 
the fractionation of medicine and 
surgery increased rapidly. By 1991, 
the RCPSC officially recognized 52 
specialty and subspecialty qualifica­
tions. It became apparent to general 
surgeons that the College could not 
be an advocate of any one specialty 
group. Therefore the delineation of 
a specialty society for general sur­
geons was considered.
The first meetings of a committee
to form what became the Canadian 
Association of General Surgeons 
(CAGS) took place in 1976 at the
FIG. 1. Canadian Association of Gener­
al Surgeons’ coat of arms.
University of Toronto. The inaugu­
ral meeting of this new association 
was held in May 1977 in Toronto.
Background
The RCPSC had received its offi­
cial grant of arms from the College 
of Arms, London, England, in 
1962. The CAGS had wanted a coat 
of arms since its inception. There 
had been one or two unsuccessful 
attempts to bring this about. Re­
newed interest was stimulated by 
the creation of a Canadian heraldic 
authority to patriate this beautiful 
form of art and honour and to make 
it accessible to all Canadians. In 
1988, Queen Elizabeth II trans­
ferred the exercise of our Canadian 
heraldic prerogative to the Gover­
nor General, making possible the 
creation of the Canadian Heraldic 
Authority. In the short time since
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the Authority was established, hun­
dreds of government bodies, corpo­
rations, institutions and individuals 
have petitioned for coats of arms, 
and dozens of new symbols have 
already been granted. Indeed, at the 
time of the application for the 
CAGS coat of arms, there were 
more than 300 grants of arms wait­
ing to be finalized. Canada’s 125th 
anniversary in 1992 added consider­
able impetus to the number of ap­
plications.
Basic Rules and Philosophies
The art of heraldry is ancient. 
Initially, in the 12th century, it had 
a practical application as a form of 
individual identification. The art 
and science of heraldry developed 
over the next several hundred 
years, becoming highly decorative 
and sophisticated.
Some generalizations can be 
made about the creation of a coat of 
arms. It should be simple, bold, 
colourful and well balanced. The 
most basic rule is that simple her­
aldry is good heraldry. Although 
this is an ancient and medieval art 
form, some modern idioms can be 
brought to bear. Each coat of arms 
is as special as an individual’s sig­
nature and must be different from 
those of all others. Because of its 
pictorial nature it must be symbolic. 
The challenge is to pick a combina­
tion of symbols and colours that 
best reflect the entity it represents.
A coat of arms or “achievement 
of arms” is made up of several 
components. The basic components 
of a coat of arms are the shield, the 
helmet, the mantling and, from the 
top of the helmet, the crest. A man 
in full armour was unrecognizable 
so that a distinctive coat was worn 
that could be recognized over his 
armour. This was called his “coat 
of arms.” These arms were dis­
played on his banners, shields and
horse cloth, as well as his coat. 
Because few people could read in 
medieval times, the coat of arms 
was depicted on a shield. A personal 
crest of light wood or boiled leather 
came to be worn like a coxcomb on 
top of the helmet. Below the crest a 
simple silken mantle hung down to 
keep the heat of the sun off the 
back of the armour. In coats of 
arms, this now has been swirled and 
slashed to make a decoration on 
either side of the shield. With the 
addition of a motto on a scroll this 
forms the normal heraldic “achieve­
ment.” Occasionally, there may be 
“supporters” on either side of the 
shield. Only five colours or tinc­
tures are in general use in heraldry 
although this is starting to change. 
There are also two metals — gold 
and silver — which may also be 
depicted as yellow and white. A 
number of furs may also be used.
On the shield there is usually a 
charge or heraldic device placed 
upon a background or field. Colour 
is not placed on another colour or 
metal on metal because this is too 
indistinct at a distance. Colour 
shows up well on metal or metal on 
colour. The colours on the shield 
are usually repeated on the man­
tling, although this may not be so if 
there is a good reason. The man­
tling has a colour on one side and is 
lined by a metal on the other.
Although charges and symbols 
may be borrowed from other 
sources and coats of arms for vari­
ous reasons, each must vary, so 
that the coat of arms is distinctive 
to an individual or to a group.
The CAGS Coat of Arms
The Shield
The shield has a red and white 
border which alludes to our barber- 
surgeon’s origin. The main charge 
on a golden field is an eagle taken
from the crest of the mother college 
of surgery, the Royal College of 
Surgeons of England. It is differ­
enced in that the imperial crown 
has been removed, the head has 
been turned 180° to look forward 
and its colour has been changed 
from gold to red to represent sur­
gery. A lance is held in its right 
claw to represent any surgical in­
strument and in combination with a 
serpent is a modified caduceus of 
the medical profession. The colour 
red and the metal gold are taken 
from the RCPSC in recognition of 
our own Canadian college.
The Crest
On the top of the helmet is a 
circlet or coronet of red maple 
leaves, which alludes to Canada. 
From it, the right hand of a sur­
geon grasps a dagger impaling a 
dragon’s head erased, symbolizing 
the dragon of disease defeated.
The Mantling
The mantling is in surgical red 
lined in gold.
The Motto
The motto below on a golden 
ribbon with red lettering is taken 
from our own Royal College’s 
motto “With a Keen Mind and 
Skilful Hand.” The last half has 
been used and combined with the 
word wisdom, which embodies 
knowledge and judgement. Thus, 
the motto of the CAGS is Sapientia 
Manuque Apta (“Wisdom and a 
Skilful Hand”). Only one language 
can be used, so Latin has been 
substituted as it has by our RCPSC.
Comments
The thrust of the coat of arms of 
the CAGS has been to recognize its
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heritage, the barber-surgeons, the 
Royal College of Surgeons of En­
gland, the RCPSC and its country 
of origin, Canada. Its aim is to 
defeat the dragon of disease by 
wisdom and a skilful hand.
The evolution of this coat of 
arms has taken many forms and 
variations. Its final form was guided 
by the noted heraldic artist, Gordon 
Macpherson of Burlington, Ont., 
who has rendered the library paint­
ing (Fig. 1) that is also depicted on 
the cover of this issue.
BOOK REVIEWS
continued from page 270
book. At 2000 pages the text is bulky 
and unwieldy. It would have been much 
better divided into two or three separate 
volumes.
James P. Waddell, MD, FRCSC
St. Michael's Orthopedic Associates
Suite 800
55 Queen St. E
Toronto, ON
M5C 1R6
CLINICAL PEDIATRIC UROLOGY. 
3rd edition. Panayotis P. Kelalis, Low­
ell R. King and A. Barry Belman. 1467 
pp. Illust. W.B. Saunders Company, 
Philadelphia. 1992. $235 (US). ISBN 
0 -7 2 1 6 -3 2 3 3 -5
This textbook is devoted to the clinical 
practice of pediatric urology. The au­
thors are recognized experts in the 
material covered in their respective 
chapters. A “changing of the guard” in 
pediatric urology can be seen in this 
book because two-thirds of the authors 
are new. Accordingly, many of the 
chapters have been extensively re­
worked.
The practice of pediatric urology has 
changed considerably since the second 
edition of this book appeared in 1985.
The coat of arms for the CAGS 
has been accepted officially by the 
Chief Herald of Canada, Robert D. 
Watt. The formal Letters Patent 
Granting Arms are issued to the 
CAGS and the arms are entered in 
the Public Register of Arms, Flags 
and Badges of Canada. A notice of 
grant is published in the Canadian 
Gazette. This document, produced 
entirely by hand on acid-free artist’s 
paper, is approximately 56 cm (22 
in) X 76 cm (30 in). It features in 
colour the coats of arms of the
The widespread use of ultrasonography 
has revolutionized the practice of pedi­
atric urology, and this change more 
than any other is reflected in the con­
tent and presentation. The textbook 
opens with a chapter on antenatal diag­
nostics and is followed by chapters 
covering ultrasonography, uroradiology 
and nuclear medicine. The chapter on 
the presentation of urologic diseases 
has been moved from chapter one in the 
second edition to chapter seven in the 
third edition. The current emphasis on 
imaging technology is obvious; howev­
er, the ability to obtain and interpret a 
urologic history cannot be overempha­
sized.
New chapters on the physiology of 
micturition and on renal physiology are 
important additions to this textbook 
because a preponderance of pediatric 
urology is devoted to facilitating blad­
der function and to preserving renal 
function. The chapter on obstructive 
uropathies has been greatly expanded. 
There is some duplication of material, 
and this emphasizes important issues 
and facilitates the flow of independently 
authored chapters; however, renal dys­
plasia and cystic disease are covered in 
several chapters and two chapters are 
devoted to cloacal and anorectal malfor­
mations.
The discussion of genitourinary
Governor General of Canada, and 
the Canadian Heraldic Authority 
across the top, the newly generated 
arms in the centre below and the 
grant text in embellished calligra­
phy in English on the left and in 
French on the right.
The coat of arms of the CAGS 
will be suitably framed with a matt 
of red velvet to represent surgery 
with a gold box frame, and it will 
then be presented to the RCPSC 
to hang in its new quarters in 
Ottawa.*
anomalies is disjointed and would be 
better served by a separate chapter on 
urogenital embryology. There is no 
chapter on pediatric anesthesia. With­
out the improvements in pediatric anes­
thesiology and the concomitant prog­
ress in understanding the unique physi­
ology of the pediatric patient, much of 
the surgery now considered routine 
would entail far greater risks. There­
fore, a discussion of the anesthetic 
requirements of infants and children 
seems prudent.
The full spectrum of pediatric urolo­
gy is otherwise covered in detail from 
enuresis to renal transplantation. Con­
sidering the delays inherent in the pub­
lication of any multiauthored textbook, 
this edition is fairly up to date, with 
references as recent as 1991. The third 
edition is well written, practical and 
easy to read. It is disappointing that 
some of the chapters are strikingly 
similar to those written by the same 
authors in other major textbooks of 
urology. It meets the demand for a 
single resource encompassing all pediat­
ric urology and as such is recommended 
for urology residents, clinicians and 
academicians. It is also well suited for 
the interested pediatric surgeon, pedia­
trician and pediatric nephrologist. The
continued on page 283
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NOUVELLES DES PARRAINS
The Canadian Association of General 
Surgeons
1993 Annual Meeting
The annual meeting of the Canadian Association of 
General Surgeons (CAGS) will be held in conjunc­
tion with the Royal College annual meeting in 
Vancouver, Sept. 9 to 13, 1993. The Program 
Committee, chaired by Dr. John MacFarlane, has 
arranged a full 5 days of courses, lectures, seminars 
and paper sessions from Thursday to Monday inclu­
sive.
There will be two postgraduate courses. The first 
course on Thursday, Sept. 9, will feature laparoscop­
ic surgery. It will include sections on gastrointestinal 
diseases, hernia repair, biliary tract disease and 
litigation and credentialling. International guests for 
this course include Professor Alfred Cuschieri from 
Scotland and Dr. John Hunter from Atlanta.
The second postgraduate course will be held 
Monday, Sept. 13. It will address malignant diseases 
of the large intestine. The presentation will involve 
screening, diagnosis, complex management and new 
technologies including laparoscopic colonic surgery. 
International faculty participating in this course are 
Professor W. Heald from England and Dr. T. Rich 
from Houston.
On Friday morning the CAGS will present a 
symposium on quality assurance in general surgical 
practice, chaired by Dr. Chris Heughan. This 2-hour 
session will define quality assurance, address clinical 
practice guidelines and introduce an approach to 
quality improvement.
Following the symposium, the annual W.R. Ghent 
Lecture will be delivered by Dr. E. Moore of Denver. 
He will speak on the effects of immediate postinjury 
enteral feeding on sepsis.
The first paper session, to be presented Friday 
afternoon, will include the CAGS resident research 
and the Lederle awards papers.
The CAGS presidential address will be delivered by 
Dr. Marvin Wexler at 16:45 and will be followed by 
the CAGS annual business meeting.
On Saturday, Sept. 11, the second paper session
will start the morning and will be followed at 09:30 
by the first Langer Lecture presented by Professor 
Cuschieri, who will speak on “The Cutting Edge of 
Minimal Access Surgery.”
Also, Saturday is the CAGS CME Day, and the 
Self-Assessment Examination with the touch-pad 
responder program will be chaired by Dr. Paul 
Belliveau from 10:15 to 11:30. A 1-hour symposium 
on management of endocrine disorders of the head 
and neck will be chaired by Dr. Ted Young, starting 
at 13:30. The Royal College Medallist in Surgery will 
speak at 14:30 and will be followed by the popular 
CAGS symposium on unexpected findings at surgery, 
chaired by Drs. John Guy of Toronto and Peter Roy 
of Halifax. The annual colorectal lecture will close 
Saturday with an invited presentation by Dr. Phil 
Gordon of Montreal. The CAGS reception will be held 
on Saturday evening.
The morning of Sunday, Sept. 12, will begin with 
a combined paper and poster session with the 
Canadian Association of Gastroenterology. The Royal 
College Gallie Lecture will be given at 11:30. At 
13:30, Dr. Bill Fitzgerald of St. Anthony, Nfld., will 
chair a symposium on efficient diagnosis and man­
agement of common abdominal problems. Professor 
Heald will present the CAGS Lecture at 14:30. He 
will speak on the management of rectal cancer. 
Sunday afternoon will conclude with a 2-hour sympo­
sium entitled “Option, Opinions and Operations for 
Obesity Surgery,” chaired by Dr. Iain Cleator of 
Vancouver.
The Program Committee has arranged an exciting 
meeting, which will be fully integrated with the 
programs of other specialty societies participating at 
the Royal College meeting. Members are reminded to 
complete the preregistration and housing forms 
circulated by the Royal College to assure satisfactory 
reservations.
The Canadian Orthopaedic Association
Upcoming Events
The Graham Apley course on the clinical examination
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of the musculoskeletal system will be held in Montre­
al from Oct. 22 to 24, 1993. For further information 
please contact: Ms. Francine Bienvenu, 3175 Cote 
Ste-Catherine, Suite 4837, Montreal, QC H3T 1C6; 
phone: (514) 345-4915.
The Canadian Orthopaedic Foundation (COF) is 
organizing the second Canadian Hip Hip Hooray 
Day. On Sunday, June 13, 1993, in centres across 
Canada, orthopedic patients walk a kilometre to raise 
funds for orthopedic research. Patterned on the 
British model, last year’s walk was a great success, 
thanks to the patients, their families and friends.
The Canadian Society for Vascular Surgery
Annual Business Meeting
The annual business meeting of the Canadian Society 
for Vascular Surgery (CSVS) will be held on Sept. 
11, 1993, at noon. This meeting will be held in 
conjunction with the annual scientific meeting of the 
Society. Any members wishing to add items to the
agenda for this meeting should contact the Secretary 
at: Victoria Hospital, 375 South St., London, ON, 
N6A 4G5; phone: (519) 667-6780.
Dr. David Taylor and the Local Arrangements 
Committee have prepared an excellent social pro­
gram, including a cocktail reception at Vancouver’s 
Museum of Anthropology and dinner at one of the 
finer Vancouver restaurants. This year’s meeting 
should prove to be a great success.
The Joseph C. Luke Award
The Joseph C. Luke Award is presented annually to 
the best clinical or basic research paper presented at 
the annual meeting of the CSVS. The Selection 
Committee comprises the following: the CSVS lectur­
er (Dr. Jonathan Towne), the Society president (Dr. 
Adrien Bouchard) and the program chairman (Dr. 
Paul Walker).
The 1992 award was presented to Dr. Joseph 
Sladen for his paper entitled “Superficial Femoral 
Vein: A Useful Alternative Arterial Conduit.”
A motion will be brought forward at the business 
meeting to include the submission of a manuscript as 
one of the criteria for winning this award.
BOOKS RECEIVED 
LIVRES REfUS
This list is an acknowledgement of 
books received. It does not preclude 
review at a later date.
Cette liste enumere les livres regus. 
Elle n’en exclut pas la critique a 
une date ulterieure.
Blood Substitutes & Oxygen Carriers.
Edited by T.M.S. Chang. 896 pp. Illust. 
Marcel Dekker Inc., New York. 1992. 
$175 (US). ISBN 0-8247-8810-9
Diagnosis of Colorectal and Ovarian 
Carcinoma. Application of Immunos- 
cintigraphic Technology (Targeted Di­
agnosis and Therapy Series/6). Edited 
by Robert T. MacGuire and Douglas 
Van Nostrand. 260 pp. Illust. Marcel 
Dekker, Inc., New York. 1992. $99.75 
(US). ISBN 0-8247-8648-7
Endovascular Surgery. 2nd edition. Ed­
ited by S.S. Ahn and W.S. Moore. 612 
pp. Illust. W.B. Saunders Company, 
Philadelphia. 1992. $182. ISBN 0- 
7216-4370-1
Gastrointestinal Bleeding. Edited by 
Choichi Sugawa, Bernard M. Schuman 
and Charles E. Lucas. 564 pp. Illust. 
Igaku-Shoin Medical Publishers Inc., 
New York. 1992. $173. ISBN 0- 
89640-221-5
High Tech Urology, Technical Innova­
tions and Their Clinical Applications.
Joseph A. Smith. 362 pp. Illust. W.B. 
Saunders Company, Philadelphia. 1992. 
$107 (US). ISBN 0-7216-3053-7
Lumbar Disc Disease. 2nd edition. Edit­
ed by Russel W. Hardy, Jr. 373 pp. 
Illust. Raven Press Ltd., New York. 
1992. $125 (US). ISBN 0-88167- 
951-8
Mechanics of Human Joints — Physi­
ology, Pathophysiology and Treat­
ment. Edited by Verna Wright and 
Erica L. Radin. 480 pp. Illust. Marcel 
Dekker Inc., New York. 1993. $185 
(US). ISBN 0-8247-8763-3 
Musculoskeletal Tissue Banking. Wil­
liam W. Tomford. 251 pp. Illust. Raven 
Press Ltd., New York. 1993. $75 (US). 
ISBN 0-88167-995-X 
Surgery: Scientific Principles and
Practice. Edited by Lazar J. Greenfield. 
2208 pp. Illust. J.B. Lippincott Co., 
Philadelphia. 1992. $92 (US). ISBN 0- 
397-51121-3
Techniques in Therapeutic Arthros­
copy. Edited by J. Serge Parisien. 385 
pp. Illust. Raven Press Ltd., New York. 
1993. $125 (US). ISBN 0-7817- 
0054-X
Total Knee Arthroplasty. Edited by 
James A. Rand. 480 pp. Illust. Raven 
Press Ltd., New York. 1992. $130 
(US). ISBN 0-88167-930-5
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illustrations are of good quality and the 
price is reasonable.
Robert E. Steckler, MD
Pediatric urology fellow 
The Hospital for Sick Children 
University of Toronto 
Toronto, Ont.
Bernard M. Churchill, MD, FRCSC
Professor of surgery 
University of Toronto.
Chief, Division of Pediatric Urology 
The Hospital for Sick Children 
Toronto, Ont.
COMPLICATIONS IN HEAD AND 
NECK SURGERY. Edited by Y.P. Kre- 
spi and R.H. Ossoff. 582 pp. Illust. 
W.B. Saunders Company/Harcourt 
Brace Jovanovich, Inc., Philadelphia. 
1993. Price not stated. ISBN 0-7216- 
2980-6
This comprehensive book outlines 
major and minor complications in head 
and neck oncology, classic otolaryngol­
ogy, head and neck trauma and recon­
structive surgery of the head and neck. 
It is modelled after John Conley’s out­
standing publication Complications of 
Head and Neck Surgery (1979). Both 
books begin by covering the complica­
tions of anesthesia, blood vessels, sepsis 
and fistulas. The middle chapters are 
devoted to complications of specific 
anatomic entities such as paranasal si­
nuses, salivary glands, thyroid, pharynx 
and larynx. The chapter on thyroid and 
parathyroid surgery gives an excellent 
account of the disabilities associated 
with superior laryngeal nerve injury and 
recurrent laryngeal nerve injury. The 
last few chapters focus on the complica­
tions of chemotherapy and radiothera­
py, trauma and plastic reconstructive 
surgery. This book has chapters on 
surgery of the skull base, voice rehabili­
tation and free tissue transfer. There is 
a very detailed chapter on maxillofacial 
trauma.
The book is easy to read, and some 
chapters are mini-books in themselves. 
Sections on anesthesia complications, 
laser surgery and blood-borne diseases 
are superficial and could have been
omitted without detracting from the 
book.
This excellent overview of complica­
tions in head and neck surgery ade­
quately replaces Dr. Conley’s 14-year- 
old edition. General surgeons, otolaryn­
gologists and plastic surgeons who per­
form head and neck surgery will find 
this an invaluable overview of head and 
neck complications. It should serve as a 
reference book and as pleasurable read­
ing material for these surgeons.
C.A. Kotwali, MD, MSc, FRCSC, FACS
Assistant professor 
University of Toronto.
Department of Surgery 
St. Michael’s Hospital 
Toronto, Ont.
ATLAS OF GYNECOLOGIC SUR­
GERY. Raymond A. Lee. 368 pp. Il­
lust. W.B. Saunders Company/Har- 
court Brace Jovanovich Inc., Philadel­
phia. 1992. $80 (US). ISBN 0 -7 2 1 6 -  
3358-7
The classical surgical procedures pre­
sented in this comprehensive atlas are 
described as a “distillation of several 
generations of Mayo surgeons which 
are presently performed by 6 surgeons 
in the section of gynecological surgery 
at the Mayo Clinic.” The focus is on the 
performance of well-planned procedures 
avoiding wasted motions. Emphasis is 
placed on the classical surgical tenets of 
adequate exposure, accurate and precise 
dissection of tissues, perfect hemosta­
sis, approximation of tissues free of 
tension and persistent attention to de­
tail.
The illustrations by John Hagan were 
based on photographs taken during 
operative procedures. The final presen­
tation in each case is “as the surgeon 
would see it.”
The atlas covers the spectrum of 
surgical procedures performed by the 
gynecologist in active practice. In addi­
tion to mundane procedures (dilatation 
and curettage), there are ample refer­
ences and descriptions of the manage­
ment of unusual conditions (ruptured 
enterocele).
1 found myself questioning some of
the presumptions accompanying the de­
scription of the unusual operative pro­
cedures. When discussing ruptured en­
terocele and prolapse of the intestines, 
the author suggests that “prolapse of 
the vagina after a hysterectomy is oc­
curring with greater frequency.” Given 
the advent of improved surgical tech­
niques, patient selection and operative 
materials presently utilized, I found it 
difficult to agree with this suggestion. 
Fortunately, many of the procedures 
described throughout the text are not 
likely to be encountered by the gynecol­
ogist in general practice.
There are major shortcomings to this 
atlas.
Many of the procedures described 
have been supplanted by newer and 
more innovative techniques utilizing 
state of the art technology. A good 
example is the treatment of benign 
diseases of the vulva, which the author 
describes as “a skinning vulvectomy” 
or a “wide local excision.” Most centres 
now use a carbon dioxide laser to 
perform many vulvar procedures. Thus, 
the skin flaps and muscle approxima­
tions, so eloquently described, are un­
likely to be used in modern practice.
My second area of disappointment is 
the failure to include simple operative 
procedures such as sacrospinous fixa­
tion for the management of vault pro­
lapse. This newer technique, which is 
becoming more common, avoids much 
of the major dissection required in the 
extensive repair described by the au­
thor. I am at a loss to understand why 
this simple and effective procedure was 
not included whereas a difficult and 
unusual hysterectomy through a nar­
row vagina was.
I was also surprised by the descrip­
tion of a simple total abdominal hyster­
ectomy, perhaps the most common 
major procedure performed by a practis­
ing gynecologist. I found it most un­
usual that routine closure of the vaginal 
vault was recommended at a time when 
many gynecologists are leaving the 
vault open. Furthermore, I see no place 
for a two-layer closure of the vaginal 
vault — a procedure that can increase 
the risk of trauma to vital structures. 
Similarly, most teachers are no longer 
reperitonealizing the pelvic peritoneum. 
I was left wondering whether the au-
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thor and his associates were true to 
"distilling the work of several genera­
tions of Mayo surgeons” or whether 
they were stuck in a time warp. The 
author did not adhere to his philosophy 
of "avoiding wasted motion that pre­
vents the operation from being accom­
plished safely in the minimum of time.”
I was disappointed to see no evidence 
of newer approaches in gynecologic 
surgery involving laser technology for 
management of uterine septum or lapa­
roscopic surgery for managing adnexal 
disease. With the emphasis on short 
hospital stays, reduction of operative 
time and cost and the patient’s rapid 
return to normal activities, I believe 
that any up to date atlas of gynecologic 
surgery must include these new ap­
proaches, which are being emphasized 
in both teaching and updating pro­
grams.
Although the book describes classi­
cal gynecologic procedures in a clear, 
concise and easily understood manner, I 
felt dissatisfied upon completing my 
perusal of the contents. I tried to count 
the procedures that I would normally 
do, as described in the text, and I found 
myself staring at the fingers of one 
hand. A dilatation and curettage is more 
likely performed as an office procedure 
under paracervical block with suction 
curettage. Cone biopsies are now done 
under paracervical block by laser or 
loop electro-excision procedure and are 
only occasionally performed in the for­
mat described. Major procedures of the 
vulva are rarely undertaken as described 
for benign disease, and it is quite un­
usual to approach the internal genitalia 
through the surgical acrobatics of radi­
cal vaginal hysterectomy. Simple ab­
dominal hysterectomies are done with 
fewer steps, fewer sutures and less 
trauma to the adjacent tissues. It is 
unusual to perform a major procedure 
for uterine prolapse utilizing the com­
plicated and involved procedures de­
scribed. More and more reconstructive 
uterine and vaginal procedures are done 
with laser.
If one is collecting classical refer­
ences to use in unusual and difficult 
cases, this atlas would make excellent 
shelf material. If, however, one's tastes 
are more in keeping with state of the 
art as opposed to Studebaker styling
and nostalgia, I feel this text is best 
utilized as a reference book in the 
hospital or university library.
Wilfred M. Steinberg, MD, FRCSC
Department of Obstetrics and Gynecology 
St. Michael's Hospital 
Toronto. Ont.
TRACHEAL RECONSTRUCTION IN 
INFANCY. Edited by Thom E. Lobe. 
218 pp. Illust. W.B. Saunders Compa­
ny, Philadelphia/HBJ-Holt-Saunders 
Distribution Services, Toronto. 1991. 
$104. ISBN 0-7216-5779-6
This is a text for the specialist but is 
also useful for nurses, intensive care 
workers, neonatologists and anesthe­
tists. The conditions discussed are un­
common, and the treatment of these 
conditions is not only technically diffi­
cult but also ethically challenging. For 
the first time under one cover, a com­
prehensive plan of management for chil­
dren who require tracheal reconstruc­
tion is presented.
Initially, a general picture of the 
anomalies is given. However, the em­
bryology is too brief and may only be of 
use to those studying for fellowship or 
board examinations (51 references!). 
The title of chapter two, “Signs and 
symptoms of congenital stenosis: diag­
nosis and considerations,” is misleading 
because malacia and clefts are discussed 
in addition to stenosis. Unfortunately, 
neither the increasingly common iatro­
genic and serious problem of necrotiz­
ing tracheobronchitis nor the tracheal 
complications of tracheostomy are men­
tioned. Radiographs are wrongly refer­
enced in the text.
All caregivers of these critically ill 
babies should familiarize themselves 
with the section on perioperative man­
agement of the infant requiring recon­
structive tracheal surgery. Anesthesiol­
ogists especially should read the section 
on the anesthetic management of such 
infants. Chapter nine, which deals with 
perioperative sedation, analgesia and 
muscle relaxation, should have been 
included in the section on anesthetic 
management. Later chapters concerned
with nursing care, rehabilitation and 
ethics might have been inserted here. 
The discussion is too general and not 
specific to the infant with tracheal 
anomalies. Fortunately, the rest of the 
text is replete with good nursing advice.
Four chapters deal with surgical re­
construction. Personally, I have con­
sulted and will continue to consult this 
book for the useful advice found here. 
The technical diagrams and the clear 
prose are first rate. The references are 
complete. A more complete discussion 
of balloon dilatation would be welcome 
in the next edition. A report of six cases 
treated successfully complements the 
excellent previous technical instruction. 
Those treating infants with such com­
plex problems will find sound council 
and moral support here! A final few 
pages on experimental tracheal recon­
struction precede a useful index.
This book is an essential reference 
for all caregivers involved in the man­
agement of neonates and infants with 
complex tracheobronchial anomalies. 
The technical chapters dealing with 
operative and perioperative care are so 
useful that I would recommend the 
surgeon have the book close at hand 
when dealing with infants who require 
tracheal reconstruction.
Steven Rubin, MD, FRCS, FRCSC
Department of Surgery
Children’s Hospital of Eastern Ontario
Ottawa. Ont.
ATLAS OF LAPAROSCOPIC SUR­
GERY. Edited by Eddie J. Reddick, 
William B. Saye and John D. Corbitt 
Jr. 116 pp. Raven Press, New York. 
1993. $98 (US). ISBN 0-88167- 
932-1
This atlas for general surgeons was 
intended initially to cover only laparo­
scopic cholecystectomy but was ex­
panded to cover laparoscopic appendec­
tomy, vagotomy and pyloroplasty, left 
colonic resection and herniorrhaphy. 
On the basis of teaching experiences, 
the authors intended to elaborate on 
common mistakes made in laparoscopic 
procedures.
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The atlas is organized into five sec­
tions with a series of colour photo­
graphs, taken from videotapes, and ex­
planatory text. The first part, which is 
the longest and most detailed, is on 
laparoscopic cholecystectomy and occu­
pies more than half the atlas. It includes 
a discussion on laparoscopic access, 
both closed and open. The steps in 
laparoscopic cholecystectomy are well 
illustrated and well explained. A num­
ber of useful techniques are included, 
such as needle decompression of the 
gallbladder, cholangiography, explora­
tion of the common bile duct via the 
cystic duct, choledochoscopy, T-tube 
placement, Endoloop closure of gall­
bladder perforation, suture of large 
vessels in the gallbladder bed and 
manoeuvres to remove the gallbladder 
from the abdomen. Most of the colour 
pictures are of good quality, and the 
text is clear.
The chapter on appendectomy is very 
short but clear enough for the reader to 
visualize the essential steps. The colour 
pictures show a normal appendix being 
removed.
The last three chapters, on the man­
agement of peptic ulcer, left colonic 
resection and hernia repair, were added 
as an afterthought, and the contents 
certainly reflect this. The colour pic­
tures are few and often out of focus, 
and they lack the detailed step-by-step 
illustrations achieved in the first part on 
cholecystectomy. This is particularly so 
in the chapter on colonic resection. 
Surgeons who have not seen a laparo­
scopic colonic resection will not learn 
much from this chapter, and those who 
have will find the description in this 
atlas quite inadequate. Although the 
colour pictures are better in the chapter 
on peptic ulcer management, they are 
still inadequate. The final part on hernia
repair was cursorily prepared. Although 
the anatomical placement of the mesh is 
well illustrated in a colour drawing of 
the inguinal region, the colour pictures 
do not show these landmarks well.
Overall this atlas is strong on laparo­
scopic cholecystectomy but is weak in 
other areas. This parallels clinical expe­
rience since laparoscopic cholecystecto­
my is a well-established procedure 
whereas other procedures are still 
evolving. There is certainly a need for 
good illustrations of laparoscopic proce­
dures — a picture is worth a thousand 
words — but this need may be better 
met by producing high-quality video­
tapes for dissemination of technical in­
formation.
Jarley Koo, MD
Division of General Surgery 
St. Michael’s Hospital 
University of Toronto 
Toronto, Ont.
Like any other six-year-old. 
Almost.
Hundreds of Canadian children are sick 
with a disease that's turning their skin yellow, 
and slowly but surely turning their bodies 
against them.
Liver Disease. It's now the fourth highest 
killer disease in Canada — and it's on the rise.
Transplants have saved the lives of many 
Canadians young and old, but we can't do 
nearly enough of them.
We need your help to find cures. Please 
give to the Canadian Liver Foundation. And 
help us give little girls and boys back their lives.
1320 Yonge Street, Toronto, Ontario M4T 1X2 1-800- 563-5483
Charitable Registration No. 0367-151-13
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ORTHOPEDIC SURGEON
Dawson Creek and District Hospital is a 
major referral hospital for the Peace 
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